US20190032021A1 - Organ Chips And Uses Thereof - Google Patents
Organ Chips And Uses Thereof Download PDFInfo
- Publication number
- US20190032021A1 US20190032021A1 US16/125,433 US201816125433A US2019032021A1 US 20190032021 A1 US20190032021 A1 US 20190032021A1 US 201816125433 A US201816125433 A US 201816125433A US 2019032021 A1 US2019032021 A1 US 2019032021A1
- Authority
- US
- United States
- Prior art keywords
- cells
- chip
- organ
- chips
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 336
- 230000003285 pharmacodynamic effect Effects 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 213
- 239000012528 membrane Substances 0.000 claims description 119
- 239000003814 drug Substances 0.000 claims description 102
- 210000004072 lung Anatomy 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 73
- 238000000338 in vitro Methods 0.000 claims description 69
- 239000012530 fluid Substances 0.000 claims description 51
- 239000013543 active substance Substances 0.000 claims description 48
- 239000010409 thin film Substances 0.000 claims description 46
- 210000000663 muscle cell Anatomy 0.000 claims description 42
- 210000002027 skeletal muscle Anatomy 0.000 claims description 42
- 210000004738 parenchymal cell Anatomy 0.000 claims description 39
- 210000004185 liver Anatomy 0.000 claims description 34
- -1 particulates Substances 0.000 claims description 31
- 239000000443 aerosol Substances 0.000 claims description 30
- 239000003053 toxin Substances 0.000 claims description 29
- 231100000765 toxin Toxicity 0.000 claims description 29
- 108700012359 toxins Proteins 0.000 claims description 29
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 28
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 28
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 28
- 230000003387 muscular Effects 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 210000002919 epithelial cell Anatomy 0.000 claims description 22
- 210000005091 airway smooth muscle Anatomy 0.000 claims description 21
- 210000003734 kidney Anatomy 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 210000004556 brain Anatomy 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 239000001963 growth medium Substances 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 239000000356 contaminant Substances 0.000 claims description 17
- 230000000638 stimulation Effects 0.000 claims description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- 210000001550 testis Anatomy 0.000 claims description 15
- 239000002086 nanomaterial Substances 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 230000007613 environmental effect Effects 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- 239000003344 environmental pollutant Substances 0.000 claims description 12
- 231100000719 pollutant Toxicity 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 11
- 108091023037 Aptamer Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 150000003384 small molecules Chemical class 0.000 claims description 10
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 9
- 108020004459 Small interfering RNA Proteins 0.000 claims description 9
- 230000036982 action potential Effects 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000007789 gas Substances 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 239000002924 silencing RNA Substances 0.000 claims description 9
- 239000004055 small Interfering RNA Substances 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 7
- 238000010200 validation analysis Methods 0.000 claims description 7
- 230000005684 electric field Effects 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 230000004118 muscle contraction Effects 0.000 claims description 5
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 238000010276 construction Methods 0.000 claims description 4
- 210000005229 liver cell Anatomy 0.000 claims description 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 claims 2
- 230000001706 oxygenating effect Effects 0.000 claims 2
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 17
- 238000012258 culturing Methods 0.000 abstract description 8
- 238000007877 drug screening Methods 0.000 abstract description 6
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000017423 tissue regeneration Effects 0.000 abstract description 2
- 238000002723 toxicity assay Methods 0.000 abstract description 2
- 108091006146 Channels Proteins 0.000 description 124
- 210000004379 membrane Anatomy 0.000 description 102
- 229940079593 drug Drugs 0.000 description 79
- 241000282414 Homo sapiens Species 0.000 description 74
- 230000003278 mimic effect Effects 0.000 description 57
- 210000001519 tissue Anatomy 0.000 description 55
- 239000000758 substrate Substances 0.000 description 47
- 210000001035 gastrointestinal tract Anatomy 0.000 description 44
- 238000013461 design Methods 0.000 description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 208000006673 asthma Diseases 0.000 description 35
- 230000004044 response Effects 0.000 description 34
- 239000010410 layer Substances 0.000 description 33
- 210000004413 cardiac myocyte Anatomy 0.000 description 31
- 201000010099 disease Diseases 0.000 description 29
- 230000006870 function Effects 0.000 description 24
- 230000008602 contraction Effects 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 210000002460 smooth muscle Anatomy 0.000 description 23
- 239000000463 material Substances 0.000 description 22
- 210000001185 bone marrow Anatomy 0.000 description 21
- 210000003205 muscle Anatomy 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 230000029058 respiratory gaseous exchange Effects 0.000 description 18
- 230000035882 stress Effects 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000007788 liquid Substances 0.000 description 15
- 230000000144 pharmacologic effect Effects 0.000 description 15
- 210000001789 adipocyte Anatomy 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 210000004165 myocardium Anatomy 0.000 description 14
- 230000035790 physiological processes and functions Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- 241000700605 Viruses Species 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 230000036755 cellular response Effects 0.000 description 12
- 210000000981 epithelium Anatomy 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 10
- 210000001218 blood-brain barrier Anatomy 0.000 description 10
- 238000002565 electrocardiography Methods 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 230000033001 locomotion Effects 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 229920002635 polyurethane Polymers 0.000 description 10
- 239000004814 polyurethane Substances 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000002861 ventricular Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 208000007101 Muscle Cramp Diseases 0.000 description 9
- 208000005392 Spasm Diseases 0.000 description 9
- 229940072056 alginate Drugs 0.000 description 9
- 235000010443 alginic acid Nutrition 0.000 description 9
- 229920000615 alginic acid Polymers 0.000 description 9
- 239000013553 cell monolayer Substances 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 9
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 9
- 210000000130 stem cell Anatomy 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 108090000176 Interleukin-13 Proteins 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 239000013566 allergen Substances 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000006461 physiological response Effects 0.000 description 8
- 239000003440 toxic substance Substances 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000003678 bronchial smooth muscle cell Anatomy 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 244000005709 gut microbiome Species 0.000 description 7
- 210000005003 heart tissue Anatomy 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 238000005459 micromachining Methods 0.000 description 7
- 210000003098 myoblast Anatomy 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 231100000167 toxic agent Toxicity 0.000 description 7
- 230000002411 adverse Effects 0.000 description 6
- 239000000809 air pollutant Substances 0.000 description 6
- 231100001243 air pollutant Toxicity 0.000 description 6
- 210000004712 air sac Anatomy 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 210000003038 endothelium Anatomy 0.000 description 6
- 210000005095 gastrointestinal system Anatomy 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 238000000813 microcontact printing Methods 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 5
- 229960004373 acetylcholine Drugs 0.000 description 5
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 229960004679 doxorubicin Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 230000008520 organization Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 241000288906 Primates Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000001451 cardiotoxic effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003989 endothelium vascular Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000010874 in vitro model Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 150000002484 inorganic compounds Chemical class 0.000 description 4
- 229910010272 inorganic material Inorganic materials 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 210000002464 muscle smooth vascular Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000000107 myocyte Anatomy 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960000351 terfenadine Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 3
- UBOXGVDOUJQMTN-UHFFFAOYSA-N 1,1,2-trichloroethane Chemical compound ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 3
- PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108090000862 Ion Channels Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000009328 Perro Species 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010070863 Toxicity to various agents Diseases 0.000 description 3
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000036983 biotransformation Effects 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 239000000512 collagen gel Substances 0.000 description 3
- 230000001143 conditioned effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 230000007831 electrophysiology Effects 0.000 description 3
- 238000002001 electrophysiology Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
- 229960003592 fexofenadine Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003667 hormone antagonist Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229940039009 isoproterenol Drugs 0.000 description 3
- 238000010147 laser engraving Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 210000001087 myotubule Anatomy 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004789 organ system Anatomy 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920000307 polymer substrate Polymers 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002363 skeletal muscle cell Anatomy 0.000 description 3
- 239000000779 smoke Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 description 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000224466 Giardia Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 208000029549 Muscle injury Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000011623 Obstructive Lung disease Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- 206010061924 Pulmonary toxicity Diseases 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 241000589884 Treponema pallidum Species 0.000 description 2
- 241000710886 West Nile virus Species 0.000 description 2
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- FPNPSEMJLALQSA-MIYUEGBISA-N [[(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)[C@@H](O)C1 FPNPSEMJLALQSA-MIYUEGBISA-N 0.000 description 2
- 229940090167 advair Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 210000000270 basal cell Anatomy 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 231100000457 cardiotoxic Toxicity 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000004956 cell adhesive effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002575 chemical warfare agent Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 210000002777 columnar cell Anatomy 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 229950003387 denufosol Drugs 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 108010008250 drotrecogin alfa activated Proteins 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 230000009969 flowable effect Effects 0.000 description 2
- 239000010881 fly ash Substances 0.000 description 2
- 229940107791 foradil Drugs 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 208000004731 long QT syndrome Diseases 0.000 description 2
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 2
- 238000003754 machining Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 230000009988 metabolic benefit Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000005063 microvascular endothelium Anatomy 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000012634 optical imaging Methods 0.000 description 2
- KZAUOCCYDRDERY-UHFFFAOYSA-N oxamyl Chemical compound CNC(=O)ON=C(SC)C(=O)N(C)C KZAUOCCYDRDERY-UHFFFAOYSA-N 0.000 description 2
- 210000003540 papillary muscle Anatomy 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000001020 plasma etching Methods 0.000 description 2
- 231100000374 pneumotoxicity Toxicity 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- 208000005333 pulmonary edema Diseases 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 229960004804 rapacuronium Drugs 0.000 description 2
- LVQTUXZKLGXYIU-GWSNJHLMSA-M rapacuronium Chemical compound [Br-].N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)CC)[N+]2(CC=C)CCCCC2)CCCCC1 LVQTUXZKLGXYIU-GWSNJHLMSA-M 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000009256 replacement therapy Methods 0.000 description 2
- 238000000820 replica moulding Methods 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940090585 serevent Drugs 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 230000016160 smooth muscle contraction Effects 0.000 description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000003699 striated muscle Anatomy 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940035073 symbicort Drugs 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 229940070384 ventolin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- ZXFXBSWRVIQKOD-AQTZKLSLSA-N (1R,2R,3S,5S,6R,7S,8S)-1,6,8,9,10,11,11-heptachloro-4-oxatetracyclo[6.2.1.02,7.03,5]undec-9-ene Chemical compound ClC1=C(Cl)[C@]2(Cl)[C@H]3[C@@H]4O[C@@H]4[C@H](Cl)[C@H]3[C@@]1(Cl)C2(Cl)Cl ZXFXBSWRVIQKOD-AQTZKLSLSA-N 0.000 description 1
- GXEKYRXVRROBEV-FBXFSONDSA-N (1r,2s,3r,4s)-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid Chemical compound C1C[C@@H]2[C@@H](C(O)=O)[C@@H](C(=O)O)[C@H]1O2 GXEKYRXVRROBEV-FBXFSONDSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- IAKOZHOLGAGEJT-UHFFFAOYSA-N 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)-Ethane Chemical compound C1=CC(OC)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(OC)C=C1 IAKOZHOLGAGEJT-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- LGXVIGDEPROXKC-UHFFFAOYSA-N 1,1-dichloroethene Chemical group ClC(Cl)=C LGXVIGDEPROXKC-UHFFFAOYSA-N 0.000 description 1
- WBEJYOJJBDISQU-UHFFFAOYSA-N 1,2-Dibromo-3-chloropropane Chemical compound ClCC(Br)CBr WBEJYOJJBDISQU-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- KNKRKFALVUDBJE-UHFFFAOYSA-N 1,2-dichloropropane Chemical compound CC(Cl)CCl KNKRKFALVUDBJE-UHFFFAOYSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- RSXFZXJOBQZOOM-INBIVCPUSA-N 143591-04-2 Chemical compound O([C@@H]\1COC(=O)C[C@H](C2=CC=C(C(=N2)Cl)O[C@@H]2[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@](C)(O)C3)[C@]34O[C@H]3C#C/C=C/1C#CC4=C2)NC(=O)C=1C(O)=CC2=CC(OC(C)C)=C(C(=C2C=1)OC)OC)[C@H]1C[C@H](O)[C@H](N(C)C)[C@H](C)O1 RSXFZXJOBQZOOM-INBIVCPUSA-N 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- OWZPCEFYPSAJFR-UHFFFAOYSA-N 2-(butan-2-yl)-4,6-dinitrophenol Chemical compound CCC(C)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O OWZPCEFYPSAJFR-UHFFFAOYSA-N 0.000 description 1
- YIXDEYPPAGPYDP-IUYQGCFVSA-N 2-deoxy-D-ribono-1,4-lactone Chemical compound OC[C@H]1OC(=O)C[C@@H]1O YIXDEYPPAGPYDP-IUYQGCFVSA-N 0.000 description 1
- QGXBDMJGAMFCBF-HLUDHZFRSA-N 5α-Androsterone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-HLUDHZFRSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000228193 Aspergillus clavatus Species 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000222157 Candida viswanathii Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical class ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241001508813 Clavispora lusitaniae Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241001522864 Cryptococcus gattii VGI Species 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NDUPDOJHUQKPAG-UHFFFAOYSA-N Dalapon Chemical compound CC(Cl)(Cl)C(O)=O NDUPDOJHUQKPAG-UHFFFAOYSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 description 1
- ZLSWBLPERHFHIS-UHFFFAOYSA-N Fenoprop Chemical compound OC(=O)C(C)OC1=CC(Cl)=C(Cl)C=C1Cl ZLSWBLPERHFHIS-UHFFFAOYSA-N 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 239000005562 Glyphosate Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 1
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000724675 Hepatitis E virus Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000724709 Hepatitis delta virus Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000806846 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000835083 Homo sapiens Tissue factor pathway inhibitor 2 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241001502974 Human gammaherpesvirus 8 Species 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241001500350 Influenzavirus B Species 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000235048 Meyerozyma guilliermondii Species 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241001443590 Naganishia albida Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 239000005950 Oxamyl Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000222051 Papiliotrema laurentii Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 239000005595 Picloram Substances 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241000142787 Pneumocystis jirovecii Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 206010038460 Renal haemorrhage Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 241000223254 Rhodotorula mucilaginosa Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241001137860 Rotavirus A Species 0.000 description 1
- 241001137861 Rotavirus B Species 0.000 description 1
- 241001506005 Rotavirus C Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 241001279364 Stachybotrys chartarum Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 102100026134 Tissue factor pathway inhibitor 2 Human genes 0.000 description 1
- CRPUJAZIXJMDBK-UHFFFAOYSA-N Toxaphene Natural products C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000025845 adhesion to host Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- XCSGPAVHZFQHGE-UHFFFAOYSA-N alachlor Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl XCSGPAVHZFQHGE-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940061641 androsterone Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 210000001084 basket cell Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 210000000741 bile canaliculi Anatomy 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Chemical class [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 210000004375 bundle of his Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 231100001157 chemotherapeutic toxicity Toxicity 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- BIWJNBZANLAXMG-YQELWRJZSA-N chloordaan Chemical compound ClC1=C(Cl)[C@@]2(Cl)C3CC(Cl)C(Cl)C3[C@]1(Cl)C2(Cl)Cl BIWJNBZANLAXMG-YQELWRJZSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- KFUSEUYYWQURPO-UPHRSURJSA-N cis-1,2-dichloroethene Chemical group Cl\C=C/Cl KFUSEUYYWQURPO-UPHRSURJSA-N 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008828 contractile function Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- SYJFEGQWDCRVNX-UHFFFAOYSA-N diquat Chemical compound C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 SYJFEGQWDCRVNX-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- DFBKLUNHFCTMDC-GKRDHZSOSA-N endrin Chemical compound C([C@@H]1[C@H]2[C@@]3(Cl)C(Cl)=C([C@]([C@H]22)(Cl)C3(Cl)Cl)Cl)[C@@H]2[C@H]2[C@@H]1O2 DFBKLUNHFCTMDC-GKRDHZSOSA-N 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 210000000105 enteric nervous system Anatomy 0.000 description 1
- 230000000688 enterotoxigenic effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 210000000185 follicular epithelial cell Anatomy 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 1
- 229940097068 glyphosate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- FRCCEHPWNOQAEU-UHFFFAOYSA-N heptachlor Chemical compound ClC1=C(Cl)C2(Cl)C3C=CC(Cl)C3C1(Cl)C2(Cl)Cl FRCCEHPWNOQAEU-UHFFFAOYSA-N 0.000 description 1
- CKAPSXZOOQJIBF-UHFFFAOYSA-N hexachlorobenzene Chemical compound ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl CKAPSXZOOQJIBF-UHFFFAOYSA-N 0.000 description 1
- VUNCWTMEJYMOOR-UHFFFAOYSA-N hexachlorocyclopentadiene Chemical compound ClC1=C(Cl)C(Cl)(Cl)C(Cl)=C1Cl VUNCWTMEJYMOOR-UHFFFAOYSA-N 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003948 insulin detemir Drugs 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002032 lab-on-a-chip Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000003910 liver physiology Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000001053 micromoulding Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002048 multi walled nanotube Substances 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 239000002074 nanoribbon Substances 0.000 description 1
- 239000002073 nanorod Substances 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940053934 norethindrone Drugs 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NQQVFXUMIDALNH-UHFFFAOYSA-N picloram Chemical compound NC1=C(Cl)C(Cl)=NC(C(O)=O)=C1Cl NQQVFXUMIDALNH-UHFFFAOYSA-N 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000010069 protein adhesion Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000009613 pulmonary function test Methods 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- ODCWYMIRDDJXKW-UHFFFAOYSA-N simazine Chemical compound CCNC1=NC(Cl)=NC(NCC)=N1 ODCWYMIRDDJXKW-UHFFFAOYSA-N 0.000 description 1
- 239000002109 single walled nanotube Substances 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005127 stratified epithelium Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229950011008 tetrachloroethylene Drugs 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- OEJNXTAZZBRGDN-UHFFFAOYSA-N toxaphene Chemical compound ClC1C(Cl)C2(Cl)C(CCl)(CCl)C(=C)C1(Cl)C2(Cl)Cl OEJNXTAZZBRGDN-UHFFFAOYSA-N 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- KFUSEUYYWQURPO-OWOJBTEDSA-N trans-1,2-dichloroethene Chemical group Cl\C=C\Cl KFUSEUYYWQURPO-OWOJBTEDSA-N 0.000 description 1
- ZXFXBSWRVIQKOD-UHFFFAOYSA-N trans-heptachlor epoxide Natural products ClC1=C(Cl)C2(Cl)C3C4OC4C(Cl)C3C1(Cl)C2(Cl)Cl ZXFXBSWRVIQKOD-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 238000001039 wet etching Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/34—Internal compartments or partitions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/02—Membranes; Filters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/08—Chemical, biochemical or biological means, e.g. plasma jet, co-culture
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0668—Trapping microscopic beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0645—Electrodes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
Definitions
- the inventions provided herein relate to organ chips and applications thereof, e.g., analysis of drug efficacy, toxicity, and/or pharmacodynamics using one or a plurality of the organ chips.
- Pharmacokinetics is the study of the action of pharmaceuticals and other biologically active compounds from the time they are introduced into the body until they are eliminated.
- the sequence of events for an oral drug can include absorption through the various mucosal surfaces, distribution via the blood stream to various tissues, biotransformation in the liver and other tissues, action at the target site, and elimination of drug or metabolites in urine or bile.
- Pharmacokinetics provides a rational means of approaching the metabolism of a compound in a biological system.
- Organ chips are microfluidic devices that are configured to mimic at least one physiological function and/or response of organs of interest, e.g., from a mammal (e.g., a human), other animal or organism, an insect, or a plant.
- organ chips or organ-on-a-chip devices can be microfluidic devices that comprise at least one type of living cells, e.g., at least one type of tissue cells, cultured therein and are designed to recapitulate the three-dimensional (3D) tissue-tissue interfaces, mechanically active microenvironments, electrical stimulation, chemical conditions and/or complex organ-level functions.
- organ chips described herein can include but are not limited to, lung chips to mimic breathing lungs, heart chips to mimic beating hearts, liver chips to mimic metabolic livers, kidney chips to mimic filtering kidney, gut chips to mimic peristalsing guts, lung airway smooth muscle chips to mimic reactive airways, skeletal muscle chips to mimic contracting skeletal muscles, skin chips to mimic skin barriers, brain chips to mimic blood-brain barriers, testis chips to mimic reproductive/endocrine testes and bone marrow chips to mimic self-renewing bone marrow.
- an organ chip or organ-on-a-chip device can be configured to represent a functional microenvironment of an organ (e.g., a functional unit or section of an organ, and/or a tissue-capillary interface).
- a lung-mimicking chip or lung-on-a-chip
- the lung-on-chip can be configured to mimic the interaction of capillary cells and air sac cells in an alveolus (air sac) under a mechanical stimulation (e.g., breathing).
- the two different cell types can be cultured on opposing sides of a flexible porous membrane disposed in a channel of a microfluidic device.
- the flexible porous membrane can expand and contract to mimic the movement of an alveolar wall during lung breathing, by controlling the pressure gradient induced in the microfluidic device.
- living human cells can be cultured in organ chips described herein to mimic at least one physiological function and/or response of the corresponding human organs.
- organ chips described herein to mimic at least one physiological function and/or response of the corresponding human organs.
- microengineered human organ chips are also provided herein.
- a plurality of (e.g., 2 or more) organ chips representing various organs can be assembled or connected (e.g., fluidically connected) together to form an in vitro microphysiological system that mimics at least one physiological function and/or response of one or more systems in vivo, e.g., including, but not limited to, a circulatory system, a respiratory system, an excretory system, a nervous system, a gastrointestinal system, or any combinations thereof.
- another aspect provided herein relates to an in vitro microphysiological system that comprises at least two organ chips described herein or more, e.g., at least three organ chips, at least four organ chips or more.
- the in vitro microphysiological system can be used to model or study mammalian (e.g., human) organs and physiological systems and effects of active agents on such organs and physiological systems.
- the in vitro microphysiological system can be used to model or study organs and physiological systems of other animals (e.g., non-mammals), insects and/or plants, as well as effects of active agents on such organs and physiological systems.
- Kits comprising a plurality of organ chips, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more organ chips are also provided herein.
- the organ chips in the kit can be all the same, i.e., corresponding to the same organ.
- at least some of the organ chips in the kit can represent a different organ.
- a kit directed to a circulatory system can comprise at least one heart chip and at least one bone-marrow chip.
- a kit directed to a gastrointestinal system can comprise at least one liver chip and at least one gut chip.
- the kits can comprise a plurality of distinct organ chips that are involved in the microphysiological system.
- the organ chips can each be individually packaged, e.g., for sterility purposes.
- the kits can further comprise at least one agent, e.g., an appropriate culture medium for each different organ chip.
- the kits can further comprise an instruction manual, e.g., instructions on connecting various organ chips together to form an integrated network.
- the organ chips, microphysiological systems and/or kits described herein can be used for various applications where simulation of a physiological condition is desirable, e.g., drug screening, PK/PD studies, engineered scaffolds for tissue/organ repair or replacement, and/or development of a disease model of interest.
- the cells cultured in the organ chips can be collected from a subject, e.g., for personalized therapeutic treatment.
- subject-specific cells can be cultured in an organ chip or a microphysiological system simulated for a disease or disorder that the subject is diagnosed of, or suspected of having, and subjected to various kinds and/or dosages of drugs to determine an optimal treatment regimen for the subject.
- FIG. 1 is an image showing one embodiment of a lung-on-a-chip described herein, inside which the breathing of a lung is stimulated.
- the lung-on-a-chip comprises ports for nutrient delivery, waste disposal, and/or creation of a pressure gradient to mimic breathing.
- FIGS. 2A-2B are schematic representations of a lung-on-a chip in accordance with one embodiment described herein.
- FIG. 2A is a schematic representation showing an exemplary configuration of a lung-on-a-chip.
- FIG. 2B is a schematic representation showing movement (e.g., stretching) of a flexible porous membrane under application of vacuum to side chambers of the lung-on-a-chip.
- FIGS. 3A-3C shows that human lung-on-a-chip can be used to predict TL-2 chemotherapy toxicity (vascular leakage) responses based on mimicry of the lung's dynamic mechanically-active (breathing) microenvironment.
- FIGS. 4A-4D is a set of images showing that a contractile heart (muscle) chip mimics tissue organization ( FIG. 4A ) in a multiplexed array of “muscular thin films” (MTFs) within a microfluidic device ( FIGS. 4B and 4C ), which can be used to quantitate contractile stress in real-time ( FIG. 4D ).
- a contractile heart (muscle) chip mimics tissue organization ( FIG. 4A ) in a multiplexed array of “muscular thin films” (MTFs) within a microfluidic device ( FIGS. 4B and 4C ), which can be used to quantitate contractile stress in real-time ( FIG. 4D ).
- MTFs muscle thin films
- FIG. 5 is a set of line graphs showing that “muscular thin films” MTFs mimic whole heart tissue drug responses.
- Top row shows the dose response of engineered neonatal rat ventricular tissues in the form of muscular thin films on the heart chip, treated with calcium (left), caffeine (middle), and isoproterenol (right).
- the bottom row shows the corresponding responses of adult rat ventricular strips.
- FIG. 6 is a schematic representation showing a series of exemplary assembly steps for one embodiment of a muscular thin film contractility assay based on a PDMS thin film.
- FIG. 7 is a schematic representation showing a series of exemplary assembly steps for one embodiment of a muscular thin film contractility assay based on a patterned alginate thin film.
- FIG. 8 is a schematic diagram showing exemplary features of a heart chip according to one embodiment described herein.
- (i) depicts a dual-chamber system with a single medium stream that feeds 2 chambers: an electrophysiological (EPhys) chamber and a MTF chamber;
- EPhys electrophysiological
- MTF multi-chamber chamber
- the EPhys chamber can allow electrophysiological recordings on a monolayer of cardiac muscle in a low volume chamber with micro-electrodes embedded in the bottom of the chamber;
- a larger chamber situated next to the EPhys chamber can allow high throughput contractility measurements using an array of muscular thin films;
- the MTF chamber consists of an anisotropic layer of cardiac myocytes cultured on laser-cut horizontal MTFs whose radius of curvature can be measured optically.
- FIGS. 9A-9B is a set of schematic diagrams showing an alternative technology to monitor cellular contraction.
- FIG. 9A shows that cell monolayers are adhered to a deformable, perforated membrane within a microfluidic device (i & ii).
- FIG. 9B shows that as the muscle cell layer contracts, the substrate deforms, such that the morphology of the holes within the substrate is altered (i & ii).
- the morphology of the holes within the substrate can be monitored optically to determine the state of cellular contraction, with undeformed holes representing the relaxed state ( FIG. 9A , ii) and deformed holes representing the contracted state ( FIG. 9B , ii).
- the eccentricity of the holes can be evaluated with specifically-programmed algorithms, e.g., software (e.g., DBG software) originally designed to quantify nuclear eccentricity.
- FIGS. 10A-10D is a set of data showing physiological responses of human vascular smooth muscle (VSM) and engineered rat cardiac muscle (CM) on the same chip to drugs determined by a MTF assay.
- FIG. 10A is a schematic representation showing manufacture of an organ chip with two different kinds of muscle (striated and smooth).
- FIG. 10B is a set of data showing MTF deformation (i, v, ix), CM diastole (ii, vi, x), CM peak systole (iii, vii, xi), and CM stress (iv, viii, xii), before and after exposure to drugs (e.g., ET-1, and ROCK inhibitor) during the contractility assay.
- FIGS. 10C and 10D are data graphs showing the contractility of the VSM is considerably slower than the CM and the stress histories are depicted uniquely for each one.
- FIGS. 11A-11F are images showing a human gut chip according to one embodiment described herein.
- FIG. 11A is a schematic representation showing a portion of a human gut chip that mimics normal villus architecture of the intestine.
- FIGS. 11B-11D shows that a gut chip can mimic normal villus architecture of the intestine, in part by leveraging the lung-on-a-chip (or lung chip) mechanically activated, multi-layered microfluidic architecture ( FIG. 11B ) to rhythmically distort the epithelium as normally occurs during peristalsis ( FIGS. 11C-11D ).
- FIG. 11E is an image showing perfusion of cells in the device.
- FIG. 11F is an image showing perfusion of cells in the device can maintain cell viability for weeks and result in formation of villi that take the height of the Interstitial Channel.
- FIG. 12 is a schematic diagram showing architecture of human blood-brain-barrier and an organ chip that mimics the blood-brain-barrier.
- the normal architecture of the human blood brain barrier (top panel) is mimicked by culturing human endothelium on one side of a porous membrane and human astrocytes on the other side within a microfluidic channel with platinum electrodes embedded therein (bottom panel).
- FIG. 13 is a schematic diagram showing exemplary features of a skeletal muscle chip according to one embodiment described herein.
- (i) depicts a dual-chamber system with a single medium stream that feeds 2 chambers: an electrophysiological (EPhys) chamber and an MTF chamber;
- EPhys electrophysiological
- MTF muscular thin films
- FIG. 14 is a schematic representation of functional readouts from a co-culture of skeletal muscle and adipocyte layers, for example, using the skeletal muscle chip shown in FIG. 13 .
- (i) shows an electrophysiological (EPhys) chamber, which allows EMG recordings on a monolayer of a co-culture of adipose and skeletal muscle.
- (ii) shows a MTF chamber with an array of muscular thin films (MTFs) built from a heterogeneous co-culture of skeletal muscle and adipose tissue.
- EPhys electrophysiological
- MTFs muscular thin films
- FIGS. 15A-15C are data showing anisotropic cardiac tissue formation on micromolded alginate substrates.
- FIG. 15A is data showing that the micromolding technique replicates faithfully the original pattern.
- FIG. 15B is a phase contrast image of representative tissues.
- FIG. 15C is an immunofluorescence composite image of muscular thin films: actin is red, nuclei are blue and ⁇ -actinin is green. Scale bar equals 50 ⁇ m.
- alginate micromolded surfaces can be used to align and culture skeletal muscle cells (e.g., myotubes) in a 3-D like environment, instead of a 2-D flat substrate.
- FIGS. 16A-16B is a set of schematic representation showing an airway chip according to one embodiment described herein.
- FIG. 16A is a schematic diagram showing an airway on a chip, in one embodiment, can comprise healthy bronchial tissue, cultured in liquid media (i), e.g., with a capability of drug perfusion (ii).
- the cell monolayer can exhibit a linear arrangement of cells, adhered to the top surface of a PDMS muscular thin film.
- Incubation in culture media no drug or test agent
- incubation with drugs can yield contracted bronchial thin films (iv).
- the contractility can be measured for grading the drug response in the tissue.
- 16B is a schematic representation of exemplary dimensions of an airway chip containing multiple bronchial thin films (i), with an optional capability to add a layer of epithelial columnar cells (ii).
- This cell layer can be adhered to a porous membrane that separates the bronchial from epithelial cells, and be exposed to air flow, aerosols or a combination thereof.
- FIGS. 17A-17B are schematic representation showing exemplary features of an airway chip with two chambers in accordance with one embodiment described herein.
- FIG. 17A is a schematic representation of an airway on a chip with two chambers.
- Chamber 1 can contain healthy bronchial tissue, while an asthmatic phenotype can be contained in Chamber 2.
- the asthmatic phenotype can comprise cultures from human diseased cells or cells that are induced artificially (e.g., by toxic agents, temperature) to display at least one phenotype of diseased cells
- Chambers 1 and 2 can be cultured in liquid media (i) with an optional capability of drug perfusion (ii).
- FIG. 17B is a schematic representation of exemplary dimensions of an airway chip containing multiple bronchial thin films (i), with an optional capability to add a layer of epithelial columnar cells (ii). This epithelial cell layer can be adhered to a porous membrane that separates the bronchial muscle from the epithelium, and be exposed to air flow, aerosols, or a combination thereof.
- FIGS. 18A-18B are schematic diagrams showing an alternative technology to monitor cellular contraction.
- FIG. 18A shows that cell monolayers can be adhered to a “swiss cheese”-like substrate or a deformable, perforated membrane, situated within a microfluidic device (i & ii).
- FIG. 18B shows that as the muscle cell layer contracts, the substrate deforms, such that the morphology of the holes within the substrate is altered (i & ii).
- the morphology of the holes within the substrate can be monitored optically to determine the state of the cellular contraction, with undeformed holes representing the relaxed state ( FIG. 18A , ii) and deformed holes representing the contracted state ( FIG. 18B , ii).
- the eccentricity of the holes can be evaluated with a specifically-programmed algorithm, e.g., software (e.g., DBG software) originally designed to quantify nuclear eccentricity.
- FIGS. 19A-19B shows an exemplary setup of a multiple film chip experiment and collected data from a human asthma (e.g., a chemically-induced human asthma) induced on one embodiment of an organ chip.
- FIG. 19A is a schematic diagram showing exemplary manufacture of an organ chip comprising human bronchial smooth muscle thin films.
- FIG. 19B show data comparing the phenotypes and/or behavior of control cells and diseased cells (induced with asthma) in the organ chip.
- (i) and (ii) show actin staining of healthy engineered tissue and the chemically induced asthma model, respectively. Differences in actin alignment within the tissue constructs, as indicated by the orientational order parameter (iii) indicates significant remodeling of the contractile apparatus.
- Drug experiments (iv for healthy and v for asthma model) indicate differences in the contractile response to acetylcholine (AcH) and to a Rho kinase inhibitor (HA 1077 ).
- (vi) is a plot graph showing percentages of cell contraction and relaxation for control (healthy) and asthma models.
- FIG. 20 is a set of data showing that a synthetic bone marrow (sBM) can fully recapitulate natural mouse bone marrow (mBM) but not peripheral blood (mPB) 8 weeks after implanting an organ chip with differentiated blood cells (DMPs) or hematopoietic stem and progenitor stem cells (BMPs) subcutaneously. Similar functionality can be maintained in vitro by culturing in a microfluidic device the sBM explant.
- DMPs differentiated blood cells
- BMPs hematopoietic stem and progenitor stem cells
- organ chips also used interchangeably herein with the term “organ-on-a-chip devices”
- organ-on-a-chip devices can be configured as microfluidic devices to mimic at least one physiological function and/or response of different organs, and can be used to create in vitro microphysiological systems.
- organ chips or organ-on-a-chip devices can be microfluidic devices that comprise at least one type of living cells (e.g., mammalian cells such as human cells) cultured therein and are designed to recapitulate the three-dimensional (3D) tissue-tissue interfaces, mechanically active microenvironments, electrical stimulation, chemical conditions and/or complex organ-level functions.
- living cells e.g., mammalian cells such as human cells
- organ chips described herein include, but are not limited to, lung chips to mimic breathing lung, heart chips to mimic beating heart, liver chips to mimic metabolic liver, kidney chips to mimic filtering kidney, gut chips to mimic peristalsing gut, lung airway smooth muscle chips to mimic reactive airway, skeletal muscle chips to mimic contracting skeletal muscle, skin chips to mimic skin barrier, brain chips to mimic blood-brain barrier, testis chips to mimic reproductive/endocrine testis, bone marrow chips to mimic self-renewing bone marrow, and any combinations thereof.
- an organ chip or organ-on-a-chip device described herein can be configured to represent a functional microenvironment of an organ (e.g., a functional unit or section of an organ, and/or a tissue-capillary interface), e.g., but not limited to, an alveolar-capillary interface of a lung, a blood-brain-barrier of a brain, or a skin bather of a skin.
- a lung-mimicking chip or lung-on-a-chip, which is further described below, does not necessarily need to mimic the structure of a whole lung.
- the lung-on-chip can be configured to mimic the interaction of capillary cells and air sac cells in an alveolus (air sac) under a mechanical stimulation (e.g., breathing).
- the two different cell types e.g., capillary cells and air sac cells
- the flexible porous membrane can expand and contract to mimic the movement of an alveolar wall during lung breathing, by controlling the pressure gradient induced in the microfluidic device.
- the organ chips can be used, individually or connected together (e.g., fluidically connected), for various applications where simulation of a physiological condition is desirable, e.g., drug screening, pharmacokinetics (PK)/pharmacodynamics (PD) studies, engineered scaffolds for tissue/organ repair or replacement, development of a disease model, and/or personalized therapeutic treatment.
- PK pharmacokinetics
- PD pharmacodynamics
- fluidically connected refers to two or more organ chips connected in an appropriate manner such that a fluid or a least a portion of a fluid (e.g., any flowable material or medium, e.g., but not limited to, liquid, gas, suspension, aerosols, cell culture medium, and/or biological fluid) can directly or indirectly pass or flow from one organ chip to another organ chip.
- a fluid or a least a portion of a fluid e.g., any flowable material or medium, e.g., but not limited to, liquid, gas, suspension, aerosols, cell culture medium, and/or biological fluid
- two or more organ chips can be fluidically connected together, for example, using one or more fluid-transfer connecting means (e.g., adaptors, tubing, splitters, valves, pumps and/or channels) between the two or more organ chips.
- two or more organ chips can be fluidically connected by connecting an outlet of one organ chip to an inlet of another organ chip using tubing, a conduit, a channel, piping or any combinations thereof.
- two or more organ chips can be fluidically connected by, e.g., at least one pumping device and/or at least one valve device.
- the pumping device and/or valve device can be configured for microfluidic applications, e.g., the membrane-based fluid-flow control devices as described in U.S. Provisional Application No. 61/735,206 filed Dec. 10, 2012, the content of which is incorporated herein by reference in its entirety.
- two or more organ chips can be fluidically connected together when one or more other connecting means (e.g., devices, systems, and/or modules that can perform an additional function other than fluid transfer, e.g., but not limited to, filtration, signal detection, and/or imaging) are present between the two or more organ chips.
- one or more other connecting means e.g., devices, systems, and/or modules that can perform an additional function other than fluid transfer, e.g., but not limited to, filtration, signal detection, and/or imaging
- two or more organ chips can be fluidically connected, when the two or more organ chips are indirectly connected, e.g., through a biosensor, a filter, and/or an analytical instrument (e.g., via tubing), such that a fluid exiting the previous organ chip can be detoured to first flow through the biosensor, filter and/or analytical instrument, e.g., for detection, analysis and/or filtration of the fluid, before it enters the next organ chip.
- at least a portion of the fluid can pass or flow from one organ chip to another organ chip.
- two or more organ chips can be fluidically connected by, e.g., at least one bubble trap, e.g., the bubble trap can be a membrane-based bubble trap as described in U.S. Provisional Application No. 61/696,997, filed Sep. 5, 2012, and U.S. Provisional Application No. 61/735,215 titled “Cartridge Manifold and Membrane Based-Microfluidic Bubble Trap,” filed on Dec. 10, 2012, the contents of both of which are incorporated herein by reference in their entireties.
- two or more organ chips can be connected such that a fluid can pass or flow directly from one organ chip to another organ chip without any intervening components.
- the two or more organ chips can be designed and/or integrated on the same chip such that the outlet of one organ chip and the inlet of another organ chip share the same port.
- one or more organ chips e.g., heart chips
- one or more organ chips can be adapted to fluidically connected upstream and/or downstream to at least one or more different organ chips (e.g., but not limited to lung chips or liver chips) to form an in vitro microphysiological system, which can be used to determine biological effects (e.g., but not limited to, toxicity, and/or immune response) of active agents on more than one organs.
- organ chips e.g., heart chips
- organ chips e.g., but not limited to lung chips or liver chips
- active agents include, but are not limited to, cells (including, e.g., but not limited to, bacteria and/or virus), proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, therapeutic agents, molecular toxins, nanomaterials, particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof.
- the in vitro microphysiological system can be used to evaluate active agents that are effective in treating a disease or disorder in an organ, but might be toxic to other organ systems.
- a drug e.g., Ventolin
- a drug known to treat or prevent bronchospasm in subjects with reversible obstructive airway disease can be toxic to or adversely affect heart function.
- integration of two or more organ chips to form an in vitro microphysiological system can allow for testing or screening of drugs that are effective in treatment of a certain disease or disorder with minimal side effects or undesirable effects on other organs.
- in vitro microphysiological systems each of which mimics at least one physiological function and/or response of one or more systems in vivo, e.g., of a mammal (e.g., a human), other animal, insect and/or plant.
- the in vitro microphysiological systems described herein can mimic at least one physiological function and/or response of one or more systems in vivo, e.g., of a mammal (e.g., a human), including, e.g., but not limited to, a circulatory system, a respiratory system, an excretory system, a nervous system, a gastrointestinal system, or any combinations thereof.
- the in vitro microphysiological systems described herein are generally formed by connecting (e.g., fluidically connecting) together at least two organ chips representing different organs described herein. Different combinations of organ chips can be used in the system for different applications.
- a plurality of organ chips e.g., at least 1, at least 2, at least 3, at least 4, at least 5 or more organ chips
- Lung Chips, Heart Chips and Liver Chips can be selected to form an in vitro microphysiological system, e.g., for determination of clinically relevant pharmacokinetics (PK)/pharmacodynamics (PD) as well as efficacy and toxicity (e.g., cardiotoxicity, which is the cause of more than 30% of all drug failures).
- PK pharmacokinetics
- PD pharmacodynamics
- efficacy and toxicity e.g., cardiotoxicity, which is the cause of more than 30% of all drug failures.
- the in vitro microphysiological system can further comprise a bone marrow chip fluidically connected to the at least two different organ chips.
- the bone marrow chip described in the International Appl. No. PCT/US12/40188, the content of which is incorporated herein by reference in its entirety, can be utilized in the in vitro microphysiological system described herein.
- the in vitro microphysiological system can further comprise a spleen chip fluidically connected to the at least two different organ chips.
- the spleen chip described in the International Appl. No. WO 2012/135834, the content of which is incorporated here by reference in its entirety, can be utilized in the in vitro microphysiological system described herein.
- the in vitro microphysiological systems comprising a combination (e.g., at least 2 or more) of different organ chips can be disposed in a housing and/or the universal cartridges that can hold one or more organ chips as described in the U.S. Provisional Appl. Nos. 61/569,004 filed Dec. 9, 2011 and 61/696,997 filed Sep. 5, 2012, the contents of which are incorporated herein by reference in their entireties.
- a housing to enclose various combinations of organ chips therein can provide functionalities, e.g., but not limited to temperature control, nutrient replenishment, pressure adjustment, imaging, sample analysis, and/or any combinations thereof.
- An organ chip can also include a microfluidic device which can mimic at least one physiological function of at least one living organ from a mammal (e.g., human), other animal, insect or plant.
- an organ chip can be a microfluidic device which can mimic at least one physiological function of one mammalian (e.g., human) organ.
- an organ chip can be a microfluidic device which can mimic physiological function of at least one (including 1, 2, 3, 4, 5, 6, 7 or more) mammalian (e.g., human) organs.
- the organ chips mimic physiological functions of more than one mammalian (e.g., human) organs
- the organ chips can comprise individual sub-units, each of which can mimic physiological function of one specific mammalian (e.g., human) organ.
- the in vitro microphysiological system can comprise at least two different organ chips (e.g., each organ chip representing a different organ) and at least one or more connecting means (e.g., at least two or more connecting means) between the at least two different organ chips.
- organ chips e.g., each organ chip representing a different organ
- connecting means e.g., at least two or more connecting means
- a first organ chip can comprise: a body comprising a central channel therein, and an least partially porous and at least partially flexible first membrane positioned within the central channel and along a plane, wherein the first membrane is configured to separate the central channel to form two sub-channels, wherein one side of the first membrane is seeded with vascular endothelial cells, and the other side of the first membrane is seeded with at least one type of organ-specific parenchymal cells; and
- a second organ chip can comprise: a body comprising a first chamber enclosing a plurality of muscular thin films adapted to measure contraction of muscle cells, and a second chamber comprising a layer of muscle cells on the bottom surface of the second chamber, wherein the bottom surface is embedded with an array of microelectrodes for recording of action potentials, and wherein the top surface of the second chamber is placed with at least a pair of electrodes for providing electric field
- the at least two different organ chips can comprise at least two or more (e.g., 2, 3, 4, 5, or more) said first organ chips described herein.
- the at least to different organ chips can comprise a lung chip described herein and a gut chip described herein.
- the at least to different organ chips can comprise a lung chip described herein and a liver chip described herein.
- the at least two different organ chips can comprise at least two or more (e.g., 2, 3, 4, 5, or more) said second organ chips described herein.
- the at least two different organ chips can comprise at least one (e.g., 1, 2, 3, 4, 5 or more) said first organ chips described herein and at least one (e.g., 1, 2, 3, 4, 5, or more) said second organ chips described herein.
- the design and/or configuration of the first and second organ chips described herein generally provide the basis for development and construction of various organ chips, e.g., but not limited to, lung chips, liver chips, gut chips, kidney chips, heart chips, skin chips, brain chips, testis chips, skeletal muscle chips, lung airway smooth muscle chips (“airway chips”), and any combinations thereof.
- organ chips e.g., but not limited to, lung chips, liver chips, gut chips, kidney chips, heart chips, skin chips, brain chips, testis chips, skeletal muscle chips, lung airway smooth muscle chips (“airway chips”), and any combinations thereof.
- the organ chips can be designed to have a common shape and have positioned inlets and outlets for delivery of fluids to the Microvascular and Interstitial fluid channels lined by microvascular endothelium and organ-specific parenchymal cells (e.g., but not limited to, alveolar epithelium, heart muscle, hepatocytes), respectively.
- microvascular endothelium and organ-specific parenchymal cells e.g., but not limited to, alveolar epithelium, heart muscle, hepatocytes
- Organ chips generally comprise a base substrate and at least one channel disposed therein.
- the number and dimension of channels in an organ chip can vary depending on the design, dimension and/or function of the organ chip.
- an organ chip can comprise a plurality of channels (e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten or more channels).
- channels e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten or more channels.
- an organ chip can be constructed to comprise at least two, at least three, at least four, at least five identical channels.
- an organ chip can comprise at least two parallel (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) channels.
- an organ chip comprises four parallel channels, e.g., four identical parallel channels. Without wishing to be bound by theory, this configuration can provide quadruplicate read-outs per chip.
- the dimensions of the channels in the organ chips can each independently vary, e.g., depending on the channel function (e.g., as a conduit for fluid transfer or as a chamber for cell culture, e.g., for subsequent monitoring of cellular response), flow conditions, tissue microenvironment to be simulated, and/or methods for detecting cellular response.
- the cross-sectional dimensions of the channels can vary from about 10 ⁇ m to about 1 cm, or from about 100 ⁇ m to about 0.5 cm.
- the channels disposed in the organ chips can comprise cells.
- the channels can each be independently lined by one layer or multilayers of organ-specific parenchymal cell types (or differentiated cells) and/or vascular endothelium (a layer of vascular endothelial cells) in relevant tissue microenvironment (e.g., mechanochemical microenvironments), with or without intervening connective tissue cells (e.g., fibroblasts, smooth muscle cells, mast cells) or immune cells (e.g., neutrophils, macrophages).
- relevant tissue microenvironment e.g., mechanochemical microenvironments
- connective tissue cells e.g., fibroblasts, smooth muscle cells, mast cells
- immune cells e.g., neutrophils, macrophages
- the organ chips can be sized to a specific need, e.g., for high throughput drug screening, or scaffolding, e.g., for tissue repair and/or replacement.
- the organ chips can be implantable, and thus they can be sized to suit a target implantation site.
- the organ chips can be fabricated from any biocompatible materials.
- biocompatible materials include, but are not limited to, glass, silicons, polyurethanes or derivatives thereof, rubber, molded plastic, polymethylmethacrylate (PMMA), polycarbonate, polytetrafluoroethylene (TEFLONTM), polyvinylchloride (PVC), polydimethylsiloxane (PDMS), and polysulfone.
- organ chips can be fabricated from PDMS (poly-dimethylsiloxane).
- the organ chips can be disposable.
- the organ chips can be fabricated from one or more materials that allow sterilization (e.g., by UV, high temperature and/or pressure, ethylene oxide, or ethanol) after use.
- At least one channel of the organ chips can comprise one or more membranes, e.g., at least 1, at least 2, at least 3 or more membranes to separate the channel into sub-channels.
- the membrane can be rigid or at least partially flexible.
- the term “flexible” as used herein refers to a membrane that can be stretched and/or contracted by at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 60% or more, of its original length, without causing any macroscopic breaking, when a pressure is applied.
- a flexible membrane can fully or partially restore to its original length after the pressure is released.
- the membrane can be non-porous or at least partially porous.
- the pore size of the membrane can be large enough to allow cells pass through it. In some embodiments, the pore size of the membrane can be too small for cells to pass through, but large enough for nutrient or fluid molecules to pass through or permeate.
- the membrane can be non-coated or coated with extracellular matrix molecules (ECM) to facilitate cell adhesion (e.g., but not limited to, fibronectin, collagen, Matrigel, laminin, vitronectin, and/or any combinations thereof), other proteins such as growth factors or ligands (e.g., to facilitate cell growth and/or cell signaling).
- ECM extracellular matrix molecules
- the surface of the membrane can be modified and/or activated, e.g., with any art-recognized polymer surface modification techniques such that bioactive molecules, e.g., ECM molecules, carbohydrates, proteins such as growth factors or ligands, can be covalently or non-covalently attached to or coated on it.
- polymer surface modification such as wet chemical, organosilanization, ionized gas treatments, and UV irradiation can be used to modify the membrane to permit covalent conjugation of bioactive molecules to the modified surfaces, such as usage of hydrophilic, bifunctional, and/or branched spacer molecules. See, e.g., Goddard and Hotchkiss “Polymer surface modification for the attachment of bioactive compounds” Progress in Polymer Science, Volume 32, Issue 7, July 2007, Pages 698-725, for examples of polymer surface modification techniques.
- the material for the membrane can be selected for at least one of the following properties, but are not limited to: the material is (i) biocompatible, (ii) complies with IS 10993-5 (in vitro cytotoxicity tests for medical devices), (iii) has low absorption of hydrophobic dye/drug and other chemical compounds, (iv) is cell adhesive, (v) is optically clear, is highly flexible, moldable, bondable, (vi) has low autofluorescence, (vii) does not swell in water, or (viii) has any combinations of the aforementioned properties.
- the membrane material can include polyurethane (e.g., Clear flex 50 polyurethane).
- the membrane material can include PDMS.
- the membrane can be seeded with or without cells.
- cells can be seeded on one side or both sides of the membrane.
- both sides of the membrane can be seeded with the same cells.
- both sides of the membrane can be seeded with different cells, as described below, e.g., to create a Microvascular channel (comprising vascular endothelial cells) and an Interstitial channel (comprising organ-specific parenchymal cells).
- the membrane can be seeded with at least one layer of cells, including, at least 2 layers of cells or more. Each layer of cells can be the same or different.
- At least one channel or sub-channel of the organ chip can be filled with a gel or a hydrogel, e.g., but not limited to, collagen gel, matrigel gel, fibrin gel, or any combinations thereof.
- the gel can be seeded with or without cells.
- At least one channel or sub-channel of the organ chip can contain a tissue, e.g., a biopsy collected from a subject.
- the inner surface(s) of the channel(s) (or channel walls) and/or membrane(s) that are in contact with a fluid can be modified for reducing non-specific binding of a species in the fluid to the inner surface(s) of the channel(s).
- a fluid e.g. a liquid or a gas
- at least one surface of the channel(s) and/or membrane(s) in contact with the fluid can be coated with a surfactant, e.g., PLURONIC® 127, or a blocking protein such as bovine serum albumin, for reducing cell or protein adhesion thereto.
- a surfactant e.g., PLURONIC® 127
- a blocking protein such as bovine serum albumin
- Additional surfactant that can be used to reduce the adhesive force between the surface of the channel and non-specific binding of a species in a fluid sample can include, but are not limited to, hydrophilic (especially amphipathic) polymers and polymeric surface-acting agents; non-ionic agents such as polyhydric alcohol-type surfactants, e.g., fatty acid esters of glycerol, pentaerythritol, sorbitol, sorbitan, and more hydrophilic agents made by their alkoxylation, including polysorbates (TWEEN®); polyethylene glycol-type surfactants such as PLURONIC surfactants (e.g., poloxamers), polyethylene glycol (PEG), methoxypolyethylene glycol (MPEG), polyacrylic acid, polyglycosides, soluble polysaccharides, dextrins, microdextrins, gums, and agar; ionic agents, including anionic surfactants such as salts of carboxylic acids (
- a skilled artisan will readily be able to determine appropriate methods and/or reagents for use to reduce non-specific binding of a species in a fluid to the channel wall(s) and/or membranes, based on the substrate material of the microfluidic devices and/or types of species to be blocked.
- micro-post there can be at least one micro-post, including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more micro-posts within one or more channels.
- the dimension and/or arrangement of the micro-posts can be determined by a user.
- the micro-posts can be used to separate cell debris from a flowing fluid to prevent clogging the downstream channel.
- the micro-posts can be coated with an agent (e.g., antibodies) that permits capture of specific cells.
- the organ chips can comprise a plurality of ports.
- the organ chips can comprise at least one inlet port for introducing culture medium, nutrients or test agents such as drugs into the organ chips, and at least one outlet port for a fluid to exit.
- at least one port can be connected to a pump or a syringe, e.g., via a tubing, to facilitate the fluid transfer through the channel and/or to apply a pressure to the channel.
- at least one port can be connected to at least one electrical component, e.g., an electrode for ECG measurement.
- at least one port can be connected to a nebulizer, e.g., to generate aerosolized liquid for aerosol delivery.
- At least one port can be connected to or interfaced with a processor, which stores and/or analyzes the signal from a biosensor incorporated therein.
- the processor can transfer the data to computer memory (either hard disk or RAM) from where it can be used by a software program to further analyze, print and/or display the results.
- the organ chips can have control ports, e.g., for application of mechanical deformation (e.g., side chambers to apply cyclic vacuum, as in the Lung Chip described herein and in the International Application No.: WO 2010/009307, the contents of which are incorporated herein by reference in their entireties) and/or electrical connections (e.g., for electrophysiological analysis of muscle and nerve conduction).
- any fluid control elements can be incorporated into the organ chips and/or in vitro microphysiological systems to modulate the fluid flow.
- bubble traps can be integrated into each organ chip and/or in vitro microphysiological systems to minimize the effects of any bubbles that may form in the pumps, valves, or tubing.
- microsensors or biosensors can also be integrated into the organ chips and/or in vitro microphysiological systems for controlling the culture conditions and/or monitoring the response of cells to the culture conditions.
- Any art-recognized biosensors e.g., thin enzyme electrodes (Ref. 5) and/or microphysiometers (Ref. 6) can be used in any embodiments of the organ chips and/or in vitro microphysiological systems described herein.
- organ chips can be oxygenated either through a porous material used in the construction of the organ chips (e.g., PDMS) or using on-cartridge or systemic gas exchange membranes.
- a porous material used in the construction of the organ chips (e.g., PDMS) or using on-cartridge or systemic gas exchange membranes.
- An organ chip can be produced with or without aerosol delivery capabilities.
- an organ chip can be adapted to deliver an aerosol, e.g., comprising an active agent described herein, to cells cultured in the channels.
- aerosol e.g., comprising an active agent described herein
- Detailed information about various designs and configurations of microfluidic devices for aerosol delivery can be found, e.g., in the International Application No. WO 2012/154834, the contents of which are incorporated herein by reference in their entireties.
- the design of each organ chip can be different according to their respective physiological properties and/or functions.
- the organ chips can differ in, e.g., but not limited to, cell populations (e.g., cell types and/or initial cell seeding density), internal design, microarchitecture, dimensions, fluidic control, mechanical and electrical control and read-outs depending on the organ type (e.g., Lung Chip versus Heart Chip).
- the organ chips can be designed to have a common shape and have positioned inlets and outlets for delivery of fluids to the Microvascular channels lined by microvascular endothelium and Interstitial fluid channels lined by organ-specific parenchymal cells (e.g., but not limited to, alveolar epithelium, heart muscle, hepatocytes). See, e.g., the section ““Examples of organ chips or organ-on-a-chip devices” for exemplary design of various organ chips based in part on the two basic organ chips (e.g., Lung chips and Heart chips) described herein.
- organ-specific parenchymal cells e.g., but not limited to, alveolar epithelium, heart muscle, hepatocytes.
- organ chips described herein can comprise additional cell types, e.g., but not limited to, immune cells, stromal cells, smooth muscle cells, neurons, lymphatic cells, adipose cells, and/or microbiome in gut, based on the goals of the application.
- additional cell types e.g., but not limited to, immune cells, stromal cells, smooth muscle cells, neurons, lymphatic cells, adipose cells, and/or microbiome in gut, based on the goals of the application.
- immune cells can be incorporated into the gut or liver chip accordingly.
- the viability and/or function of various organ chips can be generally assessed, e.g., morphologically with optical imaging.
- any other art-recognized characterization techniques can be used to determine the function of various organ chips.
- the alveolar-capillary interface function of the Lung Chip can be measured, e.g., by quantifying permeability barrier function (e.g., using TEER and molecular exclusion), measuring surfactant production, and/or demonstrating physiological relevant responses to cytokines (e.g., ICAM1 expression in response to TNF ⁇ ). See e.g., Huh D. et al., 2010.
- Heart muscle function can be characterized, e.g., using force-frequency curves, measuring increases in peak contraction stress as a function of increasing field stimulation frequency, and/or analyzing electrocardiogram results during the same protocol to ensure that the tissues are functioning electrically. See Grosberg A. et al. 2011. Functionality of the Liver Chip can be assessed, e.g., via multiple well established assays including albumin secretion, transporter expression and/or function (efflux and uptake transporters), and/or CYP450 expression.
- Specific CYP450 enzyme can be determined, e.g., by incubation with FDA approved probe substrates REF1, and specific metabolite formation for each CYP450 isoform can be measured and validated, e.g., using LC/MS.
- Response of hepatocytes to prototypical CYP450 inducers e.g., Rifampacin for CYP3A4 can be assessed.
- one of skill in the art can adjust the condition of the organ chips, e.g., by modulating the flow rate of fluid (fluid shear stress), nutrient level, mechanical stimulation, electrical stimulation, cell seeding density on the membranes, cell types, ECM composition on the membrane, dimension and/or shapes of the channels, oxygen gradient and any combinations thereof, to modulate the functional outcome of the organ chips, or the in vitro microphysiological system.
- Parenchymal cells are selected to suit for specific organ chips. Parenchymal cells are generally the distinct cells of an organ contained in and supported by the connective tissue framework. The parenchymal cells typically perform a function that is unique to the particular organ. In some embodiments, the term “parenchymal” can exclude cells that are common to many organs and tissues such as fibroblasts and endothelial cells within blood vessels.
- the parenchymal cells can include hepatocytes, Kupffer cells, epithelial cells that line the biliary tract and bile ductules, and any combinations thereof.
- the major constituent of the liver parenchyma are polyhedral hepatocytes (also known as hepatic cells) that presents at least one side to an hepatic sinusoid and opposed sides to a bile canaliculus.
- Liver cells that are not parenchymal cells include cells within the blood vessels such as the endothelial cells or fibroblast cells.
- the parenchymal cells can include myoblasts, satellite cells, myotubules, myofibers, and any combinations thereof.
- the parenchymal cells can include the myocardium also known as cardiac muscle fibers or cardiac muscle cells, the cells of the impulse connecting system such as those that constitute the sinoatrial node, atrioventricular node, atrioventricular bundle, and any combinations thereof.
- the parenchymal cells can include cells within the acini such as zymogenic cells, centroacinar cells, basal or basket cells, cells within the islets of Langerhans such as alpha and beta cells, and any combinations thereof.
- the parenchymal cells can include reticular cells, blood cells (or precursors to blood cells) such as lymphocytes, monocytes, plasma cells, macrophages, and any combinations thereof.
- parenchymal cells can include cells of collecting tubules, the proximal and distal tubular cells, and any combinations thereof.
- the parenchyma can include epithelial cells.
- the parenchymal cells can include cells that produce hormones.
- the parenchymal cells can include the principal cells (chief cells), oxyphilic cells, and a combination thereof.
- the parenchymal cells can include follicular epithelial cells, parafollicular cells, and a combination thereof.
- the parenchymal cells can include the epithelial cells within the adrenal cortex and the polyhedral cells within the adrenal medulla.
- the parenchymal cells can include epithelial cells, glandular cells, basal cells, goblet cells, and any combinations thereof.
- the parenchymal cells can include the epithelial cells, mucus cells, goblet cells, alveolar cells, and any combinations thereof.
- the parenchymal cells can include the epithelial cells of the epidermis, melanocytes, cells of the sweat glands, cells of the hair root, and any combinations thereof.
- the cells (e.g., parenchymal cells and/or vascular endothelial cells) used in the organ chips can be isolated from a tissue or a fluid of subject using any methods known in the art, or differentiated from stems cells, e.g., embryonic stem cells, or iPSC cells, or directly differentiated from somatic cells.
- stem cells can be cultured inside the organ chips and be induced to differentiate to organ-specific cells.
- the cells used in the organ chips can be obtained from commercial sources, e.g., Cellular Dynamics International, Axiogenesis, Gigacyte, Biopredic, InVitrogen, Lonza, Clonetics, CDI, and Millipore, etc.).
- the cells used in the organ chips can be differentiated from the “established” cell lines that commonly exhibit poor differentiated properties (e.g., A549, CaCo2, HT29, etc.). These “established” cell lines can exhibit high levels of differentiation if presented with the relevant physical microenvironment (e.g., air-liquid interface and cyclic strain in lung, flow and cyclic strain in gut, etc.), e.g., in some embodiments of the organ chips.
- the relevant physical microenvironment e.g., air-liquid interface and cyclic strain in lung, flow and cyclic strain in gut, etc.
- the cells used in the organ chips can be genetically engineered for various purposes, e.g., to express a fluorescent protein, or to modulate an expression of a gene, or to be sensitive to an external stimulus, e.g., light, pH, temperature and/or any combinations thereof.
- An in vitro microphysiological system can comprise at least two different organ chips using one or both of the first and second organ chip designs described herein.
- the first organ chip design is based a microfluidic device comprising: a body comprising a central channel therein, and an least partially porous and at least partially flexible first membrane positioned within the central channel and along a plane, wherein the first membrane is configured to separate the central channel to form two sub-channels, wherein one side of the first membrane is seeded with vascular endothelial cells, and the other side of the first membrane is seeded with at least one type of organ-specific parenchymal cells.
- the first organ chip can further comprise at least a channel wall positioned adjacent to the two sub-channels, wherein the first membrane can be mounted to the channel wall; and an operating channel adjacent to the two sub-channels on an opposing side of the channel wall, wherein a pressure differential applied between the operating channel and the two sub-channels can cause the channel wall to flex in a desired direction to expand or contract along the plane within the two sub-channels.
- the second organ chip design is based on a microfluidic device comprising: a body comprising a first chamber enclosing a plurality of muscular thin films adapted to measure contraction of muscle cells, and a second chamber comprising a layer of muscle cells on the bottom surface of the second chamber, wherein the bottom surface is embedded with an array of microelectrodes for recording of action potentials, and wherein the top surface of the second chamber is placed with at least a pair of electrodes for providing electric field stimulation to the muscle cells.
- the second organ chip can further comprise an at least partially porous second membrane positioned within the first chamber to form a top chamber and a bottom chamber, wherein the bottom chamber can comprise the plurality of muscular thin films on its bottom surface, and wherein the surface of the second membrane in contact with the top chamber can be seeded with a layer of epithelial cells.
- the design of the first organ chip described herein can provide a basis for development of organ chips to mimic tissue-tissue interfaces, and/or mechanically-active microenvironment.
- organ chips for example, lung chips, liver chips, gut chips, kidney chips, skin chips, brain chips, testis chips, and any combinations thereof, can be constructed based on the first organ chip design with any appropriate modifications.
- the design of the second organ chip described herein can provide the basis for development of organ chips where cell contraction, and/or electric field stimulation of the cells are intended.
- organ chips where cell contraction, and/or electric field stimulation of the cells are intended.
- heart chips, skeletal muscle chips, lung airway smooth muscle chips, brain chips, and any combinations thereof can be constructed based on the second organ chip design with any appropriate modifications.
- an organ chip e.g., a brain chip can employ either or both designs of the first and second organ chips, with any appropriate modifications.
- organ chips are intended to illustrate applications and/or adaptations of the first organ chip design and/or second organ chip design to construct various organ chips, and should not be construed to be limiting. Any modifications to the organ chips described herein that are within one of skill in the art are also encompassed by the scope described herein.
- FIG. 1 and FIGS. 2A-2B The methods, multi-channeled architecture and ability of a Lung Chip ( FIG. 1 and FIGS. 2A-2B ) to mimic, at least in part, the normal physiology (e.g., normal breathing) of a lung are based on the first organ chip design and has been previously described in Huh D. et al. “Reconstituting organ-level lung function on a chip” Science (2010) 328: 1662, and in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties.
- FIGS. 2A-2B shows diagrammatic views of a lung-on-a-chip in accordance with one embodiment described herein.
- the lung chip can comprise a body 202 having a central microchannel 204 therein; and an at least partially porous and at least partially flexible membrane 206 positioned within the central microchannel 204 and along a plane.
- the membrane 206 is configured to separate the central microchannel 204 to form a first central microchannel 208 and a second central microchannel 210 , wherein a first fluid is applied through the first central microchannel 208 and a second fluid is applied through the second central microchannel 210 .
- the membrane 206 is mounted to the first microchannel wall 214 , and when a pressure is applied to the operating channel ( 212 A and/or 212 B), it can cause the membrane to expand or contract along the plane within the first 208 and the second 210 central microchannels.
- one side of the membrane 206 can be seeded with alveolar epithelial cells to mimic an epithelial layer while another side of the membrane 206 can be seeded with lung microvascular endothelial cells to mimic capillary vessels.
- lung chips in some embodiments can be used to mimic an alveolar-capillary unit, which plays a vital role in the maintenance of normal physiological function of the lung as well as in the pathogenesis and progression of various pulmonary diseases.
- a gaseous fluid e.g., air and/or aerosol
- a liquid fluid e.g., culture medium, buffered solution and/or blood
- the lung chips can be used to evaluate lung response to an active agent, e.g., but not limited to, immune response to microbial infection and/or inflammatory responses to nanoparticulate toxins.
- the active agent e.g., cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof) can be added in a liquid fluid flowing through the second central microchannel 210 , e.g., to mimic blood carrying the active agent (e.g., cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, anti
- the inventors have demonstrated, in one embodiment, that the lung chips that mimic the lung's dynamic mechanically-active (breathing) microenvironment (e.g., using the device described in the International Application No. WO 2010/009307 in which one embodiment has side channels to allow modulation of pressure to cause cyclic movement of the flexible porous membrane on which the cells are seeded) can effectively predict lung toxicity responses to the chemotherapeutic cytokine, e.g., IL-2, which has a dose-limiting toxicity due to vascular leakage leading to pulmonary edema in humans.
- the chemotherapeutic cytokine e.g., IL-2
- the IL-2 produces a small but significant increase in pulmonary vascular leakage into the air channel of the lung chip under static conditions.
- a detectable marker e.g., fluorescent-insulin as a marker of vascular permeability (fluid shifts)
- the IL-2 produces a small but significant increase in pulmonary vascular leakage into the air channel of the lung chip under static conditions.
- this response is increased by more than 3-fold (and it was accompanied by blood clot formation as seen in humans), and the critical physiological importance of providing this correct mechanical microenvironment was demonstrated in studies in a mouse ex vivo ventilation-perfusion model that demonstrated a similar dependency of pulmonary edema induction by IL2 on breathing motions ( FIG. 3 ).
- IL2-induced pulmonary toxicity in the lung chip can be pharmaceutically suppressed in vitro.
- the microchannel intended for a gaseous flow can be configured to permit delivery of aerosolized micro-droplets (e.g., aerosolized drugs, and/or nanoparticles or particulates).
- aerosolized micro-droplets e.g., aerosolized drugs, and/or nanoparticles or particulates.
- WO 2012/154834 the content of which is incorporated herein by reference in its entirety
- lung chips can be adopted in the lung chips to deliver aerosolized microdroplets, e.g., to study toxicities of nanoparticles in lungs.
- Similar findings in relation to the toxicities of nanoparticles has been observed using the lung chips, indicating that some clinically organ toxicities cannot be mimicked in vitro without providing the correct mechanical microenvironment, which is generally lacking from traditional in vitro model systems.
- Heart Chips are described, for example, in U.S. Provisional Patent Application Ser. No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, filed on Sep. 5, 2012, and PCT patent application titled “Muscle Chips and Methods of Use Thereof,” filed on Dec. 10, 2012 and which claims priority to the U.S. provisional application No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, the entire contents of all of which are incorporated herein by reference in their entireties.
- functional heart tissues can be fabricated first and then multiplexed in a microfluidic device.
- functional heart tissues can be fabricated by culturing ventricular cardiomyocytes (e.g., neonatal rat ventricular cardiomyocytes) on elastomeric polymer thin films micropatterned with cell adhesion proteins (e.g., extracellular matrix proteins) to promote spatially ordered, two-dimensional myogenesis and create “muscular thin films” (MTFs) as described previously, e.g., in Grosberg A. et al.
- ventricular cardiomyocytes e.g., neonatal rat ventricular cardiomyocytes
- cell adhesion proteins e.g., extracellular matrix proteins
- muscle thin film and “MTF” are used interchangeably herein and refer to a two-dimensional biopolymer substrate comprising heart muscle cells such as ventricular cardiomyocytes or progenitor cells, which can cause the substrate to bend and form a three-dimensional (3D) structure when the cells contract, e.g., as shown in FIG. 6 or FIG. 7 .
- heart muscle cells such as ventricular cardiomyocytes or progenitor cells
- the MTFs (e.g., at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50 or more MTFs) can then be multiplexed, e.g., in an array, within a microfluidic chip ( FIGS. 4B-4C ).
- the MTFs can be used to measure effects on heart cell contractile function in vitro during electrical and pharmacological stimulation (Grosberg et al., 2011, FIG. 5 ).
- multi-layered heart chips can be constructed.
- a multi-layered heart chip can comprise a body having a ‘Microvascular Channel’ lined by endothelium (e.g., human endothelial cells) adherent to a porous membrane that separates the Microvascular Channel from the MTF-lined ‘Interstitial Channel’, such as similar to the configuration of the lung chip as shown in FIG. 2 , but without side chambers.
- endothelium e.g., human endothelial cells
- Interstitial Channel such as similar to the configuration of the lung chip as shown in FIG. 2 , but without side chambers.
- the inventors have demonstrated that microengineered MTFs effectively mimic pharmacological responses of adult rat papillary muscle strips ( FIG. 5 ), which are commonly used to screen cardiac tissue responses to drugs by the pharmaceutical industry.
- the heart chips can be modified for various analyses.
- the heart chips 800 can have at least one set of MTF ( 804 )-lined Interstitial Channels (including at least 2 sets, at least 3 sets, at least 4 sets, at least 5 sets or more) to form a MTF Chamber 802 , e.g., for optical imaging and contractility analysis of cells exposed to a culture medium with or without an active agent described herein, e.g., by optical measurements of radius of curvatures or projected length of MTFs using microscopy.
- a curled or contracted MTF can have a smaller projected length than a relaxed MTF, e.g., as shown in FIG. 8 ( iv ).
- a laser engraving process e.g., as shown in FIG. 6
- a laser engraving process can be utilized to cut PDMS thin films of cardiomyocytes cultured as described above; followed by microcontact-printing ECM proteins and enclosing the assembly in a microfluidic chamber.
- the thin films of cardiomyocytes can be produced with alginate ( FIG. 7 ).
- muscle cells can be cultured on the thin films and the contractile stresses can be assessed by optically monitoring the extent of curvature of the muscular thin films as noted above ( FIG. 8 ).
- An alternative strategy for measuring contractility is depicted in FIG.
- the muscle cells can be grown on a wrinkling substrate 902 , e.g., a polyurethane membrane, such that as the muscle cells contract, the substrate deforms.
- the wrinkling substrate can further comprise a plurality of holes 904 (e.g., a swiss cheese-like polyurethane membrane) to facilitate optical detection of the substrate deformation due to muscle cell contraction.
- the holes within the substrate can remain as a circle when the muscle cells are relaxed, but the circle becomes deformed, e.g., becoming an oval, or an ellipse, due to muscle cell contraction.
- the dimensions of the MTF chamber can be suited for a user's need.
- the length of the MTF chamber can vary from about 5 mm to about 100 mm, or from about 10 mm to about 50 mm, or from about 10 mm to about 25 mm. In one embodiment, the length of the MTF chamber can be about 15 mm.
- the height of the MTF chamber can be adjusted, e.g., based on the size of MTFs. For example, the height of the MTF chamber is designed to be sufficient to permit the MTFs to freely bend or curl up without any spatial constraint. In some embodiments, the height of the MTF chamber can be about 0.5 mm to about 5 mm, or about 0.5 mm to about 3 mm. In one embodiment, the height of the MTF chamber can be about 1 mm.
- the heart chips e.g., the Interstitial Channels can further comprise any heart-specific parenchymal cells, e.g., but not limited to cardiomyocytes and/or vascular smooth muscle cells, to further mimic the physiological environment and/or function of the heart.
- a heart chip can be a microfluidic device in which mature cardiomyocytes (e.g., human cardiomyocytes) are cultured on a 2D polymer substrate (e.g., PDMS substrates or micromolded alginate substrates) to form MTFs.
- the heart chips can have both vascular smooth muscle and cardiac muscle cultured on the same chip (see FIG. 10 ), e.g., to form to different kinds of muscles, e.g., smooth muscles vs. striated muscles.
- the cardiomyocytes can be isolated from a tissue of a subject or obtained from a commercial source, or by differentiating stems cells to cardiomyocytes, e.g., induced pluripotent stem cell-derived cardiomyocytes.
- Cardiomyocytes e.g., human cardiomyocytes
- the culture conditions can be optimized for each source of cardiac myocytes, e.g., ES- or iPS-derived cardiac myocytes, neonatal rat or mouse myocytes.
- the human cardiomyocytes can be obtained or derived from different origins (e.g., ventricular, atrial, etc.).
- the cardiomyocytes of different origins can be co-cultured.
- the cardiomyocytes can be engineered to be photosensitive (e.g., cardiomyocytes expressing a photosensitive membrane transport mechanism that is responsive to light of a particular wavelength). See, e.g., the International Appl. No. WO 2012/006320, the content of which is incorporated herein by reference in its entirety, for information about fabrication of photosensitive cardiac rhythm modulation systems, which can be integrated into the heart chips described herein.
- aligned or anisotropic monolayers of muscle cells can be cultured on microcontact printed biocompatible substrates (e.g., PDMS substrates, microcontact printed polyurethane membranes and micromolded alginate substrates) within a microfluidic device, e.g., being integrated into a MTF chamber for contractility measurements and/or a low volume Electrophysiological Chamber (or an Electrophysiological Chamber) as described below.
- microcontact printed biocompatible substrates e.g., PDMS substrates, microcontact printed polyurethane membranes and micromolded alginate substrates
- the heart chips 800 can further have at least one another set of Interstitial Channels (including at least 2 sets, at least 3 sets, at least 4 sets, at least 5 sets or more) lined with a heart muscle cell layer under which are embedded with at least one or a plurality (e.g., an array) of microelectrodes (e.g., platinum microelectrodes) 808 (microelectrodes are placed underneath the cells), while the side of the channel opposing the heart muscle cell layer is placed with at least one or more (e.g., at least two or more) electric field stimulation electrodes 810 to form an “Electrophysiological Chamber” 806 (see, e.g., FIG. 8 ).
- microelectrodes e.g., platinum microelectrodes
- 808 microelectrodes are placed underneath the cells
- the side of the channel opposing the heart muscle cell layer is placed with at least one or more (e.g., at least two or more) electric field stimulation electrodes 810 to form
- the Electrophysiological Chamber 806 can further comprise an electrocardiography (ECG) lead port 812 for connection with an ECG lead (or a lead electrocardiogram) to measure and/or monitor electrical pacing and/or analysis of changes in cardiac electrical potential.
- ECG electrocardiography
- an anisotropic muscle cell monolayer can be cultured in a low volume chamber. Then, the muscle cells can be electrically field stimulated using the electrodes 810 on the top, and action potentials can be recorded using the microelectrode array 808 on the bottom, where the microelectrode array is placed underneath the muscle cells cultured on the bottom surface.
- the electrode readouts can be calibrated with the action potential characteristics of the cardiomyocyte monolayer.
- the dimensions of the Electrophysiological Chamber can be suited for a user's need.
- the length of the Electrophysiological Chamber can vary from about 5 mm to about 100 mm, or from about 8 mm to about 50 mm, or from about 10 mm to about 25 mm. In one embodiment, the length of the Electrophysiological Chamber can be about 10 mm.
- the height of the MTF chamber can be adjusted, e.g., based on the size of field stimulation electrodes.
- the height of the MTF chamber is designed to be sufficient to permit the MTFs to freely bend or curl up without any spatial constraint.
- the height of the MTF chamber can be about 0.5 mm to about 5 mm, or about 0.5 mm to about 3 mm. In one embodiment, the height of the MTF chamber can be about 1 mm.
- the electrophysiological chamber 806 can be placed anywhere relative to the MTF chamber 802 . In some embodiments, the electrophysiological chamber 806 can be placed in parallel to the MTF chamber 802 . In some embodiments, the MTF chamber can be larger than the Electrophysiological Chamber to permit high throughput contractility measurements.
- both the Interstitial Channels in the MTF and Electrophysiological Chambers can be fed by a single medium stream 814 .
- the culture medium can be introduced directly through the Interstitial Channels in the Electrophysiological and MTF chambers and/or introduced through an underlying endothelium-lined Microvascular Channels, e.g., in a configuration similar to the lung chips (see, for example, FIG. 2 ).
- the presence of the endothelium and its basement membrane lining the microvascular channel on the opposite side of the membrane, plus the ability to perfuse different media compositions through the Interstitial versus Microvascular Channels can allow different experimental conditions for various applications.
- the heart chips can comprise a MTF chamber and an EPhys chamber situated next to each other, for example, as shown in FIG. 8 .
- the heart chip can be adapted to fluidically connected upstream and/or downstream to at least one or more organ chips (e.g., but not limited to lung chips or liver chips).
- organ chips e.g., but not limited to lung chips or liver chips.
- the heart chips described herein can be used to determine pharmacological effects on heart-specific cells cultured therein.
- the heart-specific cells can be exposed to an active agent (e.g., cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof) by adding the active agent in a culture medium flowing through the Interstitial Channels and/or Microvascular Channels.
- an active agent e.g., cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucle
- electrophysiological information can be collected within the chip, which can be in turn modeled with a user-defined algorithm to estimate an ECG.
- the ECG can then be correlated with reference data (e.g., current in vitro and outputs, or control outputs, e.g., outputs of cells not exposed to the active agent).
- reference data e.g., current in vitro and outputs, or control outputs, e.g., outputs of cells not exposed to the active agent.
- the radius of curvature of the contracting MTFs within the chip can be modeled to estimate the stresses exerted by the cells.
- the MTF contractility measurements can then be correlated with reference data (e.g., current in vitro and clinical outputs, or control outputs, e.g., outputs of cells not exposed to the active agent).
- the cardiac myocytes inside the heart chips can be exposed to drugs that are known to be cardio-safe (e.g., ibuprofen and fexofenadine), e.g., to show that they have no toxic effects on engineered myocardial tissue constructs.
- the cardiac myocytes inside the heart chips can be exposed to drugs that are cardiotoxic (e.g., doxorubicin, trastuzumab, terfenadine).
- doxorubicin anthracycline family of chemotherapeutics
- Trastuzumab is a monoclonal antibody to HER2 receptor used for the treatment of (HER2+) breast cancers, has been shown to decrease left ventricular ejection fraction.
- Terfenadine is antihistamine formerly used to treat allergic conditions that was found to be cardiotoxic because it binds hERG channels and causes long QT syndrome.
- Sorafenib and sunitinib are tyrosine kinase inhibitors used as chemotherapeutic agents that cause poorly characterized cardiotoxic effects that usually manifest as decreased left ventricular ejection fraction and increased cardiac enzymes.
- the chambers of the heart are imperative to its function, as the ventricles of the heart are tasked with overcoming pulmonary and system vascular resistance and after load.
- drugs such as doxorubicin and trastuzumab (as noted above) generally demonstrate ventricular toxicity; thus, some embodiments of the heart chips described herein can be used to mimic the contractile action of these chambers (e.g., ventricular chambers) in vitro.
- the heart chip can be a microfluidic device that can measure electrophysiology and/or contractile performance of engineered myocardial tissues. In some embodiments, the heart chip can be a microfluidic device that can measure electrophysiology and/or contractile performance of myocardial tissues derived or obtained from a subject, e.g., to determine an appropriate treatment regimen for the specific subject.
- the heart chips can be used as disease models, e. g., to assess different physiological effects of pharmaceutical or active agents.
- the effects that can be assessed using the heart chips can include, without limitations, (1) metabolic: for example, antibody-based medications such as Trastuzumab, which is generally used to treat HER2+ breast cancer, are known to affect ATP production in myocytes through adverse effects on mitochondria (Ref. 7); (2) structural: for example, anti-proliferative agents such as doxorubicin, which is used for a wide variety of malignancies, can adversely affect myocyte growth and mass maintenance (Ref. 8); and (3) ion channel (arrhythmia-inducing): for example, hERG channel binding of many drugs (e.g.
- albuterol can generally increase action potential duration, leaving the heart susceptible to arrhythmia (long QT syndrome) and effects on other ion channels (Na, Ca), with concurrent effects on PR prolongation, conduction abnormalities and arrhythmias.
- arrhythmia long QT syndrome
- other ion channels Na, Ca
- Drug toxicity can affect the ability of cardiac myocyte contractility.
- drug toxicity can be determined by measuring contractility of cardiac myocytes within the heart chips.
- contractility can be read out via optical tracking of MTF deformation/optical tracking of membrane deformation as described above.
- electrophysiological recordings can be taken via a lead ECG.
- biomarkers of muscle damage such as creatine kinase and troponin can also be measured.
- the level of biomarkers can be measured in the culture medium upon exposure to the cells.
- the heart chips can be used for PK/PD modeling (including prediction of pharmacological effects).
- the design of other organ chips can be developed based on the basic designs of the Lung or Heart chips as described herein.
- Gut chips, Kidney chips, Liver chips, Skin chips and Testis chips can be developed, e.g., based on the basic design of the Lung chips, while Skeletal Muscle chips, Airways Smooth Muscle chips can be developed, e.g., based on the design of the Heart chips.
- each organ chip can then be incorporated with respective tissue-specific parenchymal cell (e.g., human parenchymal cell) layers within the Interstitial Channel (as described earlier) exposed to their physiological microenvironment (e.g., alveolar epithelium and skin epidermis exposed to air, gut epithelium facing a fluid filled lumen, etc.) on one surface of the ECM-coated porous membrane, with organ-specific vascular endothelium (e.g., human vascular endothelium) on the opposite side lining the Microvascular Channel.
- tissue-specific parenchymal cell e.g., human parenchymal cell
- Organ-specific differences in the mechanical microenvironment can also be mimicked by altering control and/or process parameters, e.g., but not limited to, flow rates, fluid shear stresses, cyclic mechanical strain, ECM composition, and/or compartment dimensions.
- a mammalian liver chip e.g., a human liver chip
- a mammalian liver chip can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in its entirety.
- hepatocytes e.g., from Invitrogen
- patient-specific hepatocytes isolated from a tissue
- ECM e.g., laminin, type IV collagen or Matrigel
- human microvascular endothelial cells e.g., but not limited to, laminin, type IV collagen or Matrigel
- the porous membrane, basement membrane and cell-cell junctions of the endothelium can facilitate physiologically relevant mass transport while protecting hepatocytes from fluid shear stress and serum components in the Microvascular Channel.
- the liver chips can further comprise other parenchymal cells, such as Kupffer cells (resident macrophages of the liver) under the endothelium in the Liver Chip.
- Kupffer cells resident macrophages of the liver
- oxygen gradients are essential determinants of normal liver physiology and function, as well as key contributors to acute and chronic hepatoxicity. Accordingly, in some embodiments, oxygen gradients found in vivo can be incorporated in the liver chips.
- oxygen gradients can be generated in a liver chip, e.g., by using a gas-permeable membrane material, e.g., PDMS which is permeable to gases) and flowing oxygen at different concentrations through the two side channels separated by the membrane.
- a gas-permeable membrane material e.g., PDMS which is permeable to gases
- Other art-recognized microengineering methods for example, as described in Adler M. et al. Lab Chip 2010; 10(3): 388-389 and Chen Y-A et al., Lab Chip 2011; 11: 3626-3633, can also be used to develop oxygen gradients within the organ chips.
- bile canalicular networks in pre-determined patterns can be integrated into liver chips, such that they can be coupled with microscale sampling ports in the liver chips.
- Such configuration can be used to determine intrinsic biliary clearance.
- This approach can be used to facilitate analysis of interplay between drug transporters and drug metabolizing enzymes, which is a key determinant of drug PK properties and toxicity profiles in humans.
- the gut chips e.g., as shown in FIG. 11
- the gut chips can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties.
- a gut chip can utilize a porous membrane (e.g., PDMS membrane) coated with ECM (e.g., Collagen I+Matrigel) upon one side of which human intestinal epithelial cells are cultured under flow conditions to produce a physiological shear stress ( ⁇ 0.02 dyne/cm 2 ) while simultaneously exerting cyclic mechanical strain (10% elongation, 0.15 Hz).
- ECM e.g., Collagen I+Matrigel
- Gut-specific microvascular endothelial cells can be seeded and cultured on another side of the porous membrane to form a Microvascular Channel as described above.
- human gut cells e.g., CaCo2 cells
- human gut cells cultured under these conditions can differentiate by changing their entire transcriptome (measured, e.g., using gene microarrays) and form 3D villus structures, e.g., to match the height of the microfluidic Interstitial Channel ( FIG. 11F ).
- the physiologically relevant conditions recreated in the Gut Chip can enable one to culture living gut bacteria ( Lactobacillus ) directly on top of the living human villus gut epithelium, and hence, permit interrogating the influence of gut microbiome on drug absorption and metabolism using the gut chips.
- the gut chips described herein can comprise any components of the device or can be the device described in the International Appl. No. WO 2012/118799, the content of which is incorporated herein by reference in its entirety.
- the kidney chips can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties.
- the kidney chips can utilize a porous membrane (e.g., a PDMS membrane) coated with ECM (e.g., type IV collagen) upon one side of which primary human proximal tubular epithelial cells (e.g., obtained from Biopredic or from a specific subject) are cultured under flow conditions to produce a physiological shear stress ( ⁇ 0.02 dyne/cm 2 ). Kidney-specific microvascular endothelial cells can be cultured on another side of the porous membrane to form a Microvascular Channel as described above.
- a porous membrane e.g., a PDMS membrane coated with ECM (e.g., type IV collagen) upon one side of which primary human proximal tubular epithelial cells (e.g., obtained from Biopredic or from a specific subject) are cultured under flow conditions to produce a physiological shear stress ( ⁇ 0.02 dyne/cm 2 ).
- Kidney-specific microvascular endothelial cells can be culture
- kidney chips Using such kidney chips, the in vivo nephrotoxicity observed with an active agent, e.g., cisplatin and its inhibition by cimetidine, can be recapitulated and clinically relevant endpoints or biomarkers, such as KIM-1, can be measured.
- an active agent e.g., cisplatin and its inhibition by cimetidine
- the kidney chips described herein can comprise components of the device, or can be the device described in U.S. Provisional Application No. 61/449,925, the content of which is incorporated herein by reference in its entirety.
- the skin chips can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties.
- human foreskin fibroblasts can be plated in a collagen gel on one side of the membrane, and human dermal endothelial cells on the other side of the membrane; human keratinocytes from foreskin can then be plated on top of the collagen gel layer.
- the cells seeded in the skin chips can be further induced to differentiate into a stratified epithelium with basal, spinous and cornified layers, e.g., by passing air through the “Interstitial Channel” in a similar fashion as operated in the lung chip, and creating an air-liquid interface.
- the brain chips can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties.
- a brain chip can be constructed by first creating a Blood-Brain Barrier (BBB) construct in which astrocytes (e.g., human astrocytes) are cultured on one side of a porous ECM-coated membrane and endothelial cells (e.g., human endothelial cells) on the other side of the porous membrane.
- BBB Blood-Brain Barrier
- electrodes e.g., platinum electrodes
- the channels e.g., as shown in the bottom panel of FIG. 12 .
- the inventors have demonstrated generation of an effective permeability barrier, as measured by transepithelial resistance using this approach ( FIG. 12 ).
- the brain chips can be developed and/or modified, e.g., based on the design of any embodiments of Heart Chips (e.g., as shown FIG. 8 ) described herein as well as in Grosberg A. et al. 2011 and in the International Application Nos. WO 2008/045506, WO 2010/011407 and WO2010/042856, the contents of which are incorporated herein by reference in their entireties.
- Such brain chips can be constructed, e.g., by placing the BBB construct (as described above) in at least one set of channels and then linking the outflow of its Interstitial Channel to a second electrophysiological chamber (as described in the section of Heart Chips) where human brain neuronal networks can be cultured to measure effects on nerve cell toxicity and electrical signaling.
- the brain chips described herein can be used for various applications, e.g., discovery of methods to deliver an active agent across a BBB, or as a Traumatic Brain Injury (TBI) model to develop new therapies.
- TBI Traumatic Brain Injury
- the skeletal muscle chips can be developed and/or modified, e.g., based on the design of any embodiments of Heart Chips (e.g., as shown FIG. 8 ) described herein as well as in Grosberg A. et al. 2011 and in the International Application Nos. WO 2008/045506, WO 2010/011407 and WO2010/042856, the contents of which are incorporated herein by reference in their entireties.
- Skeletal Muscle Chips are described, for example, in U.S. Provisional Patent Application Ser. No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, filed on Sep. 5, 2012, and PCT patent application titled “Muscle Chips and Methods of Use Thereof,” filed on Dec. 10, 2012 and which claims priority to the U.S. provisional application No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, the entire contents of all of which are incorporated herein by reference in their entireties.
- the skeletal muscle chip can be a heart chip adapted to culture mature skeletal muscle myoblasts or myotubes (e.g., human skeletal muscle myoblasts or myotubes), optionally with neurons, on 2D substrates (e.g., PDMS substrates) or micromolded alginate substrates.
- 2D substrates e.g., PDMS substrates
- micromolded alginate substrates e.g., cellular thin film” (MTF) chamber for contractility measurements and a low volume electrophysiological readout chamber, similar to the operation of the heart chips described herein.
- MTF muscle thin film
- the skeletal muscle chip can further comprise additional cell types, e.g., adipocytes (e.g., human adipocytes) can be added to the skeletal muscle chip as a heterogeneous co-culture cell layer, or be seeded on a separate side of the membrane to recapitulate two tissue interfaces, e.g., to create disease models within the device.
- adipocyte e.g., human adipocytes
- the adipocyte can be cultured on opposite side of porous membrane that myoblast/neurons are cultured.
- the adipocytes can be healthy or diseased, depending on the purpose of the application. Healthy human adipocytes can be obtained from a commercial source or isolated from a healthy tissue of a subject.
- commercially-available healthy primary preadipocytes e.g., Lonza; PT-5022
- adipocytes e.g., by using known differentiation medium.
- diabetic (Type I and II) human adipocytes can be used in the skeletal muscle chip.
- commercially-available primary (from patients with diabetes) preadipocytes e.g., Lonza; PT-5023—Type I and PT-5024 Type II
- Lonza; PT-5023—Type I and PT-5024 Type II can be differentiated into adipocytes by using known differentiation medium.
- aligned monolayers of muscle cells can be cultured on microcontact printed polymer substrates or membranes (e.g., microcontact printed PDMS substrates, microcontact printed polyurethane membranes and/or micromolded alginate substrates).
- the human myoblasts or satellite cells can be isolated from a tissue of a subject, and/or obtained from a commercial source, e.g., (healthy; Lonza, XM13A1 and XM15B1).
- the skeletal muscle chip can comprise at least one or more MTF chamber ( FIGS. 13-14 ), e.g., at least two or more MTF chambers.
- a laser engraving process can be utilized to cut PDMS thin films of skeletal muscle cells (e.g., myoblasts and/or myotubes) cultured as above; followed by microcontact-printing ECM proteins and enclosing the assembly in a microfluidic chamber.
- muscle cells can be cultured on the thin films and the contractile stresses can be assessed by optically monitoring the extent of curvature of the muscular thin films.
- contractility readout from skeletal muscle-adipocyte can be measured.
- the MTF chambers can be micromolded with grooves (e.g., on an alginate substrate) to create 3D cues, e.g., to help maintain mature contracting muscle in culture ( FIGS. 15A-15C ).
- the skeletal muscle chip can further comprise an Electrophysiological (EPhys) chamber, the design and operation of which can be similar to the ones employed in the heart chips described herein, except that, e.g., the Ephys chamber is cultured with skeletal muscle chips in the skeletal muscle chips.
- EPhys Electrophysiological
- anisotropic muscle cell monolayer can be cultured in a low volume chamber.
- the muscle cells can be electrically field stimulated using the electrodes on the top, and action potentials can be recorded using the microelectrode array on the bottom.
- the EMG can be measured, e.g., as shown in FIG. 14 ( i ) .
- the skeletal muscle chips described herein can be used to determine pharmacological effects on skeletal muscle-specific cells cultured therein.
- the skeletal muscle-specific cells can be exposed to an active agent by adding the active agent in a culture medium flowing through the Interstitial Channels and/or Microvascular Channels.
- electrophysiological information can be collected within the chip, which can be in turn modeled with a user-defined algorithm to estimate an ECG.
- the ECG can then be correlated with reference data (e.g., current in vitro and outputs, or control outputs, e.g., outputs of cells not exposed to the active agent).
- the radius of curvature of the contracting MTFs within the chip can be modeled to estimate the stresses exerted by the cells.
- the MTF contractility measurements can then be correlated with reference data (e.g., current in vitro and clinical outputs, or control outputs, e.g., outputs of cells not exposed to the active agent).
- statin-induced skeletal muscle myopathy can be replicated.
- cerivastatin which was voluntarily pulled from market in 2001 due to side effects which included rhabdomyolysis and mypothay, can be introduced into the skeletal muscle chips.
- Skeletal muscle damage markers such as creatine kinase and slow and fast-twitch troponin I (ssTnl, fsTnl) can also be measured (e.g., by in situ immunostaining for the specific marker in the cells, and/or collecting the cells to prepare cell lysates for quantitative measurements of the marker level), in order to validate the ability of the system to replicate injury induced by a known agent (e.g., statin-induced skeletal muscle myopathy).
- a known agent e.g., statin-induced skeletal muscle myopathy
- skeletal muscle contractility measurements can also validate statin-induced in vitro muscle weakness.
- the skeletal muscle chips can be used as diseased models.
- diabetic muscle microenvironment can be created in some embodiments of the skeletal muscle chips described herein, e.g., by co-culturing type I and type II preadipocytes with the skeletal muscle cells.
- Type I diabetic mimic chip can be used to evaluate insulin replacement therapies while Type II diabetic mimic chip can be used to determine effectiveness of metformin-induced metabolic benefits.
- an exemplary diabetic muscle environment (Type I and II) can be created for pharmaceutical development testing.
- Type 2 diabetes model adipocytes from type 2 diabetic patients (Lonza) and conditioned skeletal muscle can be employed. Metformin, a first line drug used to treat type II diabetes can then be introduced. Muscle contractility can be measured to determine effectiveness of metformin-induced metabolic benefits.
- Type 1 diabetes model Type 1 diabetic adipocytes along with conditioned muscle tissue in zero insulin media can be exposed to commercially-used insulin replacement therapies such as Detemir or Glargine. Improvements in contractility can then be verified due to the increased insulin.
- the lung airway smooth muscle chips can be developed and/or modified, e.g., based on the design of any embodiments of Heart Chips (e.g., as shown FIG. 8 ) described herein as well as in Grosberg A. et al. 2011 and in the International Application Nos. WO 2008/045506, WO 2010/011407 and WO2010/042856, the contents of which are incorporated herein by reference in their entireties.
- the lung airway smooth muscle chip can be a hybrid bronchial smooth muscle and columnar epithelium organ system, which can be used, e.g., to test bronchial spasms in response to drugs and/or toxins.
- a hybrid bronchial smooth muscle and columnar epithelium organ system which can be used, e.g., to test bronchial spasms in response to drugs and/or toxins.
- this hybrid chip can be installed inside a two-chamber microfluidic device that contains a top layer of epithelial cells (e.g., human epithelial cells) adhered to a porous membrane and exposed to air flow and a bottom layer containing flexible muscular thin films, each comprising a monolayer (e.g., a confluent monolayer) of bronchial smooth muscle situated on top of a thin polymer substrate (e.g., a PDMS substrate), which are incubated within a liquid medium.
- the porous membrane separating the top and bottom layers of the chamber can act as a barrier between the two cell types and allows for chemical exchange.
- the material for the membrane that separates airway smooth muscle from the epithelium within the hybrid organ system can be selected for at least one of the following properties, but not limited to: the material is (i) biocompatible, (ii) complies with IS 10993-5 (in vitro cytotoxicity tests for medical devices), (iii) has low absorption of hydrophobic dye/drug and other chemical compounds, (iv) is cell adhesive, (v) is optically clear, is highly flexible, moldable, bondable, (vi) has low autofluorescence, (vii) does not swell in water, or (viii) has any combinations of the aforementioned properties.
- the membrane material can include Clear flex 50 polyurethane.
- fabrication of an airway chip can involve micro-contact printing to fabricate engineered smooth muscle tissue and/or (e.g., human) columnar epithelium with well-defined cellular organization and tissue geometry.
- Bronchial smooth muscle cells e.g., healthy or diseased cells
- Human primary bronchial epithelial cells can be isolated from a tissue or obtained from a commercial source (e.g., healthy: ATCC; PCS-300-010, PCS-310-010, Lonza: CC-2540, CC-2547; diseased: Lonza; 00195275, 00194911)
- a commercial source e.g., healthy: ATCC; PCS-300-010, PCS-310-010, Lonza: CC-2540, CC-2547; diseased: Lonza; 00195275, 00194911
- a lung airway smooth muscle chip (“airway chip”) can comprise a MTF chamber.
- a laser engraving process can be utilized to cut PDMS thin films of muscle cells, e.g., bronchial smooth muscle cells (the thin films can be produced in a similar fashion as thin films of cardiomyocytes described above); followed by microcontact-printing ECM proteins and enclosing the assembly in a microfluidic chamber.
- the muscle cells e.g., bronchial smooth muscle cells
- the contractile stresses can be assessed by optically monitoring, e.g., the extent of curvature of the muscular thin films.
- a wrinkling substrate e.g., a PDMS membrane
- the wrinkling substrate can further comprise a plurality of holes (e.g., a swiss cheese-like PDMS membrane) to facilitate optical detection of the substrate deformation due to muscle cell contraction.
- the holes within the substrate can remain as a circle when the muscle cells are relaxed, but the circle becomes deformed, e.g., becoming an oval, or an ellipse, due to muscle cell contraction, e.g., as shown in FIGS. 18A-18B .
- a two-chamber system can also be engineered for dual outputs (e.g., as shown in FIGS. 17A-17B ).
- normal bronchial epithelial cells can be cultured in one chamber while diseased bronchial epithelial cells (e.g., with asthma phenotype) can be cultured in another chamber, e.g., for comparison of cell behavior, and/or cell response to an active agent.
- the cells can be chemically induced to become diseased cells inside a microfluidic device, e.g., by flowing an inducing agent through a separate channel to the cells.
- epithelial cells can be cultured on the chip membrane. In some embodiments, the epithelial cells can remain viable for at least about 3 weeks or longer (e.g., at least about 4 weeks, at least about 5 weeks, at least about 6 weeks or longer) inside the organ chip. For example, the epithelial cells can be cultured on, e.g., 20 ⁇ 4 lined substrates, and the structural and functional response of cells can be characterized by quantifying cytoskeletal alignment and/or effects on gene expression and/or protein translation.
- smooth muscles cells can be cultured on a substrate (e.g., a deformable substrate).
- the smooth muscle cells can remain viable for at least 3 weeks or longer (e.g., at least about 4 weeks, at least about 5 weeks, at least about 6 weeks or longer) inside the airway chip.
- the smooth muscle cells can be cultured on, e.g., 20 ⁇ 4 lined substrates, and the structural and functional response of cells (e.g., cells on a deformable substrate exhibiting morphological changes, e.g., contraction of such PDMS muscular thin film substrate as in FIGS. 16A-16B and FIG. 17A-17B and/or deformation of perforated holes in a membrane as in FIGS. 18A-18B ), can be characterized by quantifying cytoskeletal alignment and/or effects on gene expression and/or protein translation.
- the bronchial smooth muscle tissue can be monitored for contraction in response to an active agent, e.g., drug or toxic agents (e.g., without limitations, IL-13, acetylcholine).
- an active agent e.g., drug or toxic agents (e.g., without limitations, IL-13, acetylcholine).
- the contractility can be measured for grading the response of the different tissue types to the drugs.
- the lung airway smooth muscle chips can comprise other “helper” cells.
- helper cells To characterize the cellular response to different demographical conditions, e.g., addition of “helper” cells, cells can be co-cultured conditions with other “helper” cell types and/or different cell densities and their effects on gene expression and protein translation can be evaluated using any known methods in the art.
- the airway chips described herein can be used to determine pharmacological effects on airway-specific cells cultured therein.
- the airway-specific cells can be exposed to an active agent by adding the active agent in a culture medium flowing through the channels.
- the radius of curvature of the contracting MTFs within the chip can be modeled to estimate the stresses exerted by the cells.
- the eccentricity of the holes within a deformable membrane can be evaluated to determine the state of the cellular contraction (e.g., relaxation vs. contraction state).
- the contractility measurements e.g., from contraction of MTFs
- reference data e.g., current in vitro and clinical outputs, or control outputs, e.g., outputs of cells not exposed to the active agent.
- Local airway smooth muscle construct can be characterized for any pharmacological mediators of interest, e.g., but not limited to, Fexofenadine, Denufosol, Terfenadine, Isoproterenol, Amiodarone, and Xigris.
- the in vitro microphysiological system (e.g., including two or more organ chips) can also be characterized for any pharmacological mediators of interest, e.g., but not limited to, Fexofenadine, Denufosol, Terfenadine, Isoproterenol, Amiodarone, and Xigris.
- pharmacological mediators of interest e.g., but not limited to, Fexofenadine, Denufosol, Terfenadine, Isoproterenol, Amiodarone, and Xigris.
- Exemplary characterization include, without limitations, establishment of duration of therapeutic effect; establishment of apparent volume of distribution (V d ), via microfluidic channels within the system; establishment of Tmax, time to maximal media concentration, per given dose, inhaled; establishment of Cmax, maximal media concentration, per given dose, inhaled; establishment of terminal half-life, per given dose, inhaled; and/or establishment of efficacy of biotransformation as result of first bypass effect at liver chip.
- V d apparent volume of distribution
- Performance of airway smooth muscle, local and systemic, within an organ chip or an integrated system can be corrected to correspond to established pharmacokinetic and pharmacodynamics values for various categories of drugs and toxins.
- the lung airway smooth muscle chip can be used as a disease model.
- the asthmatic phenotype can present as exaggerated bronchial muscle spasms, which can be reflected by changes in contractility.
- the effect of substances with known toxicity in humans e.g., local anesthetics such as procaine, chloroprocaine, and tetracaine
- procaine, chloroprocaine, and tetracaine can be introduced to induce bronchial smooth muscle spasms and provide a calibration to existing patient response from the clinic [Ref. 14].
- a disease model can be developed, e.g., by integration of diseased cells or by chemical stimulation of a diseased phenotype (e.g., asthmatic phenotype can be induced, e.g., by introducing IL-13 to the culture medium [Ref. 11]), and/or by alteration of temperature and/or media composition [Ref. 12].
- a diseased phenotype e.g., asthmatic phenotype can be induced, e.g., by introducing IL-13 to the culture medium [Ref. 11]
- temperature and/or media composition e.g. 12
- mechanical strain, electrophysiology, and/or markers for cell injury between asthmatic phenotypes generated by integration of cells from diseased tissues and those induced by allergens or toxins can be compared and contrasted, e.g., to determine which is a better representation of a diseased model.
- the asthmatic or chronic obstructive pulmonary disease (COPD) human primary smooth muscle cells can be cultured within one of the chambers in the airway chip, e.g., on a deformable substrate, using micro-contact printing to align cells into anisotropic tissues, e.g., as shown in FIG. 19A .
- Contraction in smooth muscle cell layer can be monitored optically as described above.
- the micronenvironment conditions e.g., the levels of oxygen within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be also monitored.
- the asthmatic phenotype can be induced by introduction of allergens/drug compounds that drive bronchial spasms associated with asthmatic attacks.
- allergens/drug compounds that drive bronchial spasms associated with asthmatic attacks.
- toxic agents e.g., acetylcholine, IL-13, Foradil, Serevent, Advair, Symbicort
- Alteration in smooth muscle contraction in response to allergens or toxic agents can be monitored optically.
- the levels of oxygen within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be also monitored.
- the levels of mucus granules and/or spherules and/or presence of inflammation factors can be monitored.
- the asthmatic phenotype can be induced by introduction of allergens/drug compounds through the air, allergens (e.g. oil fly ash, dust mites, smoke) can be perfused into the aerosol routes within the upper channel of the microfluidic device containing the epithelium (see, e.g., FIG. 16B (ii)). Alterations in smooth muscle contraction in response to allergens or toxic agents can be monitored optically. In the same channel, microenvironment conditions, e.g., but not limited to, the levels of oxygen within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be monitored.
- allergens e.g. oil fly ash, dust mites, smoke
- Alterations in smooth muscle contraction in response to allergens or toxic agents can be monitored optically.
- microenvironment conditions e.g., but not limited to, the levels of oxygen within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be monitored.
- the levels of mucus granules and/or spherules and/or presence of inflammation factors can be monitored.
- inflammation factors e.g., but not limited to, IL-3, IL-4, IL-5, IL-13
- a diseased epithelial cell monolayer can be also integrated within the asthmatic microfluidic device, e.g., a co-culture of the asthmatic or COPD human primary smooth muscle cells (from either commercially available cell lines or samples from asthmatic patients) with the diseased human primary bronchial epithelial cells.
- the diseased epithelial cell monolayer can be cultured on the membrane (e.g., polyurethane membrane) and the diseased smooth muscle cells on the deformable substrate, using micro-contact printing to align cells into anisotropic tissue in a hybrid system described herein (e.g., as shown in FIG. 16B (ii)). Contraction in smooth muscle cell layer can be monitored optically.
- microenvironment conditions e.g., but not limited to, the levels of oxygen (e.g., reduction in oxygen levels) within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be monitored.
- the levels of mucus granules and/or spherules and/or presence of inflammation factors e.g., but not limited to, IL-3, IL-4, IL-5, IL-13
- inflammation factors e.g., but not limited to, IL-3, IL-4, IL-5, IL-13
- the hyperplasia and hypertrophy of the columnar epithelial cells can be assessed optically, e.g., by microscopy.
- Asthma is a prevalent disease affecting ⁇ 8% percent of the population, and it is in part due to maladaptive remodeling of bronchial smooth muscle. Airborne toxins and air pollution can affect the bronchial smooth muscle, but they are difficult to detect and to predict their effects on the tissue health (and reflect a large scale problem in developing countries). There are currently no commercially available instruments to test cytotoxicity and allergic responses and associated inflammation in vitro, despite the existence of human bronchial smooth muscle cell lines. Beyond the difference in species responses to toxic or therapeutic agents, animal models do not necessarily provide human relevance, predictability, and lower failure rates in the drug pipe-line.
- Bronchial smooth muscle spasms can be a response to allergens and/or toxins. This response can be amplified if the muscle undergoes a maladaptive remodeling prior to the introduction of the toxic agent (such as in asthmatic patients). Therefore, an in vitro organ chip system (e.g., a hybrid chip of bronchial smooth muscle tissue and epithelial cell monolayer as described herein) to test for bronchial smooth muscle spasms can provide a tool for various applications, including, but not limited to: testing drugs for curing or exacerbating asthma; testing toxins (including air-borne toxins) in the field; predicting the allergic response of different patient populations.
- an in vitro organ chip system e.g., a hybrid chip of bronchial smooth muscle tissue and epithelial cell monolayer as described herein
- the hybrid chips can be combined with a microfluidic device containing bronchial epithelial and/or pulmonary mast cells, which are important to exacerbation and inflammation response.
- the hybrid chips described herein can comprise bronchial epithelial and/or pulmonary mast cells within the same device.
- the epithelial and mast cells can produce inflammation factors (e.g., but not limited to, IL-3, IL-4, IL-5 IL-13) that would cause the spasms in the bronchial smooth muscle, and the levels of these inflammation factors can be measured to evaluate the degree of spasms.
- the chip's function can be calibrated by introducing a substance with known allergenicity, such as procaine, chloroprocaine, and tetracaine, which have been used in humans as local anesthetics and have been shown to be a plausible allergen that can induce a bronchial smooth muscle spasm [ 4 ].
- This calibration can also be compared to known patient responses, which can provide the necessary data to predict human response based on the data retrieved from the chip.
- Raplon (Rapacuronium, Organon) is an anesthetic that was approved in the USA in 1999 and withdrawn by the FDA two years later due to a high risk of fatal bronchial muscle spasm [Ref. 14].
- drugs such as Novartis AG's Foradil, GlaxoSmithKline's Serevent and Advair, and AstraZeneca's Symbicort, while approved to treat asthma, can themselves cause asthma attacks [Ref. 13].
- the chip design described herein can allow for in vitro cultures to run for long periods of time to test such effects, prior to clinical trials.
- the lung airway smooth muscle chips can be connected to at least one lung chip to function as an integral organ chip.
- the design of the lung airway smooth muscle can be incorporated into the lung chip design.
- the airway chip can be integrated into the system with other organ chips, which can then be used to evaluate drugs that are effective at treating bronchial smooth muscle tissues, but might be toxic to other organ systems (e.g., Ventolin).
- other organ systems e.g., Ventolin
- such integrated system can also allow for testing of drugs commonly used to affect the function of other organs (e.g., beta blockers that reduce cardiac contractility), but can adversely affect airway resistance in asthmatics.
- Drugs can be administered via both intravenous (e.g., via culture medium) and aerosol routes, exhibiting the versatility of the chip design.
- the airway muscle chips alone or in combinations with other organ chips, can be used in various applications.
- Non-limiting examples of applications are shown below:
- the Testis Chip can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties.
- the testis chips can employ (e.g., human) Sertoli and Leydig cells being cultured on one side of the porous ECM-coated membrane and endothelium on the other side of the coated membrane. This Testis chip design can maintain enhanced differentiated testicular functions when the two parenchymal cell types are combined in this manner (Ref. 4).
- Bone Marrow chip To construct a Bone Marrow chip, fully functional bone containing a central marrow can be formed in vivo first by implanting demineralized bone powder and BMPs 2/4 subcutaneously above a muscle layer within a polymer mold (e.g., PDMS mold and culturing it for about 4-8 weeks in vivo. Additional details of the bone marrow chips and methods of making the same can be found in the International Appl. No. PCT/US12/40188, the content of which is incorporated herein by reference in its entirety.
- the bones that form in these implanted devices can take the shape (e.g., cylindrical shape) of the flexible mold, and contain a fully developed bone marrow with normal morphology and cellular composition (hematopoietic stem cells, progenitor cells, various differentiated blood cell types), when compared to normal mouse bone marrow versus peripheral blood ( FIG. 20 ).
- the formed marrow can be maintained by placing the formed implant within microfluidic channels, as evidenced by cells isolated from this marrow after 4 days in culture being able to regenerate a functional marrow and reconstitute whole blood formation in gamma-irradiated mice.
- simultaneously reconstituting the mouse's injured marrow and forming new marrow in the microfluidic implants can be carried out by irradiating immuno-compromised mice, implanting the demineralized bone powder with BMPs subcutaneously, and then injecting human bone marrow. Once removed and maintained in microfluidic systems, the human marrow can then be used to generate all types of blood cells, which can circulate throughout the entire linked organ chip circuit, e.g., an in vitro microphysiological system, e.g., for studies on inflammation and its relation to drug toxicity.
- organ chips corresponding to other organs e.g., spleen chips for filtration of fluid, e.g., blood, as described into the International Appl. No. WO 2012/135834, the content of which is incorporated here by reference in its entirety, can also be integrated into an in vitro microphysiological system described herein.
- At least one or more organ chips can be used for any applications that involve cells.
- the organ chips and/or in vitro microphysiological systems can be used as cell culture devices. Compared to 2-D tissue culture flasks, the organ chips and/or in vitro microphysiological systems described herein can provide organ-specific cells a more physiological condition for their growth, and/or maintenance of their differentiated states.
- lung cells in vivo are generally exposed to a mechanical stimulation, e.g., during breathing.
- organ chips such as lung chips can be used to culture lungs cells as described above.
- the cells can be cultured and remain viable (e.g., capable of proliferation) for at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 9 weeks, at least about 12 weeks or longer inside the organ chips described herein.
- the organ chips and/or in vitro microphysiological systems can be used for drug screening, PD/PK studies and/or toxicity assays.
- an active agent can be delivered to target cells cultured in organ chips, e.g., by introducing the active agent into the organ chips as an aerosol and/or as a mixture with the culture medium flowing through the Interstitial Channels and/or Microvascular Channels of the organs chips described herein.
- active agents to be delivered to target cells can include, but are not limited to, cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof.
- cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms,
- Exemplary characterization that can be performed with the organ chips and/or in vitro microphysiological systems described herein can include, without limitations, establishment of duration of therapeutic effect; establishment of apparent volume of distribution (Vd), via microfluidic channels within the system; establishment of Tmax, time to maximal media concentration, per given dose; establishment of Cmax, maximal media concentration, per given dose; establishment of terminal half-life, per given dose; and/or establishment of efficacy of biotransformation as result of first bypass effect at the organ chip.
- Vd apparent volume of distribution
- drugs can include, but are limited to, pharmacologically active drugs and genetically active molecules.
- Compounds of interest include chemotherapeutic agents, anti-inflammatory agents, hormones or hormone antagonists, ion channel modifiers, and neuroactive agents.
- Exemplary of pharmaceutical agents suitable for this invention are those described in “The Pharmacological Basis of Therapeutics,” Goodman and Gilman, McGraw-Hill, New York, N.Y., (1996), Ninth edition, under the sections: Drugs Acting at Synaptic and Neuroeffector Junctional Sites; Drugs Acting on the Central Nervous System; Autacoids: Drug Therapy of Inflammation; Water, Salts and Ions; Drugs Affecting Renal Function and Electrolyte Metabolism; Cardiovascular Drugs; Drugs Affecting Gastrointestinal Function; Drugs Affecting Uterine Motility; Chemotherapy of Parasitic Infections; Chemotherapy of Microbial Diseases; Chemotherapy of Neoplastic Diseases; Drugs Used for Immuno
- Additional candidate compounds or drugs can be obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, naturally or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.
- the cells within the organ chips and/or in vitro microphysiological systems can be exposed to a drug by flowing a fluid containing the drug through a channel of an organ chip or an integrated system of different organ chips, such that the fluid is in contact with the cells.
- the cells within the organ chips and/or in vitro microphysiological systems can be exposed to an aerosol by flowing a gaseous fluid containing the aerosolized microdroplets of a drug through a channel of an organ chip or an integrated system of different organ chips such that the gaseous fluid is in contact with the cells.
- Cell response in one or more organ chips can then be measured after or monitored over a period of time.
- Examples of cell response can include, but are not limited to, viability, proliferation, respiration, metabolism, movement of the cells (e.g., migration, contractile motions), differential expression of biomarkers, and/or production and/or release of certain molecules by the cells. Any methods known in the art can be utilized for detecting or measuring a cell response, e.g., immunostaining, microscopy, immunoassays, PCR, and/or ECG measurements.
- a treatment regimen e.g., a therapeutic agent and/or dosage that works best, among others, for the subject
- a treatment regimen can be selected and/or optimized by culturing the subject-specific cells in the organ chips and/or in vitro microphysiological systems described herein, exposing the cells to different therapeutic agents and/or dosages, and monitoring the cellular response to various combinations.
- the cells can be observed by microscopy for morphological changes.
- the contractile motion of the cells can be measured by ECG measurements.
- the cells can be stained for a target protein, e.g., a biomarker, and then observed under a microscope.
- the cells can be collected from the organ chips for further analysis, such as RNA, DNA and/or protein analysis.
- the culture medium conditioned by the cells can be collected for further analysis, such as RNA, DNA and/or protein analysis.
- One of skill in the art can readily perform various assays for detecting or measuring different kinds of cell responses.
- the organ chips e.g., gut chips
- in vitro microphysiological systems described herein can be used for studying the role of gut flora (e.g., microorganisms that live in the digestive tracts of animals) and other bacteria within a body of an animal that can have a symbiotic relationship with the host.
- gut flora e.g., microorganisms that live in the digestive tracts of animals
- Various factors other than infections such as aging, geographical transplant, changes in diet, and/or various therapeutic regimens such as antibiotics can alter the gut flora demographics and the physiology of the host. See, e.g., Maynard C L et al. “Reciprocal interactions of the intestinal microbiota and immune system.” Nature. 2012 Sep.
- gut bacteria colonies can be co-cultured with gut cells and/or intestine cells in appropriate organ chips, e.g., gut chips, for example, to model gut flora in a host, and/or to study the effects of different factors on the gut flora demographics and/or physiology of the host cells.
- these gut chips can be connected to other organ chips to form in vitro microphysiological systems that can be desirable when considering the mind body axis and the coupling of the enteric and central nervous system. These systems can be also used to study, e.g., but not limited to, digestion, and mental illness.
- methods to study microbial growth, adhesion to host-related surfaces and/or the host-microbiota interactions can be integrated or utilized together with the organ chips and/or in vitro microphysiological system described herein to study the role of gut flora within a body of an animal.
- the organ chips and/or in vitro microphysiological systems described herein can be used to study and/or model parasitic infections, for example, but not limited to, co-culture of intestinal worms, rabies, toxoplasma , and any combinations thereof.
- kits comprising one or a plurality of organ chips, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more organ chips.
- the organ chips in the kit can be all the same, i.e., corresponding to the same organ.
- at least some of the organ chips in the kit can represent a different organ.
- the organ chips in the kit can be pre-assembled together, or fluidically connected together by a user, to form an integrated microphysiological system.
- a kit directed to a circulatory system can comprise at least one heart chip and at least one bone-marrow chip.
- Another kit directed to a gastrointestinal system can comprise at least one liver chip and one gut chip.
- the kits can comprise a plurality of the organ chips that are involved in the microphysiological system.
- each organ chips can be individually packaged, e.g., for sterility.
- the kits can further comprise an appropriate culture medium.
- the kit can further comprise at least one vial of cells, e.g., vascular endothelial cells and/or organ-specific parenchymal cells.
- the kits can further comprise an instruction manual, e.g., instructions on connecting various organ chips together to form an integrated network, cell culture methods, and approaches of measuring various cellular responses.
- any embodiments of the organ chip described herein can vary with the materials used, and include soft lithography methods, microassembly, bulk micromachining methods, surface micro-machining methods, standard lithographic methods, wet etching, reactive ion etching, plasma etching, stereolithography and laser chemical three-dimensional writing methods, solid-object printing, machining, modular assembly methods, replica molding methods, injection molding methods, hot molding methods, laser ablation methods, combinations of methods, and other methods known in the art.
- an organ chip described herein can be formed by replica molding, for example, in which a replica comprising at least biocompatible polymer (e.g., PDMS polymer) conforms to the shape of a master or a mold and replicates the features of the master or the mold.
- the replica can be further sealed to a surface to enclose at least one channel.
- an organ chip described herein can be formed by machining or micromachining.
- micromachining as used herein can encompass bulk micromachining or surface micromachining as recognized in the art.
- bulk micromachining defines microstructures such as channels by selectively etching inside a substrate or a body.
- an organ chip described herein can be formed by solid-object printing.
- the solid-object printing can take a three-dimensional (3D) computer-aided design file to make a series of cross-sectional slices. Each slice can then be printed on top of one another to create the 3D solid object.
- compositions, methods, and respective component(s) thereof are used in reference to compositions, methods, and respective component(s) thereof, that are essential to the invention, yet open to the inclusion of unspecified elements, whether essential or not.
- the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
- compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
- a “subject” means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters.
- domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon.
- the subject is a mammal, e.g., a primate, e.g., a human.
- a subject can be male or female.
- the subject is a mammal.
- the mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of a disease or disorder.
- the term “fluid” refers to any flowable material or medium, e.g., but not limited to, liquid, gas, suspension, aerosols, cell culture medium, and/or biological fluid).
- the fluid can comprise one or more target species, e.g., but not limited to cells, and/or active agents described herein.
- the fluid can be liquid (e.g., aqueous or non-aqueous), supercritical fluid, gases, solutions, and suspensions.
- small molecules refers to natural or synthetic molecules including, but not limited to, peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, aptamers, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
- organic or inorganic compounds i.e., including heteroorganic and organometallic compounds
- therapeutic agents is art-recognized and refers to any chemical moiety that is a biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a subject.
- therapeutic agents also referred to as “drugs”
- drug are described in well-known literature references such as the Merck Index, the Physicians Desk Reference, and The Pharmacological Basis of Therapeutics, and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment.
- a therapeutic agent may be used which are capable of being released from a composition into adjacent tissues or fluids upon administration to a subject.
- steroids and esters of steroids e.g., estrogen, progesterone, testosterone, androsterone, cholesterol, norethindrone, digoxigenin, cholic acid, deoxycholic acid, and chenodeoxycholic acid
- boron-containing compounds e.g., carborane
- chemotherapeutic nucleotides e.g., drugs (e.g., antibiotics, antivirals, antifungals), enediynes (e.g., calicheamicins, esperamicins, dynemicin, neocarzinostatin chromophore, and kedarcidin chromophore), heavy metal complexes (e.g., cisplatin), hormone antagonists (e.g., tamoxifen), non-specific (non-antibody) proteins (e
- molecular toxin refers to a compound produced by an organism which causes or initiates the development of a noxious, poisonous or deleterious effect in a host presented with the toxin. Such deleterious conditions may include fever, nausea, diarrhea, weight loss, neurologic disorders, renal disorders, hemorrhage, and the like.
- Toxins include, but are not limited to, bacterial toxins, such as cholera toxin, heat-liable and heat-stable toxins of E. coli , toxins A and B of Clostridium difficile , aerolysins, and hemolysins; toxins produced by protozoa, such as Giardia; toxins produced by fungi.
- Molecular toxins can also include exotoxins, i.e., toxins secreted by an organism as an extracellular product, and enterotoxins, i.e., toxins present in the gut of an organism.
- the term “cells” refers to biological cells selected from the group consisting of living or dead cells (prokaryotic and eukaryotic, including mammalian), viruses, bacteria, fungi, yeast, protozoan, microbes, and parasites.
- the biological cells can be a normal cell or a diseased cell.
- Mammalian cells include, without limitation; primate, human and a cell from any animal of interest, including without limitation; mouse, hamster, rabbit, dog, cat, domestic animals, such as equine, bovine, murine, ovine, canine, and feline.
- the cells can be derived from a human subject.
- the cells are derived from a domesticated animal, e.g., a dog or a cat.
- exemplary mammalian cells include, but are not limited to, stem cells, progenitor cells, immune cells, blood cells, and any combinations thereof.
- the cells can be derived from a wide variety of tissue types without limitation such as; hematopoietic, neural, mesenchymal, cutaneous, mucosal, stromal, muscle, spleen, reticuloendothelial, epithelial, endothelial, hepatic, kidney, gastrointestinal, pulmonary, cardiovascular, T-cells, and fetus.
- ES cells embryonic stem (ES) cells, ES-derived cells and stem cell progenitors are also included, including without limitation, hematopoietic, neural, stromal, muscle, cardiovascular, hepatic, pulmonary, and gastrointestinal stem cells.
- Yeast cells may also be used as cells in some embodiments described herein.
- the cells can be ex vivo or cultured cells, e.g. in vitro.
- cells can be obtained from a subject, where the subject is healthy and/or affected with a disease. While cells can be obtained from a fluid sample, e.g., a blood sample, cells can also be obtained, as a non-limiting example, by biopsy or other surgical means know to those skilled in the art.
- Exemplary fungi and yeast include, but are not limited to, Cryptococcus neoformans, Candida albicans, Candida tropicalis, Candida stellatoidea, Candida glabrata, Candida krusei, Candida parapsilosis, Candida guilliermondii, Candida viswanathii, Candida lusitaniae, Rhodotorula mucilaginosa, Aspergillus fumigatus, Aspergillus flavus, Aspergillus clavatus, Cryptococcus neoformans, Cryptococcus laurentii, Cryptococcus albidus, Cryptococcus gattii, Histoplasma capsulatum, Pneumocystis jirovecii (or Pneumocystis carinii ), Stachybotrys chartarum , and any combination thereof.
- Exemplary bacteria include, but are not limited to: anthrax, campylobacter , cholera, diphtheria, enterotoxigenic E. coli , giardia, gonococcus, Helicobacter pylori, Hemophilus influenza B, Hemophilus influenza non-typable, meningococcus, pertussis, pneumococcus, salmonella, shigella, Streptococcus B, group A Streptococcus , tetanus, Vibrio cholerae, yersinia, Staphylococcus, Pseudomonas species, Clostridia species, Myocobacterium tuberculosis, Mycobacterium leprae, Listeria monocytogenes, Salmonella typhi, Shigella dysenteriae, Yersinia pestis, Brucella species, Legionella pneumophila, Rickettsiae, Chlamydia, Clostri
- Exemplary parasites include, but are not limited to: Entamoeba histolytica; Plasmodium species, Leishmania species, Toxoplasmosis, Helminths, and any combination thereof.
- Other examples of parasites can include, but are not limited to, intestinal worms, rabies, toxoplasma , and any combinations thereof.
- viruses include, but are not limited to, HIV-1, HIV-2, hepatitis viruses (including hepatitis B and C), Ebola virus, West Nile virus, and herpes virus such as HSV-2, adenovirus, dengue serotypes 1 to 4, ebola, enterovirus, herpes simplex virus 1 or 2, influenza, Japanese equine encephalitis, Norwalk, papilloma virus, parvovirus B19, rubella, rubeola, vaccinia, varicella, Cytomegalovirus, Epstein-Barr virus, Human herpes virus 6, Human herpes virus 7, Human herpes virus 8, Variola virus, Vesicular stomatitis virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, poliovirus, Rhinovirus, Coronavirus, Influenza virus A, Influenza virus B, Measles virus, Polyomavirus, Human Paper
- environmental contaminants or pollutants refers to microorganisms, molecules, and/or substances originated from an environmental source, e.g., air, food, and/or water, that can adversely affect at least one physiological function of a subject in a temporary or permanent manner, and/or can be fatal when they are ingested or inhaled by the subject.
- Exemplary environmental contaminants or pollutants can include, but are not limited to microorganisms (e.g., Cryptosporidium, Giardia lamblia , bacteria, Legionella , Coliforms, viruses, fungi, molds, spores), bromates, chlorites, haloactic acids, trihalomethanes, chloramines, chlorine, chlorine dioxide, antimony, arsenic, mercury (inorganic), nitrates, nitrites, selenium, thallium, Acrylamide, Alachlor, Atrazine, Benzene, Benzo(a)pyrene (PAHs), Carbofuran, Carbon, etrachloride, Chlordane, Chlorobenzene, 2,4-D, Dalapon, 1,2-Dibromo-3-chloropropane (DBCP), o-Dichlorobenzene, p-Dichlorobenzene, 1,2-Dichloroethane, 1,1-Dichloro
- nanomaterials is generally meant structures having at least one dimension in nanometer range.
- Examples of nanomaterials that can be exposed to cells can include, but are not limited to, single or multi-walled nanotubes, nanowires, nanodots, quantum dots, nanorods, nanocrystals, nanotetrapods, nanotripods, nanobipods, nanoparticles, nanosaws, nanosprings, nanoribbons, nanocapsules, branched nanomaterials, and any combinations thereof.
- the nanomaterials can be made of or comprise, e.g., carbon, metal or alloy, metal oxide, polymer, or any synthetic materials.
- the nanomaterials can comprise an active agent described herein, e.g., active agent-loaded nanoparticles.
- the term “particulates” refers to fine particles, powder, flakes, etc., that exist in a relatively small form.
- the particulates are small enough to be inhaled by a subject.
- the particulates can be produced as a by-product of a chemical reaction, e.g., burning a fuel.
- the particulates can be produced by, for example, grinding, shredding, fragmenting, pulverizing, atomizing, or otherwise subdividing a larger form of the material into a relatively small form. Examples of particulates can include, but are not limited to, soot, dust, smoke, aerosols, and any combinations thereof.
- aerosols refers to gaseous suspensions or solutions of dispersed solid or liquid particles, e.g., but not limited to, sprays, colloids, mists and respirable aerosols.
- the aerosols can be in suspension, solution or dry powder form.
- An aerosol can comprise an active agent described herein, e.g., cells (including, e.g., but not limited to, bacteria and/or virus), proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, therapeutic agents, molecular toxins, nanomaterials, particulates, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants).
- an active agent described herein e.g., cells (including, e.g., but not limited to, bacteria and/or virus), proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, therapeutic agents, molecular toxins, nanomaterials, particulates, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/
- respirable aerosol refers to an aerosol having a component that can be delivered to the lungs of a subject, and/or be deposited on the surfaces of a subject's nasal passages and/or adsorbed onto the tissue of the nasal passages.
- treating refers to therapeutic treatment wherein the purpose is to prevent or slow the development of the disease or disorder.
- Treatment is generally “effective” if one or more symptoms or clinical markers are reduced.
- a treatment is “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or decrease of markers of the disease, but also a cessation or slowing of progress or worsening of a symptom that would be expected in absence of treatment.
- Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (e.g., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already diagnosed with a disease or disorder, as well as those likely to develop a disease or disorder.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Clinical Laboratory Science (AREA)
- Cell Biology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Physiology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/569,029 filed Dec. 9, 2011, the content of which is incorporated herein by reference in its entirety.
- This invention was made with government support under U01 NS073474-01 from the National Institutes of Health and Food and Drug Administration, and W911NF-12-2-0036 from the Defense Advanced Research Projects Agency. The government has certain rights in the invention.
- The inventions provided herein relate to organ chips and applications thereof, e.g., analysis of drug efficacy, toxicity, and/or pharmacodynamics using one or a plurality of the organ chips.
- Pharmacokinetics is the study of the action of pharmaceuticals and other biologically active compounds from the time they are introduced into the body until they are eliminated. For example, the sequence of events for an oral drug can include absorption through the various mucosal surfaces, distribution via the blood stream to various tissues, biotransformation in the liver and other tissues, action at the target site, and elimination of drug or metabolites in urine or bile. Pharmacokinetics provides a rational means of approaching the metabolism of a compound in a biological system.
- One of the fundamental challenges being encountered in drug, environmental, nutritional, consumer product safety, and/or toxicology studies includes the extrapolation of metabolic data and risk assessment from in vitro cell culture assays to animals. Although some conclusions can be drawn with the application of appropriate pharmacokinetic principles, there are still substantial limitations. One concern is that current screening assays utilize cells under conditions that do not replicate their function in their natural setting. The circulatory flow, interaction with other tissues, and other parameters associated with a physiological response are not found in standard tissue culture formats. While in vivo animal models can be used to perform pharmacokinetics (PK)/pharmacodynamics (PD) study, it significantly can increase the cost of the research and the screening throughput is low. Accordingly, there is a strong need in the art for developing alternatives to the use of animal studies, e.g., in vitro models that can better replicate physiological conditions for cells to function in a similar manner as they are present in vivo. Such models can be used, e.g., for PK/PD studies, drug screening, engineered scaffolds for tissue/organ repair or replacement, and/or development of a disease model of interest.
- One aspect provided herein relates to microengineered organ chips or organ-on-a-chip devices. Organ chips (also known as “organ-on-a-chip device”) are microfluidic devices that are configured to mimic at least one physiological function and/or response of organs of interest, e.g., from a mammal (e.g., a human), other animal or organism, an insect, or a plant. For example, organ chips or organ-on-a-chip devices can be microfluidic devices that comprise at least one type of living cells, e.g., at least one type of tissue cells, cultured therein and are designed to recapitulate the three-dimensional (3D) tissue-tissue interfaces, mechanically active microenvironments, electrical stimulation, chemical conditions and/or complex organ-level functions. Examples of the organ chips described herein, can include but are not limited to, lung chips to mimic breathing lungs, heart chips to mimic beating hearts, liver chips to mimic metabolic livers, kidney chips to mimic filtering kidney, gut chips to mimic peristalsing guts, lung airway smooth muscle chips to mimic reactive airways, skeletal muscle chips to mimic contracting skeletal muscles, skin chips to mimic skin barriers, brain chips to mimic blood-brain barriers, testis chips to mimic reproductive/endocrine testes and bone marrow chips to mimic self-renewing bone marrow.
- In some embodiments, an organ chip or organ-on-a-chip device can be configured to represent a functional microenvironment of an organ (e.g., a functional unit or section of an organ, and/or a tissue-capillary interface). By way of example only, a lung-mimicking chip (or lung-on-a-chip) does not necessarily need to mimic the structure of a whole lung. Instead, the lung-on-chip can be configured to mimic the interaction of capillary cells and air sac cells in an alveolus (air sac) under a mechanical stimulation (e.g., breathing). In such embodiments, the two different cell types (e.g., capillary cells and air sac cells) can be cultured on opposing sides of a flexible porous membrane disposed in a channel of a microfluidic device. The flexible porous membrane can expand and contract to mimic the movement of an alveolar wall during lung breathing, by controlling the pressure gradient induced in the microfluidic device.
- In some embodiments, living human cells can be cultured in organ chips described herein to mimic at least one physiological function and/or response of the corresponding human organs. Thus, in one embodiment, microengineered human organ chips are also provided herein.
- A plurality of (e.g., 2 or more) organ chips representing various organs can be assembled or connected (e.g., fluidically connected) together to form an in vitro microphysiological system that mimics at least one physiological function and/or response of one or more systems in vivo, e.g., including, but not limited to, a circulatory system, a respiratory system, an excretory system, a nervous system, a gastrointestinal system, or any combinations thereof. Accordingly, another aspect provided herein relates to an in vitro microphysiological system that comprises at least two organ chips described herein or more, e.g., at least three organ chips, at least four organ chips or more. In some embodiments, the in vitro microphysiological system can be used to model or study mammalian (e.g., human) organs and physiological systems and effects of active agents on such organs and physiological systems. In some embodiments, the in vitro microphysiological system can be used to model or study organs and physiological systems of other animals (e.g., non-mammals), insects and/or plants, as well as effects of active agents on such organs and physiological systems.
- Kits comprising a plurality of organ chips, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more organ chips are also provided herein. In some embodiments, the organ chips in the kit can be all the same, i.e., corresponding to the same organ. In some embodiments, at least some of the organ chips in the kit can represent a different organ. For example, a kit directed to a circulatory system can comprise at least one heart chip and at least one bone-marrow chip. In an alternative embodiment, a kit directed to a gastrointestinal system can comprise at least one liver chip and at least one gut chip. Depending on the microphysiological system of interest, the kits can comprise a plurality of distinct organ chips that are involved in the microphysiological system.
- In some embodiments, the organ chips can each be individually packaged, e.g., for sterility purposes. In some embodiments, the kits can further comprise at least one agent, e.g., an appropriate culture medium for each different organ chip. In some embodiments, the kits can further comprise an instruction manual, e.g., instructions on connecting various organ chips together to form an integrated network.
- The organ chips, microphysiological systems and/or kits described herein can be used for various applications where simulation of a physiological condition is desirable, e.g., drug screening, PK/PD studies, engineered scaffolds for tissue/organ repair or replacement, and/or development of a disease model of interest. In some embodiments, the cells cultured in the organ chips can be collected from a subject, e.g., for personalized therapeutic treatment. For example, subject-specific cells can be cultured in an organ chip or a microphysiological system simulated for a disease or disorder that the subject is diagnosed of, or suspected of having, and subjected to various kinds and/or dosages of drugs to determine an optimal treatment regimen for the subject.
-
FIG. 1 is an image showing one embodiment of a lung-on-a-chip described herein, inside which the breathing of a lung is stimulated. In this embodiment, the lung-on-a-chip comprises ports for nutrient delivery, waste disposal, and/or creation of a pressure gradient to mimic breathing. -
FIGS. 2A-2B are schematic representations of a lung-on-a chip in accordance with one embodiment described herein.FIG. 2A is a schematic representation showing an exemplary configuration of a lung-on-a-chip.FIG. 2B is a schematic representation showing movement (e.g., stretching) of a flexible porous membrane under application of vacuum to side chambers of the lung-on-a-chip. -
FIGS. 3A-3C shows that human lung-on-a-chip can be used to predict TL-2 chemotherapy toxicity (vascular leakage) responses based on mimicry of the lung's dynamic mechanically-active (breathing) microenvironment. -
FIGS. 4A-4D is a set of images showing that a contractile heart (muscle) chip mimics tissue organization (FIG. 4A ) in a multiplexed array of “muscular thin films” (MTFs) within a microfluidic device (FIGS. 4B and 4C ), which can be used to quantitate contractile stress in real-time (FIG. 4D ). -
FIG. 5 is a set of line graphs showing that “muscular thin films” MTFs mimic whole heart tissue drug responses. Top row shows the dose response of engineered neonatal rat ventricular tissues in the form of muscular thin films on the heart chip, treated with calcium (left), caffeine (middle), and isoproterenol (right). The bottom row shows the corresponding responses of adult rat ventricular strips. -
FIG. 6 is a schematic representation showing a series of exemplary assembly steps for one embodiment of a muscular thin film contractility assay based on a PDMS thin film. -
FIG. 7 is a schematic representation showing a series of exemplary assembly steps for one embodiment of a muscular thin film contractility assay based on a patterned alginate thin film. -
FIG. 8 is a schematic diagram showing exemplary features of a heart chip according to one embodiment described herein. (i) depicts a dual-chamber system with a single medium stream that feeds 2 chambers: an electrophysiological (EPhys) chamber and a MTF chamber; (ii) shows that the EPhys chamber can allow electrophysiological recordings on a monolayer of cardiac muscle in a low volume chamber with micro-electrodes embedded in the bottom of the chamber; (iii) illustrates that a larger chamber situated next to the EPhys chamber can allow high throughput contractility measurements using an array of muscular thin films; (iv) shows that the MTF chamber consists of an anisotropic layer of cardiac myocytes cultured on laser-cut horizontal MTFs whose radius of curvature can be measured optically. -
FIGS. 9A-9B is a set of schematic diagrams showing an alternative technology to monitor cellular contraction.FIG. 9A shows that cell monolayers are adhered to a deformable, perforated membrane within a microfluidic device (i & ii).FIG. 9B shows that as the muscle cell layer contracts, the substrate deforms, such that the morphology of the holes within the substrate is altered (i & ii). Hence, the morphology of the holes within the substrate can be monitored optically to determine the state of cellular contraction, with undeformed holes representing the relaxed state (FIG. 9A , ii) and deformed holes representing the contracted state (FIG. 9B , ii). The eccentricity of the holes can be evaluated with specifically-programmed algorithms, e.g., software (e.g., DBG software) originally designed to quantify nuclear eccentricity. -
FIGS. 10A-10D is a set of data showing physiological responses of human vascular smooth muscle (VSM) and engineered rat cardiac muscle (CM) on the same chip to drugs determined by a MTF assay.FIG. 10A is a schematic representation showing manufacture of an organ chip with two different kinds of muscle (striated and smooth).FIG. 10B is a set of data showing MTF deformation (i, v, ix), CM diastole (ii, vi, x), CM peak systole (iii, vii, xi), and CM stress (iv, viii, xii), before and after exposure to drugs (e.g., ET-1, and ROCK inhibitor) during the contractility assay.FIGS. 10C and 10D are data graphs showing the contractility of the VSM is considerably slower than the CM and the stress histories are depicted uniquely for each one. -
FIGS. 11A-11F are images showing a human gut chip according to one embodiment described herein.FIG. 11A is a schematic representation showing a portion of a human gut chip that mimics normal villus architecture of the intestine.FIGS. 11B-11D shows that a gut chip can mimic normal villus architecture of the intestine, in part by leveraging the lung-on-a-chip (or lung chip) mechanically activated, multi-layered microfluidic architecture (FIG. 11B ) to rhythmically distort the epithelium as normally occurs during peristalsis (FIGS. 11C-11D ).FIG. 11E is an image showing perfusion of cells in the device.FIG. 11F is an image showing perfusion of cells in the device can maintain cell viability for weeks and result in formation of villi that take the height of the Interstitial Channel. -
FIG. 12 is a schematic diagram showing architecture of human blood-brain-barrier and an organ chip that mimics the blood-brain-barrier. In one embodiment, the normal architecture of the human blood brain barrier (top panel) is mimicked by culturing human endothelium on one side of a porous membrane and human astrocytes on the other side within a microfluidic channel with platinum electrodes embedded therein (bottom panel). -
FIG. 13 is a schematic diagram showing exemplary features of a skeletal muscle chip according to one embodiment described herein. (i) depicts a dual-chamber system with a single medium stream that feeds 2 chambers: an electrophysiological (EPhys) chamber and an MTF chamber; (ii) shows that the EPhys chamber can allow EMG recordings on a monolayer of skeletal muscle in a low volume chamber with micro-electrodes embedded in the bottom of the chamber; (iii) shows that a larger chamber situated next to the EPhys chamber can allow high throughput contractility measurements using an array of muscular thin films (MTFs); (iv) shows that the MTF chamber consists of an anisotropic layer of skeletal myocytes cultured on laser-cut horizontal MTFs whose radius of curvature can be measured optically. -
FIG. 14 is a schematic representation of functional readouts from a co-culture of skeletal muscle and adipocyte layers, for example, using the skeletal muscle chip shown inFIG. 13 . (i) shows an electrophysiological (EPhys) chamber, which allows EMG recordings on a monolayer of a co-culture of adipose and skeletal muscle. (ii) shows a MTF chamber with an array of muscular thin films (MTFs) built from a heterogeneous co-culture of skeletal muscle and adipose tissue. -
FIGS. 15A-15C are data showing anisotropic cardiac tissue formation on micromolded alginate substrates.FIG. 15A is data showing that the micromolding technique replicates faithfully the original pattern.FIG. 15B is a phase contrast image of representative tissues.FIG. 15C is an immunofluorescence composite image of muscular thin films: actin is red, nuclei are blue and α-actinin is green. Scale bar equals 50 μm. In some embodiments, alginate micromolded surfaces can be used to align and culture skeletal muscle cells (e.g., myotubes) in a 3-D like environment, instead of a 2-D flat substrate. -
FIGS. 16A-16B is a set of schematic representation showing an airway chip according to one embodiment described herein.FIG. 16A is a schematic diagram showing an airway on a chip, in one embodiment, can comprise healthy bronchial tissue, cultured in liquid media (i), e.g., with a capability of drug perfusion (ii). The cell monolayer can exhibit a linear arrangement of cells, adhered to the top surface of a PDMS muscular thin film. Incubation in culture media (no drug or test agent) can yield relaxed bronchial thin films (iii), while incubation with drugs can yield contracted bronchial thin films (iv). The contractility can be measured for grading the drug response in the tissue.FIG. 16B is a schematic representation of exemplary dimensions of an airway chip containing multiple bronchial thin films (i), with an optional capability to add a layer of epithelial columnar cells (ii). This cell layer can be adhered to a porous membrane that separates the bronchial from epithelial cells, and be exposed to air flow, aerosols or a combination thereof. -
FIGS. 17A-17B are schematic representation showing exemplary features of an airway chip with two chambers in accordance with one embodiment described herein.FIG. 17A is a schematic representation of an airway on a chip with two chambers.Chamber 1 can contain healthy bronchial tissue, while an asthmatic phenotype can be contained inChamber 2. The asthmatic phenotype can comprise cultures from human diseased cells or cells that are induced artificially (e.g., by toxic agents, temperature) to display at least one phenotype ofdiseased cells Chambers Chamber 1 andChamber 2 by the closing of a valve (pictured in the legend, with a single pole, single throw (SPST) and Normal Open/Normal Close (NO/NC) valve). Monolayers of healthy and asthmatic cells can exhibit an anisotropic organization and can be adhered to the top surface of PDMS muscular thin films. Incubation in culture media can yield relaxed thin films (iii), while incubation with drugs can yield contracted thin films (iv). The contractility can be measured for grading the response of the different tissue types to the drugs.FIG. 17B is a schematic representation of exemplary dimensions of an airway chip containing multiple bronchial thin films (i), with an optional capability to add a layer of epithelial columnar cells (ii). This epithelial cell layer can be adhered to a porous membrane that separates the bronchial muscle from the epithelium, and be exposed to air flow, aerosols, or a combination thereof. -
FIGS. 18A-18B are schematic diagrams showing an alternative technology to monitor cellular contraction.FIG. 18A shows that cell monolayers can be adhered to a “swiss cheese”-like substrate or a deformable, perforated membrane, situated within a microfluidic device (i & ii).FIG. 18B shows that as the muscle cell layer contracts, the substrate deforms, such that the morphology of the holes within the substrate is altered (i & ii). The morphology of the holes within the substrate can be monitored optically to determine the state of the cellular contraction, with undeformed holes representing the relaxed state (FIG. 18A , ii) and deformed holes representing the contracted state (FIG. 18B , ii). The eccentricity of the holes can be evaluated with a specifically-programmed algorithm, e.g., software (e.g., DBG software) originally designed to quantify nuclear eccentricity. -
FIGS. 19A-19B shows an exemplary setup of a multiple film chip experiment and collected data from a human asthma (e.g., a chemically-induced human asthma) induced on one embodiment of an organ chip.FIG. 19A is a schematic diagram showing exemplary manufacture of an organ chip comprising human bronchial smooth muscle thin films.FIG. 19B show data comparing the phenotypes and/or behavior of control cells and diseased cells (induced with asthma) in the organ chip. (i) and (ii) show actin staining of healthy engineered tissue and the chemically induced asthma model, respectively. Differences in actin alignment within the tissue constructs, as indicated by the orientational order parameter (iii) indicates significant remodeling of the contractile apparatus. Drug experiments (iv for healthy and v for asthma model) indicate differences in the contractile response to acetylcholine (AcH) and to a Rho kinase inhibitor (HA 1077). (vi) is a plot graph showing percentages of cell contraction and relaxation for control (healthy) and asthma models. -
FIG. 20 is a set of data showing that a synthetic bone marrow (sBM) can fully recapitulate natural mouse bone marrow (mBM) but not peripheral blood (mPB) 8 weeks after implanting an organ chip with differentiated blood cells (DMPs) or hematopoietic stem and progenitor stem cells (BMPs) subcutaneously. Similar functionality can be maintained in vitro by culturing in a microfluidic device the sBM explant. - There is a need in developing alternative models to in vivo animal models for various applications, e.g., in analysis of drug efficacy, toxicity, and/or pharmacodynamics, or in studies of diseases or disorders. To this end, the inventors have developed various designs and configurations of “organ chips” (also used interchangeably herein with the term “organ-on-a-chip devices”), which can be configured as microfluidic devices to mimic at least one physiological function and/or response of different organs, and can be used to create in vitro microphysiological systems. For example, organ chips or organ-on-a-chip devices can be microfluidic devices that comprise at least one type of living cells (e.g., mammalian cells such as human cells) cultured therein and are designed to recapitulate the three-dimensional (3D) tissue-tissue interfaces, mechanically active microenvironments, electrical stimulation, chemical conditions and/or complex organ-level functions. Examples of the organ chips described herein, include, but are not limited to, lung chips to mimic breathing lung, heart chips to mimic beating heart, liver chips to mimic metabolic liver, kidney chips to mimic filtering kidney, gut chips to mimic peristalsing gut, lung airway smooth muscle chips to mimic reactive airway, skeletal muscle chips to mimic contracting skeletal muscle, skin chips to mimic skin barrier, brain chips to mimic blood-brain barrier, testis chips to mimic reproductive/endocrine testis, bone marrow chips to mimic self-renewing bone marrow, and any combinations thereof.
- In some embodiments, an organ chip or organ-on-a-chip device described herein can be configured to represent a functional microenvironment of an organ (e.g., a functional unit or section of an organ, and/or a tissue-capillary interface), e.g., but not limited to, an alveolar-capillary interface of a lung, a blood-brain-barrier of a brain, or a skin bather of a skin. By way of example only, a lung-mimicking chip (or lung-on-a-chip), which is further described below, does not necessarily need to mimic the structure of a whole lung. Instead, the lung-on-chip can be configured to mimic the interaction of capillary cells and air sac cells in an alveolus (air sac) under a mechanical stimulation (e.g., breathing). In such embodiments, the two different cell types (e.g., capillary cells and air sac cells) can be cultured on opposing sides of a flexible porous membrane disposed in a channel of a microfluidic device. The flexible porous membrane can expand and contract to mimic the movement of an alveolar wall during lung breathing, by controlling the pressure gradient induced in the microfluidic device.
- The organ chips can be used, individually or connected together (e.g., fluidically connected), for various applications where simulation of a physiological condition is desirable, e.g., drug screening, pharmacokinetics (PK)/pharmacodynamics (PD) studies, engineered scaffolds for tissue/organ repair or replacement, development of a disease model, and/or personalized therapeutic treatment.
- As used herein, the term “fluidically connected” refers to two or more organ chips connected in an appropriate manner such that a fluid or a least a portion of a fluid (e.g., any flowable material or medium, e.g., but not limited to, liquid, gas, suspension, aerosols, cell culture medium, and/or biological fluid) can directly or indirectly pass or flow from one organ chip to another organ chip. In some embodiments, two or more organ chips can be fluidically connected together, for example, using one or more fluid-transfer connecting means (e.g., adaptors, tubing, splitters, valves, pumps and/or channels) between the two or more organ chips. For example, two or more organ chips can be fluidically connected by connecting an outlet of one organ chip to an inlet of another organ chip using tubing, a conduit, a channel, piping or any combinations thereof. In some embodiments, two or more organ chips can be fluidically connected by, e.g., at least one pumping device and/or at least one valve device. In some embodiments, the pumping device and/or valve device can be configured for microfluidic applications, e.g., the membrane-based fluid-flow control devices as described in U.S. Provisional Application No. 61/735,206 filed Dec. 10, 2012, the content of which is incorporated herein by reference in its entirety.
- In other embodiments, two or more organ chips can be fluidically connected together when one or more other connecting means (e.g., devices, systems, and/or modules that can perform an additional function other than fluid transfer, e.g., but not limited to, filtration, signal detection, and/or imaging) are present between the two or more organ chips. In these embodiments, by way of example only, two or more organ chips can be fluidically connected, when the two or more organ chips are indirectly connected, e.g., through a biosensor, a filter, and/or an analytical instrument (e.g., via tubing), such that a fluid exiting the previous organ chip can be detoured to first flow through the biosensor, filter and/or analytical instrument, e.g., for detection, analysis and/or filtration of the fluid, before it enters the next organ chip. In these embodiments, at least a portion of the fluid can pass or flow from one organ chip to another organ chip. In some embodiments, two or more organ chips can be fluidically connected by, e.g., at least one bubble trap, e.g., the bubble trap can be a membrane-based bubble trap as described in U.S. Provisional Application No. 61/696,997, filed Sep. 5, 2012, and U.S. Provisional Application No. 61/735,215 titled “Cartridge Manifold and Membrane Based-Microfluidic Bubble Trap,” filed on Dec. 10, 2012, the contents of both of which are incorporated herein by reference in their entireties. Alternatively, two or more organ chips can be connected such that a fluid can pass or flow directly from one organ chip to another organ chip without any intervening components. In such an embodiment, the two or more organ chips can be designed and/or integrated on the same chip such that the outlet of one organ chip and the inlet of another organ chip share the same port.
- In some embodiments, one or more organ chips (e.g., heart chips) described herein can be adapted to fluidically connected upstream and/or downstream to at least one or more different organ chips (e.g., but not limited to lung chips or liver chips) to form an in vitro microphysiological system, which can be used to determine biological effects (e.g., but not limited to, toxicity, and/or immune response) of active agents on more than one organs. Examples of active agents include, but are not limited to, cells (including, e.g., but not limited to, bacteria and/or virus), proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, therapeutic agents, molecular toxins, nanomaterials, particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof. In some embodiments, the in vitro microphysiological system can be used to evaluate active agents that are effective in treating a disease or disorder in an organ, but might be toxic to other organ systems. For example, a drug, e.g., Ventolin, known to treat or prevent bronchospasm in subjects with reversible obstructive airway disease can be toxic to or adversely affect heart function. Thus, integration of two or more organ chips to form an in vitro microphysiological system can allow for testing or screening of drugs that are effective in treatment of a certain disease or disorder with minimal side effects or undesirable effects on other organs.
- Accordingly, in another aspect, provided herein are integrated network or functional in vitro microphysiological systems, each of which mimics at least one physiological function and/or response of one or more systems in vivo, e.g., of a mammal (e.g., a human), other animal, insect and/or plant. In some embodiments, the in vitro microphysiological systems described herein can mimic at least one physiological function and/or response of one or more systems in vivo, e.g., of a mammal (e.g., a human), including, e.g., but not limited to, a circulatory system, a respiratory system, an excretory system, a nervous system, a gastrointestinal system, or any combinations thereof. The in vitro microphysiological systems described herein are generally formed by connecting (e.g., fluidically connecting) together at least two organ chips representing different organs described herein. Different combinations of organ chips can be used in the system for different applications. In some embodiments, a plurality of organ chips (e.g., at least 1, at least 2, at least 3, at least 4, at least 5 or more organ chips) can be fluidically connected, e.g., via a tubing, to each other to form a microphysiological system, e.g., a circulatory system (comprising a heart chip with vascular endothelium and a bone marrow chip), a respiratory system (comprising a lung chip, and an airway smooth muscle chip), an immune system (comprising a bone marrow chip with other immune cells, e.g., macrophages); a musculoskeletal system (comprising a skeletal muscle chip), an excretory system (comprising a lung chip, a gut chip, and a kidney chip), an urinary system (comprising a bladder chip and a kidney chip), a nervous system (comprising a brain chip with astrocytes and neuronal networks), a reproductive system (comprising testis chip), an endocrine system (comprising a testis chip), a gastrointestinal system (comprising a liver chip, and a gut chip), an integumentary system (comprising a skin chip), and a urinary system (comprising a kidney chip).
- Depending on various target applications, e.g., for use as a disease model or for pharmacokinetics study of a drug, different combinations of organ chips can be selected. For example, in one embodiment, Lung Chips, Heart Chips and Liver Chips can be selected to form an in vitro microphysiological system, e.g., for determination of clinically relevant pharmacokinetics (PK)/pharmacodynamics (PD) as well as efficacy and toxicity (e.g., cardiotoxicity, which is the cause of more than 30% of all drug failures).
- In some embodiments, the in vitro microphysiological system can further comprise a bone marrow chip fluidically connected to the at least two different organ chips. In one embodiment, the bone marrow chip described in the International Appl. No. PCT/US12/40188, the content of which is incorporated herein by reference in its entirety, can be utilized in the in vitro microphysiological system described herein.
- In some embodiments, the in vitro microphysiological system can further comprise a spleen chip fluidically connected to the at least two different organ chips. In one embodiment, the spleen chip described in the International Appl. No. WO 2012/135834, the content of which is incorporated here by reference in its entirety, can be utilized in the in vitro microphysiological system described herein.
- In some embodiments, the in vitro microphysiological systems comprising a combination (e.g., at least 2 or more) of different organ chips can be disposed in a housing and/or the universal cartridges that can hold one or more organ chips as described in the U.S. Provisional Appl. Nos. 61/569,004 filed Dec. 9, 2011 and 61/696,997 filed Sep. 5, 2012, the contents of which are incorporated herein by reference in their entireties. For example, a housing to enclose various combinations of organ chips therein can provide functionalities, e.g., but not limited to temperature control, nutrient replenishment, pressure adjustment, imaging, sample analysis, and/or any combinations thereof.
- An organ chip can also include a microfluidic device which can mimic at least one physiological function of at least one living organ from a mammal (e.g., human), other animal, insect or plant. In some embodiments, an organ chip can be a microfluidic device which can mimic at least one physiological function of one mammalian (e.g., human) organ. In some embodiments, an organ chip can be a microfluidic device which can mimic physiological function of at least one (including 1, 2, 3, 4, 5, 6, 7 or more) mammalian (e.g., human) organs. In some embodiments where the organ chips mimic physiological functions of more than one mammalian (e.g., human) organs, the organ chips can comprise individual sub-units, each of which can mimic physiological function of one specific mammalian (e.g., human) organ.
- In some embodiments, the in vitro microphysiological system can comprise at least two different organ chips (e.g., each organ chip representing a different organ) and at least one or more connecting means (e.g., at least two or more connecting means) between the at least two different organ chips. The at least two different organ chips can be selected from one or both of the following design and/or configuration: (i) a first organ chip can comprise: a body comprising a central channel therein, and an least partially porous and at least partially flexible first membrane positioned within the central channel and along a plane, wherein the first membrane is configured to separate the central channel to form two sub-channels, wherein one side of the first membrane is seeded with vascular endothelial cells, and the other side of the first membrane is seeded with at least one type of organ-specific parenchymal cells; and (ii) a second organ chip can comprise: a body comprising a first chamber enclosing a plurality of muscular thin films adapted to measure contraction of muscle cells, and a second chamber comprising a layer of muscle cells on the bottom surface of the second chamber, wherein the bottom surface is embedded with an array of microelectrodes for recording of action potentials, and wherein the top surface of the second chamber is placed with at least a pair of electrodes for providing electric field stimulation to the muscle cells.
- In some embodiments, the at least two different organ chips can comprise at least two or more (e.g., 2, 3, 4, 5, or more) said first organ chips described herein. In one embodiment, the at least to different organ chips can comprise a lung chip described herein and a gut chip described herein. In one embodiment, the at least to different organ chips can comprise a lung chip described herein and a liver chip described herein.
- In some embodiments, the at least two different organ chips can comprise at least two or more (e.g., 2, 3, 4, 5, or more) said second organ chips described herein.
- In some embodiments, the at least two different organ chips can comprise at least one (e.g., 1, 2, 3, 4, 5 or more) said first organ chips described herein and at least one (e.g., 1, 2, 3, 4, 5, or more) said second organ chips described herein.
- The design and/or configuration of the first and second organ chips described herein generally provide the basis for development and construction of various organ chips, e.g., but not limited to, lung chips, liver chips, gut chips, kidney chips, heart chips, skin chips, brain chips, testis chips, skeletal muscle chips, lung airway smooth muscle chips (“airway chips”), and any combinations thereof. The application and modifications of these two basic organ chip designs to create various organ chips are illustrated and described in the section below “Examples of organ chips or organ-on-a-chip devices.” As described below, in some embodiments, the organ chips can be designed to have a common shape and have positioned inlets and outlets for delivery of fluids to the Microvascular and Interstitial fluid channels lined by microvascular endothelium and organ-specific parenchymal cells (e.g., but not limited to, alveolar epithelium, heart muscle, hepatocytes), respectively.
- Organ chips generally comprise a base substrate and at least one channel disposed therein. The number and dimension of channels in an organ chip can vary depending on the design, dimension and/or function of the organ chip. In some embodiments, an organ chip can comprise a plurality of channels (e.g., at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten or more channels). One of skill in the art will readily be able to design and determine optimum number and/or dimension of channels required to achieve a certain application. For example, if assessment of reproducibility and/or comparison of at least two experimental conditions are desirable, an organ chip can be constructed to comprise at least two, at least three, at least four, at least five identical channels. This can provide for a number of read-outs per chip, e.g., allowing assessment of reproducibility and/or for validation and implementation of the technology. For example, each channel can run a different condition (e.g., culturing normal (healthy) cells vs. diseased cells in different channels, or applying different dosages of the same drug to different channels, or applying different drugs at the same dosage to different channels). In some embodiments, an organ chip can comprise at least two parallel (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) channels. In one embodiment, an organ chip comprises four parallel channels, e.g., four identical parallel channels. Without wishing to be bound by theory, this configuration can provide quadruplicate read-outs per chip.
- The dimensions of the channels in the organ chips can each independently vary, e.g., depending on the channel function (e.g., as a conduit for fluid transfer or as a chamber for cell culture, e.g., for subsequent monitoring of cellular response), flow conditions, tissue microenvironment to be simulated, and/or methods for detecting cellular response. Thus, the cross-sectional dimensions of the channels can vary from about 10 μm to about 1 cm, or from about 100 μm to about 0.5 cm.
- In some embodiments, at least a portion of the channels disposed in the organ chips can comprise cells. In these embodiments, the channels can each be independently lined by one layer or multilayers of organ-specific parenchymal cell types (or differentiated cells) and/or vascular endothelium (a layer of vascular endothelial cells) in relevant tissue microenvironment (e.g., mechanochemical microenvironments), with or without intervening connective tissue cells (e.g., fibroblasts, smooth muscle cells, mast cells) or immune cells (e.g., neutrophils, macrophages).
- The organ chips can be sized to a specific need, e.g., for high throughput drug screening, or scaffolding, e.g., for tissue repair and/or replacement. In some embodiments, the organ chips can be implantable, and thus they can be sized to suit a target implantation site.
- In some embodiments, the organ chips can be fabricated from any biocompatible materials. Examples of biocompatible materials include, but are not limited to, glass, silicons, polyurethanes or derivatives thereof, rubber, molded plastic, polymethylmethacrylate (PMMA), polycarbonate, polytetrafluoroethylene (TEFLON™), polyvinylchloride (PVC), polydimethylsiloxane (PDMS), and polysulfone. In one embodiment, organ chips can be fabricated from PDMS (poly-dimethylsiloxane). In some embodiments, the organ chips can be disposable. In some embodiments, the organ chips can be fabricated from one or more materials that allow sterilization (e.g., by UV, high temperature and/or pressure, ethylene oxide, or ethanol) after use.
- In some embodiments, at least one channel of the organ chips can comprise one or more membranes, e.g., at least 1, at least 2, at least 3 or more membranes to separate the channel into sub-channels. The membrane can be rigid or at least partially flexible. The term “flexible” as used herein refers to a membrane that can be stretched and/or contracted by at least about 3%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 50%, at least about 60% or more, of its original length, without causing any macroscopic breaking, when a pressure is applied. In some embodiments, a flexible membrane can fully or partially restore to its original length after the pressure is released.
- In some embodiments, the membrane can be non-porous or at least partially porous. In some embodiments, the pore size of the membrane can be large enough to allow cells pass through it. In some embodiments, the pore size of the membrane can be too small for cells to pass through, but large enough for nutrient or fluid molecules to pass through or permeate.
- In some embodiments, the membrane can be non-coated or coated with extracellular matrix molecules (ECM) to facilitate cell adhesion (e.g., but not limited to, fibronectin, collagen, Matrigel, laminin, vitronectin, and/or any combinations thereof), other proteins such as growth factors or ligands (e.g., to facilitate cell growth and/or cell signaling). In some embodiments, the surface of the membrane can be modified and/or activated, e.g., with any art-recognized polymer surface modification techniques such that bioactive molecules, e.g., ECM molecules, carbohydrates, proteins such as growth factors or ligands, can be covalently or non-covalently attached to or coated on it. Examples of polymer surface modification such as wet chemical, organosilanization, ionized gas treatments, and UV irradiation can be used to modify the membrane to permit covalent conjugation of bioactive molecules to the modified surfaces, such as usage of hydrophilic, bifunctional, and/or branched spacer molecules. See, e.g., Goddard and Hotchkiss “Polymer surface modification for the attachment of bioactive compounds” Progress in Polymer Science, Volume 32,
Issue 7, July 2007, Pages 698-725, for examples of polymer surface modification techniques. - The material for the membrane can be selected for at least one of the following properties, but are not limited to: the material is (i) biocompatible, (ii) complies with IS 10993-5 (in vitro cytotoxicity tests for medical devices), (iii) has low absorption of hydrophobic dye/drug and other chemical compounds, (iv) is cell adhesive, (v) is optically clear, is highly flexible, moldable, bondable, (vi) has low autofluorescence, (vii) does not swell in water, or (viii) has any combinations of the aforementioned properties. In one embodiment, the membrane material can include polyurethane (e.g.,
Clear flex 50 polyurethane). In another embodiment, the membrane material can include PDMS. - In some embodiments, the membrane can be seeded with or without cells. In some embodiments where cells are seeded on the membrane, cells can be seeded on one side or both sides of the membrane. In some embodiments, both sides of the membrane can be seeded with the same cells. In other embodiments, both sides of the membrane can be seeded with different cells, as described below, e.g., to create a Microvascular channel (comprising vascular endothelial cells) and an Interstitial channel (comprising organ-specific parenchymal cells). In some embodiments, the membrane can be seeded with at least one layer of cells, including, at least 2 layers of cells or more. Each layer of cells can be the same or different.
- In some embodiments, at least one channel or sub-channel of the organ chip can be filled with a gel or a hydrogel, e.g., but not limited to, collagen gel, matrigel gel, fibrin gel, or any combinations thereof. The gel can be seeded with or without cells.
- In some embodiments, at least one channel or sub-channel of the organ chip can contain a tissue, e.g., a biopsy collected from a subject.
- In some embodiments, the inner surface(s) of the channel(s) (or channel walls) and/or membrane(s) that are in contact with a fluid (e.g. a liquid or a gas) can be modified for reducing non-specific binding of a species in the fluid to the inner surface(s) of the channel(s). For example, at least one surface of the channel(s) and/or membrane(s) in contact with the fluid can be coated with a surfactant, e.g., PLURONIC® 127, or a blocking protein such as bovine serum albumin, for reducing cell or protein adhesion thereto. Additional surfactant that can be used to reduce the adhesive force between the surface of the channel and non-specific binding of a species in a fluid sample can include, but are not limited to, hydrophilic (especially amphipathic) polymers and polymeric surface-acting agents; non-ionic agents such as polyhydric alcohol-type surfactants, e.g., fatty acid esters of glycerol, pentaerythritol, sorbitol, sorbitan, and more hydrophilic agents made by their alkoxylation, including polysorbates (TWEEN®); polyethylene glycol-type surfactants such as PLURONIC surfactants (e.g., poloxamers), polyethylene glycol (PEG), methoxypolyethylene glycol (MPEG), polyacrylic acid, polyglycosides, soluble polysaccharides, dextrins, microdextrins, gums, and agar; ionic agents, including anionic surfactants such as salts of carboxylic acids (soaps), sulfuric acids, sulfuric esters of higher alcohols; cationic surfactants such as salts of alkylamine type, quaternary ammonium salts, or amphoteric surfactants such as amino acid type surfactants and betaine type surfactants. A skilled artisan will readily be able to determine appropriate methods and/or reagents for use to reduce non-specific binding of a species in a fluid to the channel wall(s) and/or membranes, based on the substrate material of the microfluidic devices and/or types of species to be blocked.
- In some embodiments, there can be at least one micro-post, including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more micro-posts within one or more channels. The dimension and/or arrangement of the micro-posts can be determined by a user. For example, the micro-posts can be used to separate cell debris from a flowing fluid to prevent clogging the downstream channel. In some embodiments, the micro-posts can be coated with an agent (e.g., antibodies) that permits capture of specific cells.
- In some embodiments, the organ chips can comprise a plurality of ports. For example, the organ chips can comprise at least one inlet port for introducing culture medium, nutrients or test agents such as drugs into the organ chips, and at least one outlet port for a fluid to exit. In some embodiments, at least one port can be connected to a pump or a syringe, e.g., via a tubing, to facilitate the fluid transfer through the channel and/or to apply a pressure to the channel. In some embodiments, at least one port can be connected to at least one electrical component, e.g., an electrode for ECG measurement. In some embodiments, at least one port can be connected to a nebulizer, e.g., to generate aerosolized liquid for aerosol delivery. In some embodiments, at least one port can be connected to or interfaced with a processor, which stores and/or analyzes the signal from a biosensor incorporated therein. The processor can transfer the data to computer memory (either hard disk or RAM) from where it can be used by a software program to further analyze, print and/or display the results. In some embodiments, the organ chips can have control ports, e.g., for application of mechanical deformation (e.g., side chambers to apply cyclic vacuum, as in the Lung Chip described herein and in the International Application No.: WO 2010/009307, the contents of which are incorporated herein by reference in their entireties) and/or electrical connections (e.g., for electrophysiological analysis of muscle and nerve conduction).
- In some embodiments of any types of organ chips and/or in vitro microphysiological systems described herein, any fluid control elements can be incorporated into the organ chips and/or in vitro microphysiological systems to modulate the fluid flow. For example, bubble traps can be integrated into each organ chip and/or in vitro microphysiological systems to minimize the effects of any bubbles that may form in the pumps, valves, or tubing. In some embodiments, microsensors or biosensors can also be integrated into the organ chips and/or in vitro microphysiological systems for controlling the culture conditions and/or monitoring the response of cells to the culture conditions. Any art-recognized biosensors, e.g., thin enzyme electrodes (Ref. 5) and/or microphysiometers (Ref. 6) can be used in any embodiments of the organ chips and/or in vitro microphysiological systems described herein.
- In some embodiments of any types of organ chips described herein, organ chips can be oxygenated either through a porous material used in the construction of the organ chips (e.g., PDMS) or using on-cartridge or systemic gas exchange membranes.
- An organ chip can be produced with or without aerosol delivery capabilities. In some embodiments, an organ chip can be adapted to deliver an aerosol, e.g., comprising an active agent described herein, to cells cultured in the channels. Detailed information about various designs and configurations of microfluidic devices for aerosol delivery can be found, e.g., in the International Application No. WO 2012/154834, the contents of which are incorporated herein by reference in their entireties.
- As an organ chip is developed to mimic the respective function of an organ, the design of each organ chip can be different according to their respective physiological properties and/or functions. For example, the organ chips can differ in, e.g., but not limited to, cell populations (e.g., cell types and/or initial cell seeding density), internal design, microarchitecture, dimensions, fluidic control, mechanical and electrical control and read-outs depending on the organ type (e.g., Lung Chip versus Heart Chip).
- In some embodiments, the organ chips can be designed to have a common shape and have positioned inlets and outlets for delivery of fluids to the Microvascular channels lined by microvascular endothelium and Interstitial fluid channels lined by organ-specific parenchymal cells (e.g., but not limited to, alveolar epithelium, heart muscle, hepatocytes). See, e.g., the section ““Examples of organ chips or organ-on-a-chip devices” for exemplary design of various organ chips based in part on the two basic organ chips (e.g., Lung chips and Heart chips) described herein.
- Without limitations, different kinds of organ chips described herein can comprise additional cell types, e.g., but not limited to, immune cells, stromal cells, smooth muscle cells, neurons, lymphatic cells, adipose cells, and/or microbiome in gut, based on the goals of the application. By way of example only, if inflammatory response is desired to be studied in a gut or liver model, immune cells can be incorporated into the gut or liver chip accordingly.
- Functional Assessment of Organ Chips:
- The viability and/or function of various organ chips can be generally assessed, e.g., morphologically with optical imaging. In some embodiments, any other art-recognized characterization techniques can be used to determine the function of various organ chips. For example, the alveolar-capillary interface function of the Lung Chip can be measured, e.g., by quantifying permeability barrier function (e.g., using TEER and molecular exclusion), measuring surfactant production, and/or demonstrating physiological relevant responses to cytokines (e.g., ICAM1 expression in response to TNFα). See e.g., Huh D. et al., 2010. Heart muscle function can be characterized, e.g., using force-frequency curves, measuring increases in peak contraction stress as a function of increasing field stimulation frequency, and/or analyzing electrocardiogram results during the same protocol to ensure that the tissues are functioning electrically. See Grosberg A. et al. 2011. Functionality of the Liver Chip can be assessed, e.g., via multiple well established assays including albumin secretion, transporter expression and/or function (efflux and uptake transporters), and/or CYP450 expression. Specific CYP450 enzyme can be determined, e.g., by incubation with FDA approved probe substrates REF1, and specific metabolite formation for each CYP450 isoform can be measured and validated, e.g., using LC/MS. Response of hepatocytes to prototypical CYP450 inducers (e.g., Rifampacin for CYP3A4) can be assessed.
- Based on the functional assessments, one of skill in the art can adjust the condition of the organ chips, e.g., by modulating the flow rate of fluid (fluid shear stress), nutrient level, mechanical stimulation, electrical stimulation, cell seeding density on the membranes, cell types, ECM composition on the membrane, dimension and/or shapes of the channels, oxygen gradient and any combinations thereof, to modulate the functional outcome of the organ chips, or the in vitro microphysiological system.
- Parenchymal cells are selected to suit for specific organ chips. Parenchymal cells are generally the distinct cells of an organ contained in and supported by the connective tissue framework. The parenchymal cells typically perform a function that is unique to the particular organ. In some embodiments, the term “parenchymal” can exclude cells that are common to many organs and tissues such as fibroblasts and endothelial cells within blood vessels.
- For example, in a liver organ, the parenchymal cells can include hepatocytes, Kupffer cells, epithelial cells that line the biliary tract and bile ductules, and any combinations thereof. The major constituent of the liver parenchyma are polyhedral hepatocytes (also known as hepatic cells) that presents at least one side to an hepatic sinusoid and opposed sides to a bile canaliculus. Liver cells that are not parenchymal cells include cells within the blood vessels such as the endothelial cells or fibroblast cells.
- In striated muscle, the parenchymal cells can include myoblasts, satellite cells, myotubules, myofibers, and any combinations thereof.
- In cardiac muscle, the parenchymal cells can include the myocardium also known as cardiac muscle fibers or cardiac muscle cells, the cells of the impulse connecting system such as those that constitute the sinoatrial node, atrioventricular node, atrioventricular bundle, and any combinations thereof.
- In a pancreas, the parenchymal cells can include cells within the acini such as zymogenic cells, centroacinar cells, basal or basket cells, cells within the islets of Langerhans such as alpha and beta cells, and any combinations thereof.
- In spleen, thymus, lymph nodes and bone marrow, the parenchymal cells can include reticular cells, blood cells (or precursors to blood cells) such as lymphocytes, monocytes, plasma cells, macrophages, and any combinations thereof.
- In the kidney, parenchymal cells can include cells of collecting tubules, the proximal and distal tubular cells, and any combinations thereof.
- In the prostate, the parenchyma can include epithelial cells.
- In glandular tissues and organs, the parenchymal cells can include cells that produce hormones. In the parathyroid glands, the parenchymal cells can include the principal cells (chief cells), oxyphilic cells, and a combination thereof. In the thyroid gland, the parenchymal cells can include follicular epithelial cells, parafollicular cells, and a combination thereof. In the adrenal glands, the parenchymal cells can include the epithelial cells within the adrenal cortex and the polyhedral cells within the adrenal medulla.
- In the parenchyma of the gastrointestinal tract such as the esophagus, stomach, and intestines, the parenchymal cells can include epithelial cells, glandular cells, basal cells, goblet cells, and any combinations thereof.
- In the parenchyma of lung, the parenchymal cells can include the epithelial cells, mucus cells, goblet cells, alveolar cells, and any combinations thereof.
- In the skin, the parenchymal cells can include the epithelial cells of the epidermis, melanocytes, cells of the sweat glands, cells of the hair root, and any combinations thereof.
- Cell Sources:
- The cells (e.g., parenchymal cells and/or vascular endothelial cells) used in the organ chips can be isolated from a tissue or a fluid of subject using any methods known in the art, or differentiated from stems cells, e.g., embryonic stem cells, or iPSC cells, or directly differentiated from somatic cells. In some embodiments, stem cells can be cultured inside the organ chips and be induced to differentiate to organ-specific cells. Alternatively, the cells used in the organ chips can be obtained from commercial sources, e.g., Cellular Dynamics International, Axiogenesis, Gigacyte, Biopredic, InVitrogen, Lonza, Clonetics, CDI, and Millipore, etc.).
- In some embodiments, the cells used in the organ chips can be differentiated from the “established” cell lines that commonly exhibit poor differentiated properties (e.g., A549, CaCo2, HT29, etc.). These “established” cell lines can exhibit high levels of differentiation if presented with the relevant physical microenvironment (e.g., air-liquid interface and cyclic strain in lung, flow and cyclic strain in gut, etc.), e.g., in some embodiments of the organ chips.
- In some embodiments, the cells used in the organ chips can be genetically engineered for various purposes, e.g., to express a fluorescent protein, or to modulate an expression of a gene, or to be sensitive to an external stimulus, e.g., light, pH, temperature and/or any combinations thereof.
- An in vitro microphysiological system can comprise at least two different organ chips using one or both of the first and second organ chip designs described herein. The first organ chip design is based a microfluidic device comprising: a body comprising a central channel therein, and an least partially porous and at least partially flexible first membrane positioned within the central channel and along a plane, wherein the first membrane is configured to separate the central channel to form two sub-channels, wherein one side of the first membrane is seeded with vascular endothelial cells, and the other side of the first membrane is seeded with at least one type of organ-specific parenchymal cells.
- In some embodiments, the first organ chip can further comprise at least a channel wall positioned adjacent to the two sub-channels, wherein the first membrane can be mounted to the channel wall; and an operating channel adjacent to the two sub-channels on an opposing side of the channel wall, wherein a pressure differential applied between the operating channel and the two sub-channels can cause the channel wall to flex in a desired direction to expand or contract along the plane within the two sub-channels.
- The second organ chip design is based on a microfluidic device comprising: a body comprising a first chamber enclosing a plurality of muscular thin films adapted to measure contraction of muscle cells, and a second chamber comprising a layer of muscle cells on the bottom surface of the second chamber, wherein the bottom surface is embedded with an array of microelectrodes for recording of action potentials, and wherein the top surface of the second chamber is placed with at least a pair of electrodes for providing electric field stimulation to the muscle cells.
- In some embodiments, the second organ chip can further comprise an at least partially porous second membrane positioned within the first chamber to form a top chamber and a bottom chamber, wherein the bottom chamber can comprise the plurality of muscular thin films on its bottom surface, and wherein the surface of the second membrane in contact with the top chamber can be seeded with a layer of epithelial cells.
- The design of the first organ chip described herein can provide a basis for development of organ chips to mimic tissue-tissue interfaces, and/or mechanically-active microenvironment. For example, lung chips, liver chips, gut chips, kidney chips, skin chips, brain chips, testis chips, and any combinations thereof, can be constructed based on the first organ chip design with any appropriate modifications.
- The design of the second organ chip described herein can provide the basis for development of organ chips where cell contraction, and/or electric field stimulation of the cells are intended. For example, heart chips, skeletal muscle chips, lung airway smooth muscle chips, brain chips, and any combinations thereof can be constructed based on the second organ chip design with any appropriate modifications.
- In some embodiments, an organ chip, e.g., a brain chip can employ either or both designs of the first and second organ chips, with any appropriate modifications.
- The following examples of organ chips are intended to illustrate applications and/or adaptations of the first organ chip design and/or second organ chip design to construct various organ chips, and should not be construed to be limiting. Any modifications to the organ chips described herein that are within one of skill in the art are also encompassed by the scope described herein.
- Lung Chips or Lung-On-a-Chip:
- The methods, multi-channeled architecture and ability of a Lung Chip (
FIG. 1 andFIGS. 2A-2B ) to mimic, at least in part, the normal physiology (e.g., normal breathing) of a lung are based on the first organ chip design and has been previously described in Huh D. et al. “Reconstituting organ-level lung function on a chip” Science (2010) 328: 1662, and in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties. - For example,
FIGS. 2A-2B shows diagrammatic views of a lung-on-a-chip in accordance with one embodiment described herein. The lung chip can comprise abody 202 having acentral microchannel 204 therein; and an at least partially porous and at least partiallyflexible membrane 206 positioned within thecentral microchannel 204 and along a plane. Themembrane 206 is configured to separate thecentral microchannel 204 to form a firstcentral microchannel 208 and a secondcentral microchannel 210, wherein a first fluid is applied through the firstcentral microchannel 208 and a second fluid is applied through the secondcentral microchannel 210. There is at least one operating channel (212A, 212B) separated from the first 208 and second 210 central microchannels by afirst microchannel wall 214. Themembrane 206 is mounted to thefirst microchannel wall 214, and when a pressure is applied to the operating channel (212A and/or 212B), it can cause the membrane to expand or contract along the plane within the first 208 and the second 210 central microchannels. - In some embodiments, one side of the
membrane 206 can be seeded with alveolar epithelial cells to mimic an epithelial layer while another side of themembrane 206 can be seeded with lung microvascular endothelial cells to mimic capillary vessels. Accordingly, lung chips, in some embodiments can be used to mimic an alveolar-capillary unit, which plays a vital role in the maintenance of normal physiological function of the lung as well as in the pathogenesis and progression of various pulmonary diseases. - In such embodiments, a gaseous fluid, e.g., air and/or aerosol, can flow through the first
central microchannel 208 in which the alveolar epithelial cells are resided, while a liquid fluid, e.g., culture medium, buffered solution and/or blood, can flow through the second central microchannel 210 (Microvascular channel) in which the microvascular endothelial cells are resided. - The lung chips can be used to evaluate lung response to an active agent, e.g., but not limited to, immune response to microbial infection and/or inflammatory responses to nanoparticulate toxins. For example, the active agent (e.g., cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof) can be added in a liquid fluid flowing through the second
central microchannel 210, e.g., to mimic blood carrying the active agent (e.g., cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof). The inventors have demonstrated, in one embodiment, that the lung chips that mimic the lung's dynamic mechanically-active (breathing) microenvironment (e.g., using the device described in the International Application No. WO 2010/009307 in which one embodiment has side channels to allow modulation of pressure to cause cyclic movement of the flexible porous membrane on which the cells are seeded) can effectively predict lung toxicity responses to the chemotherapeutic cytokine, e.g., IL-2, which has a dose-limiting toxicity due to vascular leakage leading to pulmonary edema in humans. Using the lung-on-a-chip with a detectable marker, e.g., fluorescent-insulin as a marker of vascular permeability (fluid shifts), the IL-2 produces a small but significant increase in pulmonary vascular leakage into the air channel of the lung chip under static conditions. However, with physiological breathing motions akin to normal breathing motions (10% cyclic strain), this response is increased by more than 3-fold (and it was accompanied by blood clot formation as seen in humans), and the critical physiological importance of providing this correct mechanical microenvironment was demonstrated in studies in a mouse ex vivo ventilation-perfusion model that demonstrated a similar dependency of pulmonary edema induction by IL2 on breathing motions (FIG. 3 ). Using the lung chips, various kinds of drugs or candidate agents can be tested to determine what would be the effective treatment. In fact, the IL2-induced pulmonary toxicity in the lung chip can be pharmaceutically suppressed in vitro. These results provide proof-of-principle for organ chips lined by human cells (e.g., organ-specific parenchymal cells) as a means to predict clinically relevant toxicity responses in humans. - In some embodiments, the microchannel intended for a gaseous flow, e.g., the first
central microchannel 208 allowing air to flow through, can be configured to permit delivery of aerosolized micro-droplets (e.g., aerosolized drugs, and/or nanoparticles or particulates). Detailed information about various designs and configurations of microfluidic devices for aerosol delivery can be found, e.g., in the International Application No. WO 2012/154834, the content of which is incorporated herein by reference in its entirety, and can be adopted in the lung chips to deliver aerosolized microdroplets, e.g., to study toxicities of nanoparticles in lungs. Similar findings in relation to the toxicities of nanoparticles has been observed using the lung chips, indicating that some clinically organ toxicities cannot be mimicked in vitro without providing the correct mechanical microenvironment, which is generally lacking from traditional in vitro model systems. - Heart Chips:
- The methods, architecture and ability of a Heart Chip (e.g.,
FIG. 8 ) to mimic, at least in part, the normal physiology (e.g., cell contraction) of a heart are based on the second organ chip design described herein. Heart Chips are described, for example, in U.S. Provisional Patent Application Ser. No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, filed on Sep. 5, 2012, and PCT patent application titled “Muscle Chips and Methods of Use Thereof,” filed on Dec. 10, 2012 and which claims priority to the U.S. provisional application No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, the entire contents of all of which are incorporated herein by reference in their entireties. - In order to fabricate heart chips to mimic tissue organization, in some embodiments, functional heart tissues can be fabricated first and then multiplexed in a microfluidic device. For example, functional heart tissues can be fabricated by culturing ventricular cardiomyocytes (e.g., neonatal rat ventricular cardiomyocytes) on elastomeric polymer thin films micropatterned with cell adhesion proteins (e.g., extracellular matrix proteins) to promote spatially ordered, two-dimensional myogenesis and create “muscular thin films” (MTFs) as described previously, e.g., in Grosberg A. et al. “Ensembles of engineered cardiac tissues for physiological and pharmacological study: Heart on a chip” Lab on a chip (2011) 11: 4165, as well as the International Application Nos. WO 2008/045506, WO 2010/011407 and WO2010/042856, the contents of which are incorporated herein by reference in their entireties. These heart tissue constructs are electrically functional and actively contractile, generating stresses comparable to those produced by whole papillary muscle.
- As used herein, the terms “muscular thin film” and “MTF” are used interchangeably herein and refer to a two-dimensional biopolymer substrate comprising heart muscle cells such as ventricular cardiomyocytes or progenitor cells, which can cause the substrate to bend and form a three-dimensional (3D) structure when the cells contract, e.g., as shown in
FIG. 6 orFIG. 7 . The MTFs (e.g., at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 20, at least about 30, at least about 40, at least about 50 or more MTFs) can then be multiplexed, e.g., in an array, within a microfluidic chip (FIGS. 4B-4C ). The MTFs can be used to measure effects on heart cell contractile function in vitro during electrical and pharmacological stimulation (Grosberg et al., 2011,FIG. 5 ). - In another embodiment, multi-layered heart chips can be constructed. For example, a multi-layered heart chip can comprise a body having a ‘Microvascular Channel’ lined by endothelium (e.g., human endothelial cells) adherent to a porous membrane that separates the Microvascular Channel from the MTF-lined ‘Interstitial Channel’, such as similar to the configuration of the lung chip as shown in
FIG. 2 , but without side chambers. The inventors have demonstrated that microengineered MTFs effectively mimic pharmacological responses of adult rat papillary muscle strips (FIG. 5 ), which are commonly used to screen cardiac tissue responses to drugs by the pharmaceutical industry. - In some embodiments, the heart chips can be modified for various analyses. For example, as shown in
FIG. 8 , the heart chips 800 can have at least one set of MTF (804)-lined Interstitial Channels (including at least 2 sets, at least 3 sets, at least 4 sets, at least 5 sets or more) to form aMTF Chamber 802, e.g., for optical imaging and contractility analysis of cells exposed to a culture medium with or without an active agent described herein, e.g., by optical measurements of radius of curvatures or projected length of MTFs using microscopy. By way of example only, a curled or contracted MTF can have a smaller projected length than a relaxed MTF, e.g., as shown inFIG. 8 (iv). - To create a MTF chamber, by way of example only, a laser engraving process, e.g., as shown in
FIG. 6 , can be utilized to cut PDMS thin films of cardiomyocytes cultured as described above; followed by microcontact-printing ECM proteins and enclosing the assembly in a microfluidic chamber. Alternatively, the thin films of cardiomyocytes can be produced with alginate (FIG. 7 ). To operate a MTF chamber, muscle cells can be cultured on the thin films and the contractile stresses can be assessed by optically monitoring the extent of curvature of the muscular thin films as noted above (FIG. 8 ). An alternative strategy for measuring contractility is depicted inFIG. 9 , where instead of making MTFs, the muscle cells can be grown on awrinkling substrate 902, e.g., a polyurethane membrane, such that as the muscle cells contract, the substrate deforms. In this embodiment, the wrinkling substrate can further comprise a plurality of holes 904 (e.g., a swiss cheese-like polyurethane membrane) to facilitate optical detection of the substrate deformation due to muscle cell contraction. For example, the holes within the substrate can remain as a circle when the muscle cells are relaxed, but the circle becomes deformed, e.g., becoming an oval, or an ellipse, due to muscle cell contraction. - The dimensions of the MTF chamber can be suited for a user's need. For example, the length of the MTF chamber can vary from about 5 mm to about 100 mm, or from about 10 mm to about 50 mm, or from about 10 mm to about 25 mm. In one embodiment, the length of the MTF chamber can be about 15 mm. The height of the MTF chamber can be adjusted, e.g., based on the size of MTFs. For example, the height of the MTF chamber is designed to be sufficient to permit the MTFs to freely bend or curl up without any spatial constraint. In some embodiments, the height of the MTF chamber can be about 0.5 mm to about 5 mm, or about 0.5 mm to about 3 mm. In one embodiment, the height of the MTF chamber can be about 1 mm.
- In some embodiments, the heart chips, e.g., the Interstitial Channels can further comprise any heart-specific parenchymal cells, e.g., but not limited to cardiomyocytes and/or vascular smooth muscle cells, to further mimic the physiological environment and/or function of the heart. In some embodiments, a heart chip can be a microfluidic device in which mature cardiomyocytes (e.g., human cardiomyocytes) are cultured on a 2D polymer substrate (e.g., PDMS substrates or micromolded alginate substrates) to form MTFs. In some embodiments, the heart chips can have both vascular smooth muscle and cardiac muscle cultured on the same chip (see
FIG. 10 ), e.g., to form to different kinds of muscles, e.g., smooth muscles vs. striated muscles. - The cardiomyocytes can be isolated from a tissue of a subject or obtained from a commercial source, or by differentiating stems cells to cardiomyocytes, e.g., induced pluripotent stem cell-derived cardiomyocytes. Cardiomyocytes (e.g., human cardiomyocytes) can be obtained from a commercial source, e.g., from Axiogenesis, CDI, Vistagen, Coriell, Reprocell. The culture conditions can be optimized for each source of cardiac myocytes, e.g., ES- or iPS-derived cardiac myocytes, neonatal rat or mouse myocytes. The human cardiomyocytes can be obtained or derived from different origins (e.g., ventricular, atrial, etc.). In some embodiments, the cardiomyocytes of different origins can be co-cultured. In some embodiments, the cardiomyocytes can be engineered to be photosensitive (e.g., cardiomyocytes expressing a photosensitive membrane transport mechanism that is responsive to light of a particular wavelength). See, e.g., the International Appl. No. WO 2012/006320, the content of which is incorporated herein by reference in its entirety, for information about fabrication of photosensitive cardiac rhythm modulation systems, which can be integrated into the heart chips described herein.
- To fabricate an in vitro myocardial construct that recapitulates the structural complexity of the human heart chambers, in one embodiment, aligned or anisotropic monolayers of muscle cells (e.g., a monolayer of cardiomyocytes with a laminar organization) can be cultured on microcontact printed biocompatible substrates (e.g., PDMS substrates, microcontact printed polyurethane membranes and micromolded alginate substrates) within a microfluidic device, e.g., being integrated into a MTF chamber for contractility measurements and/or a low volume Electrophysiological Chamber (or an Electrophysiological Chamber) as described below.
- In some embodiments, the heart chips 800 can further have at least one another set of Interstitial Channels (including at least 2 sets, at least 3 sets, at least 4 sets, at least 5 sets or more) lined with a heart muscle cell layer under which are embedded with at least one or a plurality (e.g., an array) of microelectrodes (e.g., platinum microelectrodes) 808 (microelectrodes are placed underneath the cells), while the side of the channel opposing the heart muscle cell layer is placed with at least one or more (e.g., at least two or more) electric
field stimulation electrodes 810 to form an “Electrophysiological Chamber” 806 (see, e.g.,FIG. 8 ). In such embodiments, theElectrophysiological Chamber 806 can further comprise an electrocardiography (ECG)lead port 812 for connection with an ECG lead (or a lead electrocardiogram) to measure and/or monitor electrical pacing and/or analysis of changes in cardiac electrical potential. - To fabricate an Electrophysiological (EPhys)
Chamber 806, an anisotropic muscle cell monolayer can be cultured in a low volume chamber. Then, the muscle cells can be electrically field stimulated using theelectrodes 810 on the top, and action potentials can be recorded using themicroelectrode array 808 on the bottom, where the microelectrode array is placed underneath the muscle cells cultured on the bottom surface. The electrode readouts can be calibrated with the action potential characteristics of the cardiomyocyte monolayer. - The dimensions of the Electrophysiological Chamber can be suited for a user's need. For example, the length of the Electrophysiological Chamber can vary from about 5 mm to about 100 mm, or from about 8 mm to about 50 mm, or from about 10 mm to about 25 mm. In one embodiment, the length of the Electrophysiological Chamber can be about 10 mm. The height of the MTF chamber can be adjusted, e.g., based on the size of field stimulation electrodes. For example, the height of the MTF chamber is designed to be sufficient to permit the MTFs to freely bend or curl up without any spatial constraint. In some embodiments, the height of the MTF chamber can be about 0.5 mm to about 5 mm, or about 0.5 mm to about 3 mm. In one embodiment, the height of the MTF chamber can be about 1 mm.
- The
electrophysiological chamber 806 can be placed anywhere relative to theMTF chamber 802. In some embodiments, theelectrophysiological chamber 806 can be placed in parallel to theMTF chamber 802. In some embodiments, the MTF chamber can be larger than the Electrophysiological Chamber to permit high throughput contractility measurements. - While the
Electrophysiological 806 andMTF 802 Chambers can each be independently fed by a separate culture medium stream, in some embodiments, both the Interstitial Channels in the MTF and Electrophysiological Chambers can be fed by a singlemedium stream 814. In some embodiments, the culture medium can be introduced directly through the Interstitial Channels in the Electrophysiological and MTF chambers and/or introduced through an underlying endothelium-lined Microvascular Channels, e.g., in a configuration similar to the lung chips (see, for example,FIG. 2 ). The presence of the endothelium and its basement membrane lining the microvascular channel on the opposite side of the membrane, plus the ability to perfuse different media compositions through the Interstitial versus Microvascular Channels can allow different experimental conditions for various applications. - In some embodiments, the heart chips can comprise a MTF chamber and an EPhys chamber situated next to each other, for example, as shown in
FIG. 8 . - In some embodiments, the heart chip can be adapted to fluidically connected upstream and/or downstream to at least one or more organ chips (e.g., but not limited to lung chips or liver chips).
- Prediction/Determination and Validation of Pharmacological Effects:
- The heart chips described herein can be used to determine pharmacological effects on heart-specific cells cultured therein. For example, the heart-specific cells can be exposed to an active agent (e.g., cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof) by adding the active agent in a culture medium flowing through the Interstitial Channels and/or Microvascular Channels. In some embodiments where the heart chip comprises an Electrophysiological Chamber, electrophysiological information can be collected within the chip, which can be in turn modeled with a user-defined algorithm to estimate an ECG. The ECG can then be correlated with reference data (e.g., current in vitro and outputs, or control outputs, e.g., outputs of cells not exposed to the active agent). In one embodiment, the radius of curvature of the contracting MTFs within the chip can be modeled to estimate the stresses exerted by the cells. The MTF contractility measurements can then be correlated with reference data (e.g., current in vitro and clinical outputs, or control outputs, e.g., outputs of cells not exposed to the active agent).
- To validate the heart chips for assessment of pharmacological effects, known drugs within the system can be used, such that the response of the heart chips can be correlated with clinical response to the known drugs. In some embodiments, the cardiac myocytes inside the heart chips can be exposed to drugs that are known to be cardio-safe (e.g., ibuprofen and fexofenadine), e.g., to show that they have no toxic effects on engineered myocardial tissue constructs. In some embodiments, the cardiac myocytes inside the heart chips can be exposed to drugs that are cardiotoxic (e.g., doxorubicin, trastuzumab, terfenadine). For example, doxorubicin (anthracycline family of chemotherapeutics) generally displays cardiotoxic effects primarily by inducing dilated cardiomyopathy, predominately affect the ventricles with some left atrial involvement. Trastuzumab is a monoclonal antibody to HER2 receptor used for the treatment of (HER2+) breast cancers, has been shown to decrease left ventricular ejection fraction. Terfenadine is antihistamine formerly used to treat allergic conditions that was found to be cardiotoxic because it binds hERG channels and causes long QT syndrome. Sorafenib and sunitinib are tyrosine kinase inhibitors used as chemotherapeutic agents that cause poorly characterized cardiotoxic effects that usually manifest as decreased left ventricular ejection fraction and increased cardiac enzymes.
- Exemplary Applications of Heart Chips:
- Although various drug toxicities can affect myocytes with distinct mechanisms, most of the drugs can adversely affect cardiac contractility and ultimately the ability of the heart to pump blood. Therefore, by measuring the contractility and/or electrophysiological output of the heart chip, one can quantitatively measure the impact of various active agents on heart performance. Further, the chambers of the heart are imperative to its function, as the ventricles of the heart are tasked with overcoming pulmonary and system vascular resistance and after load. For example, drugs such as doxorubicin and trastuzumab (as noted above) generally demonstrate ventricular toxicity; thus, some embodiments of the heart chips described herein can be used to mimic the contractile action of these chambers (e.g., ventricular chambers) in vitro. In some embodiments, the heart chip can be a microfluidic device that can measure electrophysiology and/or contractile performance of engineered myocardial tissues. In some embodiments, the heart chip can be a microfluidic device that can measure electrophysiology and/or contractile performance of myocardial tissues derived or obtained from a subject, e.g., to determine an appropriate treatment regimen for the specific subject.
- In some embodiments, the heart chips can be used as disease models, e. g., to assess different physiological effects of pharmaceutical or active agents. Examples of the effects that can be assessed using the heart chips can include, without limitations, (1) metabolic: for example, antibody-based medications such as Trastuzumab, which is generally used to treat HER2+ breast cancer, are known to affect ATP production in myocytes through adverse effects on mitochondria (Ref. 7); (2) structural: for example, anti-proliferative agents such as doxorubicin, which is used for a wide variety of malignancies, can adversely affect myocyte growth and mass maintenance (Ref. 8); and (3) ion channel (arrhythmia-inducing): for example, hERG channel binding of many drugs (e.g. albuterol) can generally increase action potential duration, leaving the heart susceptible to arrhythmia (long QT syndrome) and effects on other ion channels (Na, Ca), with concurrent effects on PR prolongation, conduction abnormalities and arrhythmias. While there are in vitro models exist for hERG channel binding assays (Ref. 9), there is a lack of in vitro assays for evaluating drugs exerting metabolic and/or structural effects that can deliver quantitative data relating to cardiac function. Accordingly, a robust in vitro system that can recapitulate the heart can provide a platform to screen a large number of compounds for toxicity, a feat not possible with current in vivo animal models or existing in vitro models.
- Since tissue architecture can be controlled within heart chips, which can in turn affect contractile efficiency, various disease states can be created accordingly. Drug toxicity (e.g., Trastuzumab or Doxorubicin) can affect the ability of cardiac myocyte contractility. Thus, in one embodiment, drug toxicity can be determined by measuring contractility of cardiac myocytes within the heart chips. For example, contractility can be read out via optical tracking of MTF deformation/optical tracking of membrane deformation as described above. Optionally, electrophysiological recordings can be taken via a lead ECG. In some embodiments, biomarkers of muscle damage such as creatine kinase and troponin can also be measured. For example, the level of biomarkers can be measured in the culture medium upon exposure to the cells.
- In some embodiments, the heart chips can be used for PK/PD modeling (including prediction of pharmacological effects).
- Generally, the design of other organ chips can be developed based on the basic designs of the Lung or Heart chips as described herein. For example, without being construed to be limiting, Gut chips, Kidney chips, Liver chips, Skin chips and Testis chips can be developed, e.g., based on the basic design of the Lung chips, while Skeletal Muscle chips, Airways Smooth Muscle chips can be developed, e.g., based on the design of the Heart chips. Depending on different organs, each organ chip can then be incorporated with respective tissue-specific parenchymal cell (e.g., human parenchymal cell) layers within the Interstitial Channel (as described earlier) exposed to their physiological microenvironment (e.g., alveolar epithelium and skin epidermis exposed to air, gut epithelium facing a fluid filled lumen, etc.) on one surface of the ECM-coated porous membrane, with organ-specific vascular endothelium (e.g., human vascular endothelium) on the opposite side lining the Microvascular Channel. Organ-specific differences in the mechanical microenvironment can also be mimicked by altering control and/or process parameters, e.g., but not limited to, flow rates, fluid shear stresses, cyclic mechanical strain, ECM composition, and/or compartment dimensions.
- Liver Chips:
- In some embodiments, a mammalian liver chip (e.g., a human liver chip) can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in
FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in its entirety. For example, commercially available human hepatocytes (e.g., from Invitrogen) or patient-specific hepatocytes (isolated from a tissue) can be placed on one side of the ECM (e.g., but not limited to, laminin, type IV collagen or Matrigel)-coated membrane, and human microvascular endothelial cells on the other side. Without wishing to be bound by theory, the porous membrane, basement membrane and cell-cell junctions of the endothelium can facilitate physiologically relevant mass transport while protecting hepatocytes from fluid shear stress and serum components in the Microvascular Channel. - In some embodiments, the liver chips can further comprise other parenchymal cells, such as Kupffer cells (resident macrophages of the liver) under the endothelium in the Liver Chip.
- Without wishing to be bound by theory, oxygen gradients are essential determinants of normal liver physiology and function, as well as key contributors to acute and chronic hepatoxicity. Accordingly, in some embodiments, oxygen gradients found in vivo can be incorporated in the liver chips. By way of example only, oxygen gradients can be generated in a liver chip, e.g., by using a gas-permeable membrane material, e.g., PDMS which is permeable to gases) and flowing oxygen at different concentrations through the two side channels separated by the membrane. Other art-recognized microengineering methods, for example, as described in Adler M. et al. Lab Chip 2010; 10(3): 388-389 and Chen Y-A et al., Lab Chip 2011; 11: 3626-3633, can also be used to develop oxygen gradients within the organ chips.
- In some embodiments, bile canalicular networks in pre-determined patterns (e.g., by art-recognized micropatterning techniques) can be integrated into liver chips, such that they can be coupled with microscale sampling ports in the liver chips. Such configuration can be used to determine intrinsic biliary clearance. This approach can be used to facilitate analysis of interplay between drug transporters and drug metabolizing enzymes, which is a key determinant of drug PK properties and toxicity profiles in humans.
- Gut Chips:
- In some embodiments, the gut chips, e.g., as shown in
FIG. 11 , can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown inFIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties. In some embodiments, a gut chip can utilize a porous membrane (e.g., PDMS membrane) coated with ECM (e.g., Collagen I+Matrigel) upon one side of which human intestinal epithelial cells are cultured under flow conditions to produce a physiological shear stress (˜0.02 dyne/cm2) while simultaneously exerting cyclic mechanical strain (10% elongation, 0.15 Hz). Gut-specific microvascular endothelial cells can be seeded and cultured on another side of the porous membrane to form a Microvascular Channel as described above. For example, human gut cells (e.g., CaCo2 cells) cultured under these conditions can differentiate by changing their entire transcriptome (measured, e.g., using gene microarrays) and form 3D villus structures, e.g., to match the height of the microfluidic Interstitial Channel (FIG. 11F ). In addition, the physiologically relevant conditions recreated in the Gut Chip can enable one to culture living gut bacteria (Lactobacillus) directly on top of the living human villus gut epithelium, and hence, permit interrogating the influence of gut microbiome on drug absorption and metabolism using the gut chips. - In some embodiments, the gut chips described herein can comprise any components of the device or can be the device described in the International Appl. No. WO 2012/118799, the content of which is incorporated herein by reference in its entirety.
- Kidney Chips:
- Without limitations, in some embodiments, the kidney chips can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in
FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties. In some embodiments, the kidney chips can utilize a porous membrane (e.g., a PDMS membrane) coated with ECM (e.g., type IV collagen) upon one side of which primary human proximal tubular epithelial cells (e.g., obtained from Biopredic or from a specific subject) are cultured under flow conditions to produce a physiological shear stress (˜0.02 dyne/cm2). Kidney-specific microvascular endothelial cells can be cultured on another side of the porous membrane to form a Microvascular Channel as described above. Using such kidney chips, the in vivo nephrotoxicity observed with an active agent, e.g., cisplatin and its inhibition by cimetidine, can be recapitulated and clinically relevant endpoints or biomarkers, such as KIM-1, can be measured. - In some embodiments, the kidney chips described herein can comprise components of the device, or can be the device described in U.S. Provisional Application No. 61/449,925, the content of which is incorporated herein by reference in its entirety.
- Skin Chips:
- Without limitations, in some embodiments, the skin chips can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in
FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties. In some embodiments, human foreskin fibroblasts can be plated in a collagen gel on one side of the membrane, and human dermal endothelial cells on the other side of the membrane; human keratinocytes from foreskin can then be plated on top of the collagen gel layer. - In some embodiments, the cells seeded in the skin chips can be further induced to differentiate into a stratified epithelium with basal, spinous and cornified layers, e.g., by passing air through the “Interstitial Channel” in a similar fashion as operated in the lung chip, and creating an air-liquid interface.
- Brain Chips:
- Without limitations, in some embodiments, the brain chips can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in
FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties. For example, a brain chip can be constructed by first creating a Blood-Brain Barrier (BBB) construct in which astrocytes (e.g., human astrocytes) are cultured on one side of a porous ECM-coated membrane and endothelial cells (e.g., human endothelial cells) on the other side of the porous membrane. In some embodiments, electrodes (e.g., platinum electrodes) are embedded inside the channels, e.g., as shown in the bottom panel ofFIG. 12 . The inventors have demonstrated generation of an effective permeability barrier, as measured by transepithelial resistance using this approach (FIG. 12 ). - In alternative embodiments, the brain chips can be developed and/or modified, e.g., based on the design of any embodiments of Heart Chips (e.g., as shown
FIG. 8 ) described herein as well as in Grosberg A. et al. 2011 and in the International Application Nos. WO 2008/045506, WO 2010/011407 and WO2010/042856, the contents of which are incorporated herein by reference in their entireties. Such brain chips can be constructed, e.g., by placing the BBB construct (as described above) in at least one set of channels and then linking the outflow of its Interstitial Channel to a second electrophysiological chamber (as described in the section of Heart Chips) where human brain neuronal networks can be cultured to measure effects on nerve cell toxicity and electrical signaling. Without limitations, the brain chips described herein can be used for various applications, e.g., discovery of methods to deliver an active agent across a BBB, or as a Traumatic Brain Injury (TBI) model to develop new therapies. - Skeletal Muscle Chips:
- Without limitations, in some embodiments, the skeletal muscle chips can be developed and/or modified, e.g., based on the design of any embodiments of Heart Chips (e.g., as shown
FIG. 8 ) described herein as well as in Grosberg A. et al. 2011 and in the International Application Nos. WO 2008/045506, WO 2010/011407 and WO2010/042856, the contents of which are incorporated herein by reference in their entireties. - Skeletal Muscle Chips are described, for example, in U.S. Provisional Patent Application Ser. No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, filed on Sep. 5, 2012, and PCT patent application titled “Muscle Chips and Methods of Use Thereof,” filed on Dec. 10, 2012 and which claims priority to the U.S. provisional application No. 61/569,028, filed on Dec. 9, 2011, U.S. Provisional Patent Application Ser. No. 61/697,121, the entire contents of all of which are incorporated herein by reference in their entireties.
- In some embodiments, the skeletal muscle chip can be a heart chip adapted to culture mature skeletal muscle myoblasts or myotubes (e.g., human skeletal muscle myoblasts or myotubes), optionally with neurons, on 2D substrates (e.g., PDMS substrates) or micromolded alginate substrates. These tissue constructs can then be integrated into both a “muscular thin film” (MTF) chamber for contractility measurements and a low volume electrophysiological readout chamber, similar to the operation of the heart chips described herein.
- In some embodiments, the skeletal muscle chip can further comprise additional cell types, e.g., adipocytes (e.g., human adipocytes) can be added to the skeletal muscle chip as a heterogeneous co-culture cell layer, or be seeded on a separate side of the membrane to recapitulate two tissue interfaces, e.g., to create disease models within the device. For example, in one embodiment, the adipocyte can be cultured on opposite side of porous membrane that myoblast/neurons are cultured. The adipocytes can be healthy or diseased, depending on the purpose of the application. Healthy human adipocytes can be obtained from a commercial source or isolated from a healthy tissue of a subject. Alternatively, commercially-available healthy primary preadipocytes (e.g., Lonza; PT-5022) can be differentiated into adipocytes, e.g., by using known differentiation medium. In some embodiments, diabetic (Type I and II) human adipocytes can be used in the skeletal muscle chip. For example, commercially-available primary (from patients with diabetes) preadipocytes (e.g., Lonza; PT-5023—Type I and PT-5024 Type II) can be differentiated into adipocytes by using known differentiation medium.
- To create an in vitro skeletal muscle system in a microfluidic device, in some embodiments, aligned monolayers of muscle cells (e.g., human myoblasts) can be cultured on microcontact printed polymer substrates or membranes (e.g., microcontact printed PDMS substrates, microcontact printed polyurethane membranes and/or micromolded alginate substrates). The human myoblasts or satellite cells (healthy or diseased) can be isolated from a tissue of a subject, and/or obtained from a commercial source, e.g., (healthy; Lonza, XM13A1 and XM15B1).
- In some embodiments, the skeletal muscle chip can comprise at least one or more MTF chamber (
FIGS. 13-14 ), e.g., at least two or more MTF chambers. To create a MTF chamber, in one embodiment, a laser engraving process can be utilized to cut PDMS thin films of skeletal muscle cells (e.g., myoblasts and/or myotubes) cultured as above; followed by microcontact-printing ECM proteins and enclosing the assembly in a microfluidic chamber. To operate the MTF chamber, muscle cells can be cultured on the thin films and the contractile stresses can be assessed by optically monitoring the extent of curvature of the muscular thin films. In some embodiments where the muscle cells and adipose cells are co-cultured in the MTF chamber (e.g., as shown inFIG. 14 (ii)), contractility readout from skeletal muscle-adipocyte can be measured. - In some embodiments, the MTF chambers can be micromolded with grooves (e.g., on an alginate substrate) to create 3D cues, e.g., to help maintain mature contracting muscle in culture (
FIGS. 15A-15C ). - In some embodiments, the skeletal muscle chip can further comprise an Electrophysiological (EPhys) chamber, the design and operation of which can be similar to the ones employed in the heart chips described herein, except that, e.g., the Ephys chamber is cultured with skeletal muscle chips in the skeletal muscle chips. By way of example only, to fabricate the EPhys chamber, anisotropic muscle cell monolayer can be cultured in a low volume chamber. Then, the muscle cells can be electrically field stimulated using the electrodes on the top, and action potentials can be recorded using the microelectrode array on the bottom. In some embodiments where the muscle cells and adipose cells are co-culture in the EPhys chamber, the EMG can be measured, e.g., as shown in
FIG. 14 (i) . - Prediction/Determination and Validation of Pharmacological Effects:
- The skeletal muscle chips described herein can be used to determine pharmacological effects on skeletal muscle-specific cells cultured therein. For example, the skeletal muscle-specific cells can be exposed to an active agent by adding the active agent in a culture medium flowing through the Interstitial Channels and/or Microvascular Channels. In some embodiments where the skeletal muscle chip comprises an Electrophysiological Chamber, electrophysiological information can be collected within the chip, which can be in turn modeled with a user-defined algorithm to estimate an ECG. The ECG can then be correlated with reference data (e.g., current in vitro and outputs, or control outputs, e.g., outputs of cells not exposed to the active agent). In one embodiment, the radius of curvature of the contracting MTFs within the chip can be modeled to estimate the stresses exerted by the cells. The MTF contractility measurements can then be correlated with reference data (e.g., current in vitro and clinical outputs, or control outputs, e.g., outputs of cells not exposed to the active agent).
- For validation, in one embodiment, statin-induced skeletal muscle myopathy can be replicated. Additionally or alternatively, cerivastatin, which was voluntarily pulled from market in 2001 due to side effects which included rhabdomyolysis and mypothay, can be introduced into the skeletal muscle chips. Skeletal muscle damage markers such as creatine kinase and slow and fast-twitch troponin I (ssTnl, fsTnl) can also be measured (e.g., by in situ immunostaining for the specific marker in the cells, and/or collecting the cells to prepare cell lysates for quantitative measurements of the marker level), in order to validate the ability of the system to replicate injury induced by a known agent (e.g., statin-induced skeletal muscle myopathy). Additionally, since muscle weakness is also a generalized complaint of patients undergoing statin treatment, skeletal muscle contractility measurements can also validate statin-induced in vitro muscle weakness.
- In some embodiments, the skeletal muscle chips can be used as diseased models. For example, diabetic muscle microenvironment can be created in some embodiments of the skeletal muscle chips described herein, e.g., by co-culturing type I and type II preadipocytes with the skeletal muscle cells. Type I diabetic mimic chip can be used to evaluate insulin replacement therapies while Type II diabetic mimic chip can be used to determine effectiveness of metformin-induced metabolic benefits.
- Further, an exemplary diabetic muscle environment (Type I and II) can be created for pharmaceutical development testing. In some embodiments of
Type 2 diabetes model, adipocytes fromtype 2 diabetic patients (Lonza) and conditioned skeletal muscle can be employed. Metformin, a first line drug used to treat type II diabetes can then be introduced. Muscle contractility can be measured to determine effectiveness of metformin-induced metabolic benefits. In some embodiments ofType 1 diabetes model,Type 1 diabetic adipocytes along with conditioned muscle tissue in zero insulin media can be exposed to commercially-used insulin replacement therapies such as Detemir or Glargine. Improvements in contractility can then be verified due to the increased insulin. - Lung Airway Smooth Muscle Chips:
- Without limitations, in some embodiments, the lung airway smooth muscle chips can be developed and/or modified, e.g., based on the design of any embodiments of Heart Chips (e.g., as shown
FIG. 8 ) described herein as well as in Grosberg A. et al. 2011 and in the International Application Nos. WO 2008/045506, WO 2010/011407 and WO2010/042856, the contents of which are incorporated herein by reference in their entireties. - In some embodiments, the lung airway smooth muscle chip can be a hybrid bronchial smooth muscle and columnar epithelium organ system, which can be used, e.g., to test bronchial spasms in response to drugs and/or toxins. For example, as shown in
FIG. 16B (ii), this hybrid chip can be installed inside a two-chamber microfluidic device that contains a top layer of epithelial cells (e.g., human epithelial cells) adhered to a porous membrane and exposed to air flow and a bottom layer containing flexible muscular thin films, each comprising a monolayer (e.g., a confluent monolayer) of bronchial smooth muscle situated on top of a thin polymer substrate (e.g., a PDMS substrate), which are incubated within a liquid medium. The porous membrane separating the top and bottom layers of the chamber can act as a barrier between the two cell types and allows for chemical exchange. - The material for the membrane that separates airway smooth muscle from the epithelium within the hybrid organ system (e.g., lung airway smooth muscle chips) can be selected for at least one of the following properties, but not limited to: the material is (i) biocompatible, (ii) complies with IS 10993-5 (in vitro cytotoxicity tests for medical devices), (iii) has low absorption of hydrophobic dye/drug and other chemical compounds, (iv) is cell adhesive, (v) is optically clear, is highly flexible, moldable, bondable, (vi) has low autofluorescence, (vii) does not swell in water, or (viii) has any combinations of the aforementioned properties. In one embodiment, the membrane material can include
Clear flex 50 polyurethane. - In some embodiments, fabrication of an airway chip can involve micro-contact printing to fabricate engineered smooth muscle tissue and/or (e.g., human) columnar epithelium with well-defined cellular organization and tissue geometry. Bronchial smooth muscle cells (e.g., healthy or diseased cells) can be obtained isolated from a tissue of a subject (e.g., a human), and/or obtained from a commercial source (e.g., healthy: Lonza, CC2576; diseased (COPD); Lonza, 00195274; diseased (asthmatic): Lonza, 00194850).
- Human primary bronchial epithelial cells (e.g., healthy or diseased cells) can be isolated from a tissue or obtained from a commercial source (e.g., healthy: ATCC; PCS-300-010, PCS-310-010, Lonza: CC-2540, CC-2547; diseased: Lonza; 00195275, 00194911)
- In some embodiments, a lung airway smooth muscle chip (“airway chip”) can comprise a MTF chamber. To create a MTF chamber, in one embodiment, a laser engraving process can be utilized to cut PDMS thin films of muscle cells, e.g., bronchial smooth muscle cells (the thin films can be produced in a similar fashion as thin films of cardiomyocytes described above); followed by microcontact-printing ECM proteins and enclosing the assembly in a microfluidic chamber. To operate the MTF chamber, the muscle cells, e.g., bronchial smooth muscle cells, can be cultured on the thin films and the contractile stresses can be assessed by optically monitoring, e.g., the extent of curvature of the muscular thin films. In some embodiments, approximately 0.25 million muscle cells or more can be seeded in each MTF chamber. An alternative strategy for measuring muscle contraction is to grow muscle cells on a wrinkling substrate, e.g., a PDMS membrane, such that as the muscle cells contract, the substrate deforms. In this embodiment, the wrinkling substrate can further comprise a plurality of holes (e.g., a swiss cheese-like PDMS membrane) to facilitate optical detection of the substrate deformation due to muscle cell contraction. For example, the holes within the substrate can remain as a circle when the muscle cells are relaxed, but the circle becomes deformed, e.g., becoming an oval, or an ellipse, due to muscle cell contraction, e.g., as shown in
FIGS. 18A-18B . - In some embodiments, a two-chamber system can also be engineered for dual outputs (e.g., as shown in
FIGS. 17A-17B ). For example, normal bronchial epithelial cells can be cultured in one chamber while diseased bronchial epithelial cells (e.g., with asthma phenotype) can be cultured in another chamber, e.g., for comparison of cell behavior, and/or cell response to an active agent. In some embodiments, the cells can be chemically induced to become diseased cells inside a microfluidic device, e.g., by flowing an inducing agent through a separate channel to the cells. - In some embodiments, epithelial cells can be cultured on the chip membrane. In some embodiments, the epithelial cells can remain viable for at least about 3 weeks or longer (e.g., at least about 4 weeks, at least about 5 weeks, at least about 6 weeks or longer) inside the organ chip. For example, the epithelial cells can be cultured on, e.g., 20×4 lined substrates, and the structural and functional response of cells can be characterized by quantifying cytoskeletal alignment and/or effects on gene expression and/or protein translation.
- In some embodiments, smooth muscles cells can be cultured on a substrate (e.g., a deformable substrate). In some embodiments, the smooth muscle cells can remain viable for at least 3 weeks or longer (e.g., at least about 4 weeks, at least about 5 weeks, at least about 6 weeks or longer) inside the airway chip. For example, the smooth muscle cells can be cultured on, e.g., 20×4 lined substrates, and the structural and functional response of cells (e.g., cells on a deformable substrate exhibiting morphological changes, e.g., contraction of such PDMS muscular thin film substrate as in
FIGS. 16A-16B andFIG. 17A-17B and/or deformation of perforated holes in a membrane as inFIGS. 18A-18B ), can be characterized by quantifying cytoskeletal alignment and/or effects on gene expression and/or protein translation. - To characterize cellular response to mechanical stimuli, the bronchial smooth muscle tissue can be monitored for contraction in response to an active agent, e.g., drug or toxic agents (e.g., without limitations, IL-13, acetylcholine). The contractility can be measured for grading the response of the different tissue types to the drugs.
- In some embodiments, the lung airway smooth muscle chips can comprise other “helper” cells. To characterize the cellular response to different demographical conditions, e.g., addition of “helper” cells, cells can be co-cultured conditions with other “helper” cell types and/or different cell densities and their effects on gene expression and protein translation can be evaluated using any known methods in the art.
- Prediction/Determination and Validation of Pharmacological Effects:
- The airway chips described herein can be used to determine pharmacological effects on airway-specific cells cultured therein. For example, the airway-specific cells can be exposed to an active agent by adding the active agent in a culture medium flowing through the channels. In one embodiment, the radius of curvature of the contracting MTFs within the chip can be modeled to estimate the stresses exerted by the cells. In another embodiment, the eccentricity of the holes within a deformable membrane can be evaluated to determine the state of the cellular contraction (e.g., relaxation vs. contraction state). The contractility measurements (e.g., from contraction of MTFs) can then be correlated with reference data (e.g., current in vitro and clinical outputs, or control outputs, e.g., outputs of cells not exposed to the active agent).
- Local airway smooth muscle construct can be characterized for any pharmacological mediators of interest, e.g., but not limited to, Fexofenadine, Denufosol, Terfenadine, Isoproterenol, Amiodarone, and Xigris. Characterization of airway smooth muscle absorption can include, e.g., but not limited to, establishment of absorptive rate constant (ka); establishment of bioavailability (F): Determined by F=AUCINH/AUCIV and determination of onset of action.
- The in vitro microphysiological system (e.g., including two or more organ chips) can also be characterized for any pharmacological mediators of interest, e.g., but not limited to, Fexofenadine, Denufosol, Terfenadine, Isoproterenol, Amiodarone, and Xigris. Exemplary characterization include, without limitations, establishment of duration of therapeutic effect; establishment of apparent volume of distribution (Vd), via microfluidic channels within the system; establishment of Tmax, time to maximal media concentration, per given dose, inhaled; establishment of Cmax, maximal media concentration, per given dose, inhaled; establishment of terminal half-life, per given dose, inhaled; and/or establishment of efficacy of biotransformation as result of first bypass effect at liver chip.
- Performance of airway smooth muscle, local and systemic, within an organ chip or an integrated system, can be corrected to correspond to established pharmacokinetic and pharmacodynamics values for various categories of drugs and toxins.
- Disease Models:
- In some embodiments, the lung airway smooth muscle chip can be used as a disease model. The asthmatic phenotype can present as exaggerated bronchial muscle spasms, which can be reflected by changes in contractility. As a control, the effect of substances with known toxicity in humans (e.g., local anesthetics such as procaine, chloroprocaine, and tetracaine) can be introduced to induce bronchial smooth muscle spasms and provide a calibration to existing patient response from the clinic [Ref. 14].
- A disease model can be developed, e.g., by integration of diseased cells or by chemical stimulation of a diseased phenotype (e.g., asthmatic phenotype can be induced, e.g., by introducing IL-13 to the culture medium [Ref. 11]), and/or by alteration of temperature and/or media composition [Ref. 12]. Optionally, mechanical strain, electrophysiology, and/or markers for cell injury between asthmatic phenotypes generated by integration of cells from diseased tissues and those induced by allergens or toxins can be compared and contrasted, e.g., to determine which is a better representation of a diseased model.
- By way of example only, to integrate the asthmatic muscle phenotype into the microfluidic device, the asthmatic or chronic obstructive pulmonary disease (COPD) human primary smooth muscle cells (from either commercially available cell lines or samples from asthmatic patients) can be cultured within one of the chambers in the airway chip, e.g., on a deformable substrate, using micro-contact printing to align cells into anisotropic tissues, e.g., as shown in
FIG. 19A . Contraction in smooth muscle cell layer can be monitored optically as described above. In the same channel, the micronenvironment conditions, e.g., the levels of oxygen within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be also monitored. - Alternatively, the asthmatic phenotype can be induced by introduction of allergens/drug compounds that drive bronchial spasms associated with asthmatic attacks. For example, toxic agents (e.g., acetylcholine, IL-13, Foradil, Serevent, Advair, Symbicort) can be perfused into the culture medium containing the muscle cell monolayer (
FIG. 19B ). Alteration in smooth muscle contraction in response to allergens or toxic agents can be monitored optically. In the same channel, the levels of oxygen within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be also monitored. - In some embodiments where the upper channel containing an epithelium (e.g., in a hybrid system as shown in
FIG. 16 (ii)), the levels of mucus granules and/or spherules and/or presence of inflammation factors (e.g., but not limited to, IL-3, IL-4, TL-5, IL-13) can be monitored. - The asthmatic phenotype can be induced by introduction of allergens/drug compounds through the air, allergens (e.g. oil fly ash, dust mites, smoke) can be perfused into the aerosol routes within the upper channel of the microfluidic device containing the epithelium (see, e.g.,
FIG. 16B (ii)). Alterations in smooth muscle contraction in response to allergens or toxic agents can be monitored optically. In the same channel, microenvironment conditions, e.g., but not limited to, the levels of oxygen within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be monitored. In the upper channel containing the epithelium, the levels of mucus granules and/or spherules and/or presence of inflammation factors (e.g., but not limited to, IL-3, IL-4, IL-5, IL-13) can be monitored. - A diseased epithelial cell monolayer can be also integrated within the asthmatic microfluidic device, e.g., a co-culture of the asthmatic or COPD human primary smooth muscle cells (from either commercially available cell lines or samples from asthmatic patients) with the diseased human primary bronchial epithelial cells. By way of example only, the diseased epithelial cell monolayer can be cultured on the membrane (e.g., polyurethane membrane) and the diseased smooth muscle cells on the deformable substrate, using micro-contact printing to align cells into anisotropic tissue in a hybrid system described herein (e.g., as shown in
FIG. 16B (ii)). Contraction in smooth muscle cell layer can be monitored optically. In the same channel, microenvironment conditions, e.g., but not limited to, the levels of oxygen (e.g., reduction in oxygen levels) within the medium, cellular ATP, apoptosis, and/or intracellular calcium can be monitored. In the upper channel containing the epithelium, the levels of mucus granules and/or spherules and/or presence of inflammation factors (e.g., but not limited to, IL-3, IL-4, IL-5, IL-13) can be monitored. Further, the hyperplasia and hypertrophy of the columnar epithelial cells (hallmarks of obstructive pulmonary disease) can be assessed optically, e.g., by microscopy. - Asthma is a prevalent disease affecting ˜8% percent of the population, and it is in part due to maladaptive remodeling of bronchial smooth muscle. Airborne toxins and air pollution can affect the bronchial smooth muscle, but they are difficult to detect and to predict their effects on the tissue health (and reflect a large scale problem in developing countries). There are currently no commercially available instruments to test cytotoxicity and allergic responses and associated inflammation in vitro, despite the existence of human bronchial smooth muscle cell lines. Beyond the difference in species responses to toxic or therapeutic agents, animal models do not necessarily provide human relevance, predictability, and lower failure rates in the drug pipe-line.
- Bronchial smooth muscle spasms can be a response to allergens and/or toxins. This response can be amplified if the muscle undergoes a maladaptive remodeling prior to the introduction of the toxic agent (such as in asthmatic patients). Therefore, an in vitro organ chip system (e.g., a hybrid chip of bronchial smooth muscle tissue and epithelial cell monolayer as described herein) to test for bronchial smooth muscle spasms can provide a tool for various applications, including, but not limited to: testing drugs for curing or exacerbating asthma; testing toxins (including air-borne toxins) in the field; predicting the allergic response of different patient populations. Further, the hybrid chips can be combined with a microfluidic device containing bronchial epithelial and/or pulmonary mast cells, which are important to exacerbation and inflammation response. In other embodiments, the hybrid chips described herein can comprise bronchial epithelial and/or pulmonary mast cells within the same device. In some embodiments where epithelial and mast cells are co-cultured, the epithelial and mast cells can produce inflammation factors (e.g., but not limited to, IL-3, IL-4, IL-5 IL-13) that would cause the spasms in the bronchial smooth muscle, and the levels of these inflammation factors can be measured to evaluate the degree of spasms.
- An exemplary protocol of fabricating a lung smooth muscle chip and using the same for evaluating cell response to a drug is shown below: (Any modifications to the protocol within one of skill in the art are also within the scope of the inventions.)
-
- Create a chip with a desirable number of chambers, e.g., one or more chambers (
FIG. 16A (i)-(ii)); - Control cell shape and tissue alignment within the chambers to recapitulate the native microenvironments. This can be achieved, e.g., by either patterning of ECM, microgrooves, stretching of the membrane, or other similar techniques as described herein;
- Seed cells and supply media through micro-fluidic channels (
FIG. 16A (i)). The bronchial smooth muscle cells (e.g., human cells) can be obtained from commercially available cell-lines [Ref. 10] and/or primary cells from a subject, e.g., human healthy or asthmatic patients; - The organ chip can also allow for co-culture with other cell types:
- Bronchial epithelial cells can be cultured within the same chamber separated by a membrane (e.g., a transwell membrane), and exposed to exacerbating pollutants, such as oil fly ash (available commercially), dust mites, or smoke;
- The bronchial smooth muscle cells can be combined with pulmonary mast cells either upstream in the microfluidic device or co-cultured within a transwell chamber;
- Induce an asthmatic phenotype chemically (e.g., IL-13 during culture [Ref. 11]), by temperature control, and/or alteration of media composition [Ref. 12] in some of the chambers (
FIG. 17A (i), chamber 2). Additionally or alternatively, the asthmatic phenotype can be incorporated into the chip by samples derived from asthmatic patients - If desired, add a therapeutic drug to the asthmatic chamber
- Introduce a drug to induce a normal smooth muscle contractile response, and/or a toxic agent to test for bronchial spasms (e.g., acetylcholine)
- Contraction of the muscle can be detected using multiple approaches, or any approaches known in the art.
Approaches 2 and 3 (below) can be used to mimic the function of the bronchial muscle where the cells close-off micro-holes the same way as they close-off the bronchia (Without construed to be limiting, various approaches described below to measure cell contraction can also be integrated into any organ chips described herein): - 1. By making the chamber substrates out of PDMS muscular thin films, it can be used to optically track the bending of each film as a measure of contractility (e.g.,
FIGS. 16A-16B ) - 2. Alternatively, a substrate can be created with micro-holes, which are small enough to be impermeable to the cells. These holes can provide the material with greater flexibility, and their shape can be used as an indicator of the amount of contraction by reading out their shape based on the transmitted light (
FIGS. 18A-18B ); - 3. Rows of oval micro-holes can be created with varying eccentricity, such that conduction is possible through the wires in the material if the holes are completely closed. The row of micro-holes with minimal eccentricity that still conducts can be used to provide the readout of the degree of contraction of the tissue; and/or
- 4. Materials that are capable of varying color with different degrees of stress can also be used;
- The output readout of the contractility and proliferation of the bronchial smooth muscle can then be related to lung capacity curves (rate of inhale/exhale) through the modeling:
- 1. Average material properties of the endothelial layer can be estimated from histological data;
- 2. Stiffness of the muscle layer can be calculated from the in vitro experimental data (from chip); and/or
- 3. These can be used to calculate the diameter of the bronchia tube, which can then be used to calculate the airflow/resistance—clinical outputs
- Create a chip with a desirable number of chambers, e.g., one or more chambers (
- In some embodiments, the chip's function can be calibrated by introducing a substance with known allergenicity, such as procaine, chloroprocaine, and tetracaine, which have been used in humans as local anesthetics and have been shown to be a plausible allergen that can induce a bronchial smooth muscle spasm [4]. This calibration can also be compared to known patient responses, which can provide the necessary data to predict human response based on the data retrieved from the chip.
- For a more recent drug, Raplon (Rapacuronium, Organon) is an anesthetic that was approved in the USA in 1999 and withdrawn by the FDA two years later due to a high risk of fatal bronchial muscle spasm [Ref. 14]. Additionally, drugs such as Novartis AG's Foradil, GlaxoSmithKline's Serevent and Advair, and AstraZeneca's Symbicort, while approved to treat asthma, can themselves cause asthma attacks [Ref. 13]. The chip design described herein can allow for in vitro cultures to run for long periods of time to test such effects, prior to clinical trials.
- In some embodiments, the lung airway smooth muscle chips can be connected to at least one lung chip to function as an integral organ chip. In some embodiments, the design of the lung airway smooth muscle can be incorporated into the lung chip design.
- In some embodiments, the airway chip can be integrated into the system with other organ chips, which can then be used to evaluate drugs that are effective at treating bronchial smooth muscle tissues, but might be toxic to other organ systems (e.g., Ventolin). Alternatively, such integrated system can also allow for testing of drugs commonly used to affect the function of other organs (e.g., beta blockers that reduce cardiac contractility), but can adversely affect airway resistance in asthmatics.
- Drugs can be administered via both intravenous (e.g., via culture medium) and aerosol routes, exhibiting the versatility of the chip design.
- The airway muscle chips, alone or in combinations with other organ chips, can be used in various applications. Non-limiting examples of applications are shown below:
-
- Provide an in vitro platform for bronchial smooth muscle spasm testing;
- Provide a platform to test the contractility of human bronchial smooth muscle tissue;
- Primary cells isolated from different population of patients can be used with this platform to study the effectiveness of drugs for different subsets of the population;
- Provide key endpoints—translating chip outputs to clinical diagnostic tools:
- The chip readout of the contractility and proliferation of the bronchial smooth muscle can be related to lung capacity curves (rate of inhale/exhale) and compared to the output of pulmonary function tests in the clinic;
- The secretion of mucus granules and spherules in the epithelium can be monitored optically as a means to test for mucous secretion that is a hallmark of bronchitis and other obstructive pulmonary diseases; and/or
- Patients with advanced chronic obstructive pulmonary disease like chronic bronchitis often exhibit bluish tinted skin, resulting from hypoxia and fluid retention. Thus, the media can be tested for low oxygen levels and arterial blood gas (measuring ability to oxygenate blood at alveoli) “downstream” of obstructed airways.
- Testis Chips:
- Without limitations, in some embodiments, the Testis Chip can be developed and/or modified, e.g., from the basic Lung Chip multichannel design described herein (e.g., as shown in
FIG. 2 ) as well as in Huh D. et al., 2010 and/or in the International Application No. WO 2010/009307, the contents of which are incorporated herein by reference in their entireties. In some embodiments, the testis chips can employ (e.g., human) Sertoli and Leydig cells being cultured on one side of the porous ECM-coated membrane and endothelium on the other side of the coated membrane. This Testis chip design can maintain enhanced differentiated testicular functions when the two parenchymal cell types are combined in this manner (Ref. 4). - Bone Marrow Chips:
- To construct a Bone Marrow chip, fully functional bone containing a central marrow can be formed in vivo first by implanting demineralized bone powder and
BMPs 2/4 subcutaneously above a muscle layer within a polymer mold (e.g., PDMS mold and culturing it for about 4-8 weeks in vivo. Additional details of the bone marrow chips and methods of making the same can be found in the International Appl. No. PCT/US12/40188, the content of which is incorporated herein by reference in its entirety. The bones that form in these implanted devices can take the shape (e.g., cylindrical shape) of the flexible mold, and contain a fully developed bone marrow with normal morphology and cellular composition (hematopoietic stem cells, progenitor cells, various differentiated blood cell types), when compared to normal mouse bone marrow versus peripheral blood (FIG. 20 ). The formed marrow can be maintained by placing the formed implant within microfluidic channels, as evidenced by cells isolated from this marrow after 4 days in culture being able to regenerate a functional marrow and reconstitute whole blood formation in gamma-irradiated mice. - Alternatively, simultaneously reconstituting the mouse's injured marrow and forming new marrow in the microfluidic implants can be carried out by irradiating immuno-compromised mice, implanting the demineralized bone powder with BMPs subcutaneously, and then injecting human bone marrow. Once removed and maintained in microfluidic systems, the human marrow can then be used to generate all types of blood cells, which can circulate throughout the entire linked organ chip circuit, e.g., an in vitro microphysiological system, e.g., for studies on inflammation and its relation to drug toxicity.
- Without limitations, additional organ chips corresponding to other organs, e.g., spleen chips for filtration of fluid, e.g., blood, as described into the International Appl. No. WO 2012/135834, the content of which is incorporated here by reference in its entirety, can also be integrated into an in vitro microphysiological system described herein.
- Exemplary Applications of Organ Chips and/or In Vitro Microphysiological Systems Described Herein
- At least one or more organ chips can be used for any applications that involve cells. In some embodiments, the organ chips and/or in vitro microphysiological systems can be used as cell culture devices. Compared to 2-D tissue culture flasks, the organ chips and/or in vitro microphysiological systems described herein can provide organ-specific cells a more physiological condition for their growth, and/or maintenance of their differentiated states. For example, lung cells in vivo are generally exposed to a mechanical stimulation, e.g., during breathing. To mimic the breathing action in vitro, organ chips such as lung chips can be used to culture lungs cells as described above. In some embodiments, the cells can be cultured and remain viable (e.g., capable of proliferation) for at least about 3 weeks, at least about 4 weeks, at least about 5 weeks, at least about 6 weeks, at least about 9 weeks, at least about 12 weeks or longer inside the organ chips described herein.
- In some embodiments, the organ chips and/or in vitro microphysiological systems can be used for drug screening, PD/PK studies and/or toxicity assays. For example, an active agent can be delivered to target cells cultured in organ chips, e.g., by introducing the active agent into the organ chips as an aerosol and/or as a mixture with the culture medium flowing through the Interstitial Channels and/or Microvascular Channels of the organs chips described herein. Examples of active agents to be delivered to target cells can include, but are not limited to, cells including, e.g., but not limited to, bacteria and/or virus, proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, drugs or therapeutic agents, molecular toxins, nanomaterials or particulates, aerosols, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants), and any combinations thereof. Exemplary characterization that can be performed with the organ chips and/or in vitro microphysiological systems described herein can include, without limitations, establishment of duration of therapeutic effect; establishment of apparent volume of distribution (Vd), via microfluidic channels within the system; establishment of Tmax, time to maximal media concentration, per given dose; establishment of Cmax, maximal media concentration, per given dose; establishment of terminal half-life, per given dose; and/or establishment of efficacy of biotransformation as result of first bypass effect at the organ chip.
- Examples of drugs can include, but are limited to, pharmacologically active drugs and genetically active molecules. Compounds of interest include chemotherapeutic agents, anti-inflammatory agents, hormones or hormone antagonists, ion channel modifiers, and neuroactive agents. Exemplary of pharmaceutical agents suitable for this invention are those described in “The Pharmacological Basis of Therapeutics,” Goodman and Gilman, McGraw-Hill, New York, N.Y., (1996), Ninth edition, under the sections: Drugs Acting at Synaptic and Neuroeffector Junctional Sites; Drugs Acting on the Central Nervous System; Autacoids: Drug Therapy of Inflammation; Water, Salts and Ions; Drugs Affecting Renal Function and Electrolyte Metabolism; Cardiovascular Drugs; Drugs Affecting Gastrointestinal Function; Drugs Affecting Uterine Motility; Chemotherapy of Parasitic Infections; Chemotherapy of Microbial Diseases; Chemotherapy of Neoplastic Diseases; Drugs Used for Immunosuppression; Drugs Acting on Blood-Forming Organs; Hormones and Hormone Antagonists; Vitamins, Dermatology; and Toxicology, all incorporated herein by reference. Also included are toxins, and biological and chemical warfare agents, for example see Somani, S. M. (Ed.), “Chemical Warfare Agents,” Academic Press, New York, 1992).
- Additional candidate compounds or drugs can be obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, naturally or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.
- By way of example only, the cells within the organ chips and/or in vitro microphysiological systems can be exposed to a drug by flowing a fluid containing the drug through a channel of an organ chip or an integrated system of different organ chips, such that the fluid is in contact with the cells. In some embodiments, the cells within the organ chips and/or in vitro microphysiological systems can be exposed to an aerosol by flowing a gaseous fluid containing the aerosolized microdroplets of a drug through a channel of an organ chip or an integrated system of different organ chips such that the gaseous fluid is in contact with the cells. Cell response in one or more organ chips can then be measured after or monitored over a period of time. Examples of cell response can include, but are not limited to, viability, proliferation, respiration, metabolism, movement of the cells (e.g., migration, contractile motions), differential expression of biomarkers, and/or production and/or release of certain molecules by the cells. Any methods known in the art can be utilized for detecting or measuring a cell response, e.g., immunostaining, microscopy, immunoassays, PCR, and/or ECG measurements.
- In some embodiments where the cells are collected from a subject, a treatment regimen (e.g., a therapeutic agent and/or dosage that works best, among others, for the subject) can be selected and/or optimized by culturing the subject-specific cells in the organ chips and/or in vitro microphysiological systems described herein, exposing the cells to different therapeutic agents and/or dosages, and monitoring the cellular response to various combinations.
- In some embodiments, the cells can be observed by microscopy for morphological changes. In some embodiments, the contractile motion of the cells can be measured by ECG measurements. In some embodiments, the cells can be stained for a target protein, e.g., a biomarker, and then observed under a microscope. In some embodiments, the cells can be collected from the organ chips for further analysis, such as RNA, DNA and/or protein analysis. In some embodiments, the culture medium conditioned by the cells can be collected for further analysis, such as RNA, DNA and/or protein analysis. One of skill in the art can readily perform various assays for detecting or measuring different kinds of cell responses.
- In some embodiments, the organ chips (e.g., gut chips) and/or in vitro microphysiological systems described herein can be used for studying the role of gut flora (e.g., microorganisms that live in the digestive tracts of animals) and other bacteria within a body of an animal that can have a symbiotic relationship with the host. Various factors other than infections, such as aging, geographical transplant, changes in diet, and/or various therapeutic regimens such as antibiotics can alter the gut flora demographics and the physiology of the host. See, e.g., Maynard C L et al. “Reciprocal interactions of the intestinal microbiota and immune system.” Nature. 2012 Sep. 13; 489(7415):231-41; Tremaroli V. and Bäckhed F. “Functional interactions between the gut microbiota and host metabolism.” Nature. 2012 Sep. 13; 489(7415):242-9; Lozupone C A et al. “Diversity, stability and resilience of the human gut microbiota” Nature. 2012 Sep. 13; 489(7415):220-30; and Ottman N et al. “The function of our microbiota: who is out there and what do they do?” Front Cell Infect Microbiol. 2012; 2:104. Epub 2012 Aug. 9, for information on gut microbiome and human health/disease. For example, C. difficile is a serious cause of antibiotic-associated diarrhea (AAD) and can lead to pseudomembranous colitis, a severe inflammation of the colon, often resulting from eradication of the normal gut flora by antibiotics. Accordingly, in some embodiments, “cassettes” of gut bacteria colonies can be co-cultured with gut cells and/or intestine cells in appropriate organ chips, e.g., gut chips, for example, to model gut flora in a host, and/or to study the effects of different factors on the gut flora demographics and/or physiology of the host cells. In some embodiments, these gut chips can be connected to other organ chips to form in vitro microphysiological systems that can be desirable when considering the mind body axis and the coupling of the enteric and central nervous system. These systems can be also used to study, e.g., but not limited to, digestion, and mental illness.
- In some embodiments, methods to study microbial growth, adhesion to host-related surfaces and/or the host-microbiota interactions, e.g., as described in the U.S. Pat. App. No. US 2012/0058551, the content of which is incorporated herein by reference, can be integrated or utilized together with the organ chips and/or in vitro microphysiological system described herein to study the role of gut flora within a body of an animal.
- In some embodiments, the organ chips and/or in vitro microphysiological systems described herein can be used to study and/or model parasitic infections, for example, but not limited to, co-culture of intestinal worms, rabies, toxoplasma, and any combinations thereof.
- Another aspect provided herein relates to kits comprising one or a plurality of organ chips, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more organ chips. In some embodiments, the organ chips in the kit can be all the same, i.e., corresponding to the same organ. In some embodiments, at least some of the organ chips in the kit can represent a different organ. In some embodiments, the organ chips in the kit can be pre-assembled together, or fluidically connected together by a user, to form an integrated microphysiological system. For example, a kit directed to a circulatory system can comprise at least one heart chip and at least one bone-marrow chip. Another kit directed to a gastrointestinal system can comprise at least one liver chip and one gut chip. Depending on the microphysiological system of interest, the kits can comprise a plurality of the organ chips that are involved in the microphysiological system.
- In some embodiments, each organ chips can be individually packaged, e.g., for sterility. In some embodiments, the kits can further comprise an appropriate culture medium. In some embodiments, the kit can further comprise at least one vial of cells, e.g., vascular endothelial cells and/or organ-specific parenchymal cells. In some embodiments, the kits can further comprise an instruction manual, e.g., instructions on connecting various organ chips together to form an integrated network, cell culture methods, and approaches of measuring various cellular responses.
- The methods used in fabrication of any embodiments of the organ chip described herein can vary with the materials used, and include soft lithography methods, microassembly, bulk micromachining methods, surface micro-machining methods, standard lithographic methods, wet etching, reactive ion etching, plasma etching, stereolithography and laser chemical three-dimensional writing methods, solid-object printing, machining, modular assembly methods, replica molding methods, injection molding methods, hot molding methods, laser ablation methods, combinations of methods, and other methods known in the art. A variety of exemplary fabrication methods are described in Fiorini and Chiu, 2005, “Disposable microfluidic devices: fabrication, function, and application” Biotechniques 38:429-446; Beebe et al., 2000, “Microfluidic tectonics: a comprehensive construction platform for microfluidic systems.” Proc. Natl. Acad. Sci. USA 97:13488-13493; Rossier et al., 2002, “Plasma etched polymer microelectrochemical systems” Lab Chip 2:145-150; Becker et al., 2002, “Polymer microfluidic devices” Talanta 56:267-287; Becker et al., 2000, “Polymer microfabrication methods for microfluidic analytical applications” Electrophoresis 21:12-26; U.S. Pat. No. 6,767,706 B2, e.g., Section 6.8 “Microfabrication of a Silicon Device”; McDonald et al., 2002, “Poly(dimethylsiloxane) as a material for fabricating microfluidic devices” Accounts of Chemical Research 35: 491-499. Piccin et al., 2007, “Polyurethane from biosource as a new material for fabrication of microfluidic devices by rapid prototyping” Journal of Chromatography A 1173: 151-158. Each of these references is incorporated herein by reference.
- In some embodiments, an organ chip described herein can be formed by replica molding, for example, in which a replica comprising at least biocompatible polymer (e.g., PDMS polymer) conforms to the shape of a master or a mold and replicates the features of the master or the mold. In some embodiments, the replica can be further sealed to a surface to enclose at least one channel.
- In some embodiments, an organ chip described herein can be formed by machining or micromachining. The term “micromachining” as used herein can encompass bulk micromachining or surface micromachining as recognized in the art. In one embodiment, bulk micromachining defines microstructures such as channels by selectively etching inside a substrate or a body.
- In some embodiments, an organ chip described herein can be formed by solid-object printing. In some embodiments, the solid-object printing can take a three-dimensional (3D) computer-aided design file to make a series of cross-sectional slices. Each slice can then be printed on top of one another to create the 3D solid object.
- Embodiments of the various aspects described herein can be illustrated by the following numbered paragraphs.
- 1. An in vitro microphysiological system comprising:
- a. at least two different organ chips, wherein said at least different two organ chips are selected from either one or both of the following:
- (i) a first organ chip comprising: a body comprising a central channel therein, and an least partially porous and at least partially flexible first membrane positioned within the central channel and along a plane, wherein the first membrane is configured to separate the central channel to form two sub-channels, wherein one side of the first membrane is seeded with vascular endothelial cells, and the other side of the first membrane is seeded with at least one type of organ-specific parenchymal cells;
- (ii) a second organ chip comprising: a body comprising a first chamber enclosing a plurality of muscular thin films adapted to measure contraction of muscle cells, and a second chamber comprising a layer of muscle cells on the bottom surface of the second chamber, wherein the bottom surface is embedded with an array of microelectrodes for recording of action potentials, and wherein the top surface of the second chamber is placed with at least a pair of electrodes for providing electric field stimulation to the muscle cells; or
- (iii) a combination of the first organ chip and the second organ chip; and
- b. at least one connecting means between said at least two different organ chips.
- a. at least two different organ chips, wherein said at least different two organ chips are selected from either one or both of the following:
- 2. The system of
paragraph 1, wherein the system comprises at least three organ chips. - 3. The system of
paragraph - 4. The system of any of paragraphs 1-3, wherein the first organ chip is selected from the group consisting of a lung chip, a liver chip, a gut chip, a kidney chip, a skin chip, a brain chip, a testis chip, and any combinations thereof.
- 5. The system of any of paragraphs 1-3, wherein the second organ chip is selected from the group consisting of a heart chip, a skeletal muscle chip, a lung airway smooth muscle chip, a brain chip, and any combinations thereof.
- 6. The system of any of paragraphs 1-5, further comprising a bone marrow chip fluidically connected to said at least two different organ chips.
- 7. The system of any of paragraphs 1-6, further comprising a spleen chip fluidically connected to said at least two different organ chips.
- 8. The system of any of paragraphs 1-7, wherein the first organ chip further comprises at least a channel wall positioned adjacent to the two sub-channels, wherein the first membrane is mounted to the channel wall; and an operating channel adjacent to the two sub-channels on an opposing side of the channel wall, wherein a pressure differential applied between the operating channel and the two sub-channels causes the channel wall to flex in a desired direction to expand or contract along the plane within the two sub-channels.
- 9. The system of any of paragraphs 1-8, wherein the second organ chip further comprises an at least partially porous second membrane positioned within the first chamber to form a top chamber and a bottom chamber, wherein the bottom chamber comprises the plurality of muscular thin films on its bottom surface, and wherein the surface of the second membrane in contact with the top chamber is seeded with a layer of epithelial cells.
- 10. The system of any of paragraphs 1-9, wherein when the system comprises a circulatory system, said at least two different organ chips comprise a heart chip and a bone marrow chip.
- 11. The system of any of paragraphs 1-10, wherein when the system comprises a respiratory system, said at least two different organ chips comprise a lung chip and an airway smooth muscle chip.
- 12. The system of any of paragraphs 1-11, wherein when the system comprises an excretory system, said at least two different organ chips comprise a lung chip, a gut chip, and a kidney chip.
- 13. The system of any of paragraphs 1-12, wherein when the system comprises a nervous system, said at least two different organ chips comprise a brain chip and a chip with neuronal networks.
- 14. The system of any of paragraphs 1-13, wherein when the system comprises a gastrointestinal system, said at least two different organ chips comprise a liver chip, and a gut chip.
- 15. The system of any of paragraphs 1-14, wherein the system is adapted to determine at least one pharmacokinetic and/or pharmacodynamics parameter of an active agent.
- 16. The system of
paragraph 15, wherein the active agent is selected from the group consisting of cells, proteins, peptides, antigens, antibodies or portions thereof, antibody-like molecules, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, therapeutic agents, molecular toxins, nanomaterials, particulates, aerosols, environmental contaminants or pollutants, and any combinations thereof. - 17. The system of any of paragraphs 1-16, wherein said at least two different organ chips are connected in parallel.
- 18. The system of any of paragraphs 1-17, wherein said at least two different organ chips are connected in series.
- 19. The system of any of paragraphs 1-18, further comprising a housing enclosing said at least two different organ chips.
- 20. The system of any of paragraphs 1-19, wherein said at least two different organ chips comprise at least two said first organ chips.
- 21. The system of any of paragraphs 1-20, wherein said at least two different organ chips comprise at least two said second organ chips.
- 22. A kit comprising:
- a. at least one in vitro microphysiological system of any of paragraphs 1-21; and
- b. at least one agent.
- 23. The kit of paragraph 22, wherein said at least one agent comprises a culture medium, an agent for calibration and/or validation of the system, or a combination thereof.
- 24. The kit of any of paragraphs 22-23, further comprising at least one vial of vascular endothelial cells.
- 25. The kit of any of paragraphs 22-24, further comprising at least one vial of organ-specific parenchymal cells.
- 26. The kit of any of paragraphs 22-25, wherein the organ chips involved in the microphysiological system are each individually packaged.
- 27. A method comprising:
- a. contacting either one or both of the organ-specific parenchymal cells and the muscle cells cultured in said at least two different organ chips of the in vitro microphysiological system of any of paragraphs 1-21 with at least one active agent for a period of time;
- b. measuring a response of the cells cultured in said at least two different organ chips of the in vitro microphysiological system to determine the effect of the at least one active agent on at least two organs.
- 28. The method of paragraph 27, wherein the cells are contacted with said at least one active agent by flowing the active agent through the channel or chamber where the cells are cultured.
- 29. The method of paragraph 28, wherein the active agent is added to a liquid flowing through the channel or the chamber.
- 30. The method of paragraph 29, wherein the liquid comprises cell culture medium, blood, or a combination thereof.
- 31. The method of paragraph 28, wherein the active agent is in a form of an aerosol flowing through the channel or the chamber.
- 32. The method of any of paragraphs 27-31, wherein the response of the cells is selected from the group consisting of viability, proliferation, respiration, metabolism, cell migration, cell contractility, differential expression of cell biomarkers, production and/or release of biomolecules, action potentials, and any combinations thereof.
- 33. The method of any of paragraphs 27-32, wherein the organ-specific parenchymal cells, the muscle cells, or both are collected from a subject.
- 34. The method of any of paragraphs 27-32, wherein the organ-specific parenchymal cells, the muscle cells, or both are differentiated from stems cells collected from a subject.
- 35. The method of paragraph 33 or 34, further comprising comparing the responses of the cells to that of control cells not contacted with said at least one active agent.
- 36. The method of any of paragraphs 27-35, wherein the active agent is selected from the group consisting of cells, proteins, peptides, antigens, antibodies or portions thereof, antibody-like molecules, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, therapeutic agents, molecular toxins, nanomaterials, particulates, aerosols, environmental contaminants or pollutants, and any combinations thereof.
- 37. The method of paragraph 36, wherein when said at least active agent comprises a therapeutic agent, the method further comprises selecting a treatment regimen comprising the therapeutic agent.
- 38. The method of paragraph 37, further comprising administering the therapeutic agent to the subject.
- 39. The method of any of paragraphs 33-38, wherein the subject is a human subject.
- 40. The method of any of paragraphs 27-39, further comprising growing the cells for at least about 3 weeks.
- Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. Unless explicitly stated otherwise, or apparent from context, the terms and phrases below do not exclude the meaning that the term or phrase has acquired in the art to which it pertains. The definitions are provided to aid in describing particular embodiments of the aspects described herein, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
- As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are essential to the invention, yet open to the inclusion of unspecified elements, whether essential or not.
- As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.
- The term “consisting of” refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.
- Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages may mean±1%.
- The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. Thus for example, references to “the method” includes one or more methods, and/or steps of the type described herein and/or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.
- Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The term “comprises” means “includes.” The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.”
- As used herein, a “subject” means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon. In certain embodiments of the aspects described herein, the subject is a mammal, e.g., a primate, e.g., a human. A subject can be male or female. Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but are not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of a disease or disorder.
- As used herein, the term “fluid” refers to any flowable material or medium, e.g., but not limited to, liquid, gas, suspension, aerosols, cell culture medium, and/or biological fluid). In some embodiments, the fluid can comprise one or more target species, e.g., but not limited to cells, and/or active agents described herein. Without wishing to be bound by theory, the fluid can be liquid (e.g., aqueous or non-aqueous), supercritical fluid, gases, solutions, and suspensions.
- As used herein, the term “small molecules” refers to natural or synthetic molecules including, but not limited to, peptides, peptidomimetics, amino acids, amino acid analogs, polynucleotides, polynucleotide analogs, aptamers, nucleotides, nucleotide analogs, organic or inorganic compounds (i.e., including heteroorganic and organometallic compounds) having a molecular weight less than about 10,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 5,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 1,000 grams per mole, organic or inorganic compounds having a molecular weight less than about 500 grams per mole, and salts, esters, and other pharmaceutically acceptable forms of such compounds.
- The term “therapeutic agents” is art-recognized and refers to any chemical moiety that is a biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a subject. Examples of therapeutic agents, also referred to as “drugs”, are described in well-known literature references such as the Merck Index, the Physicians Desk Reference, and The Pharmacological Basis of Therapeutics, and they include, without limitation, medicaments; vitamins; mineral supplements; substances used for the treatment, prevention, diagnosis, cure or mitigation of a disease or illness; substances which affect the structure or function of the body; or pro-drugs, which become biologically active or more active after they have been placed in a physiological environment. Various forms of a therapeutic agent may be used which are capable of being released from a composition into adjacent tissues or fluids upon administration to a subject. Examples include steroids and esters of steroids (e.g., estrogen, progesterone, testosterone, androsterone, cholesterol, norethindrone, digoxigenin, cholic acid, deoxycholic acid, and chenodeoxycholic acid), boron-containing compounds (e.g., carborane), chemotherapeutic nucleotides, drugs (e.g., antibiotics, antivirals, antifungals), enediynes (e.g., calicheamicins, esperamicins, dynemicin, neocarzinostatin chromophore, and kedarcidin chromophore), heavy metal complexes (e.g., cisplatin), hormone antagonists (e.g., tamoxifen), non-specific (non-antibody) proteins (e.g., sugar oligomers), oligonucleotides (e.g., antisense oligonucleotides that bind to a target nucleic acid sequence (e.g., mRNA sequence)), peptides, proteins, antibodies, photodynamic agents (e.g., rhodamine 123), radionuclides (e.g., I-131, Re-186, Re-188, Y-90, Bi-212, At-211, Sr-89, Ho-166, Sm-153, Cu-67 and Cu-64), toxins (e.g., ricin), and transcription-based pharmaceuticals, anti-inflammatory agents, vaccines, and any combinations thereof.
- As used herein, the term “molecular toxin” refers to a compound produced by an organism which causes or initiates the development of a noxious, poisonous or deleterious effect in a host presented with the toxin. Such deleterious conditions may include fever, nausea, diarrhea, weight loss, neurologic disorders, renal disorders, hemorrhage, and the like. Toxins include, but are not limited to, bacterial toxins, such as cholera toxin, heat-liable and heat-stable toxins of E. coli, toxins A and B of Clostridium difficile, aerolysins, and hemolysins; toxins produced by protozoa, such as Giardia; toxins produced by fungi. Molecular toxins can also include exotoxins, i.e., toxins secreted by an organism as an extracellular product, and enterotoxins, i.e., toxins present in the gut of an organism.
- As used herein, the term “cells” refers to biological cells selected from the group consisting of living or dead cells (prokaryotic and eukaryotic, including mammalian), viruses, bacteria, fungi, yeast, protozoan, microbes, and parasites. The biological cells can be a normal cell or a diseased cell. Mammalian cells include, without limitation; primate, human and a cell from any animal of interest, including without limitation; mouse, hamster, rabbit, dog, cat, domestic animals, such as equine, bovine, murine, ovine, canine, and feline. In some embodiments, the cells can be derived from a human subject. In other embodiments, the cells are derived from a domesticated animal, e.g., a dog or a cat. Exemplary mammalian cells include, but are not limited to, stem cells, progenitor cells, immune cells, blood cells, and any combinations thereof. The cells can be derived from a wide variety of tissue types without limitation such as; hematopoietic, neural, mesenchymal, cutaneous, mucosal, stromal, muscle, spleen, reticuloendothelial, epithelial, endothelial, hepatic, kidney, gastrointestinal, pulmonary, cardiovascular, T-cells, and fetus. Stem cells, embryonic stem (ES) cells, ES-derived cells and stem cell progenitors are also included, including without limitation, hematopoietic, neural, stromal, muscle, cardiovascular, hepatic, pulmonary, and gastrointestinal stem cells. Yeast cells may also be used as cells in some embodiments described herein. In some embodiments, the cells can be ex vivo or cultured cells, e.g. in vitro. For example, for ex vivo cells, cells can be obtained from a subject, where the subject is healthy and/or affected with a disease. While cells can be obtained from a fluid sample, e.g., a blood sample, cells can also be obtained, as a non-limiting example, by biopsy or other surgical means know to those skilled in the art.
- Exemplary fungi and yeast include, but are not limited to, Cryptococcus neoformans, Candida albicans, Candida tropicalis, Candida stellatoidea, Candida glabrata, Candida krusei, Candida parapsilosis, Candida guilliermondii, Candida viswanathii, Candida lusitaniae, Rhodotorula mucilaginosa, Aspergillus fumigatus, Aspergillus flavus, Aspergillus clavatus, Cryptococcus neoformans, Cryptococcus laurentii, Cryptococcus albidus, Cryptococcus gattii, Histoplasma capsulatum, Pneumocystis jirovecii (or Pneumocystis carinii), Stachybotrys chartarum, and any combination thereof.
- Exemplary bacteria include, but are not limited to: anthrax, campylobacter, cholera, diphtheria, enterotoxigenic E. coli, giardia, gonococcus, Helicobacter pylori, Hemophilus influenza B, Hemophilus influenza non-typable, meningococcus, pertussis, pneumococcus, salmonella, shigella, Streptococcus B, group A Streptococcus, tetanus, Vibrio cholerae, yersinia, Staphylococcus, Pseudomonas species, Clostridia species, Myocobacterium tuberculosis, Mycobacterium leprae, Listeria monocytogenes, Salmonella typhi, Shigella dysenteriae, Yersinia pestis, Brucella species, Legionella pneumophila, Rickettsiae, Chlamydia, Clostridium perfringens, Clostridium botulinum, Staphylococcus aureus, Treponema pallidum, Haemophilus influenzae, Treponema pallidum, Klebsiella pneumoniae, Pseudomonas aeruginosa, Cryptosporidium parvum, Streptococcus pneumoniae, Bordetella pertussis, Neisseria meningitides, and any combination thereof.
- Exemplary parasites include, but are not limited to: Entamoeba histolytica; Plasmodium species, Leishmania species, Toxoplasmosis, Helminths, and any combination thereof. Other examples of parasites can include, but are not limited to, intestinal worms, rabies, toxoplasma, and any combinations thereof.
- Exemplary viruses include, but are not limited to, HIV-1, HIV-2, hepatitis viruses (including hepatitis B and C), Ebola virus, West Nile virus, and herpes virus such as HSV-2, adenovirus, dengue serotypes 1 to 4, ebola, enterovirus, herpes simplex virus 1 or 2, influenza, Japanese equine encephalitis, Norwalk, papilloma virus, parvovirus B19, rubella, rubeola, vaccinia, varicella, Cytomegalovirus, Epstein-Barr virus, Human herpes virus 6, Human herpes virus 7, Human herpes virus 8, Variola virus, Vesicular stomatitis virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus, poliovirus, Rhinovirus, Coronavirus, Influenza virus A, Influenza virus B, Measles virus, Polyomavirus, Human Papilomavirus, Respiratory syncytial virus, Adenovirus, Coxsackie virus, Dengue virus, Mumps virus, Rabies virus, Rous sarcoma virus, Yellow fever virus, Ebola virus, Marburg virus, Lassa fever virus, Eastern Equine Encephalitis virus, Japanese Encephalitis virus, St. Louis Encephalitis virus, Murray Valley fever virus, West Nile virus, Rift Valley fever virus, Rotavirus A, Rotavirus B, Rotavirus C, Sindbis virus, Human T-cell Leukemia virus type-1, Hantavirus, Rubella virus, Simian Immunodeficiency viruses, and any combination thereof.
- As used herein, the term “environmental contaminants or pollutants” refers to microorganisms, molecules, and/or substances originated from an environmental source, e.g., air, food, and/or water, that can adversely affect at least one physiological function of a subject in a temporary or permanent manner, and/or can be fatal when they are ingested or inhaled by the subject. Exemplary environmental contaminants or pollutants can include, but are not limited to microorganisms (e.g., Cryptosporidium, Giardia lamblia, bacteria, Legionella, Coliforms, viruses, fungi, molds, spores), bromates, chlorites, haloactic acids, trihalomethanes, chloramines, chlorine, chlorine dioxide, antimony, arsenic, mercury (inorganic), nitrates, nitrites, selenium, thallium, Acrylamide, Alachlor, Atrazine, Benzene, Benzo(a)pyrene (PAHs), Carbofuran, Carbon, etrachloride, Chlordane, Chlorobenzene, 2,4-D, Dalapon, 1,2-Dibromo-3-chloropropane (DBCP), o-Dichlorobenzene, p-Dichlorobenzene, 1,2-Dichloroethane, 1,1-Dichloroethylene, cis-1,2-Dichloroethylene, trans-1,2-Dichloroethylene, Dichloromethane, 1,2-Dichloropropane, Di(2-ethylhexyl) adipate, Di(2-ethylhexyl) phthalate, Dinoseb, Dioxin (2,3,7,8-TCDD), Diquat, Endothall, Endrin, Epichlorohydrin, Ethylbenzene, Ethylene dibromide, Glyphosate, Heptachlor, Heptachlor epoxide, Hexachlorobenzene, Hexachlorocyclopentadiene, Lead, Lindane, Methoxychlor, Oxamyl (Vydate), Polychlorinated, biphenyl s (PCBs), Pentachlorophenol, Picloram, Simazine, Styrene, Tetrachloroethylene, Toluene, Toxaphene, 2,4,5-TP (Silvex), 1,2,4-Trichlorobenzene, 1,1,1-Trichloroethane, 1,1,2-Trichloroethane, Trichloroethylene, Vinyl chloride, and Xylenes, smog, carbon monoxide, sulfur dioxide, and any combinations thereof.
- By the term “nanomaterials” is generally meant structures having at least one dimension in nanometer range. Examples of nanomaterials that can be exposed to cells can include, but are not limited to, single or multi-walled nanotubes, nanowires, nanodots, quantum dots, nanorods, nanocrystals, nanotetrapods, nanotripods, nanobipods, nanoparticles, nanosaws, nanosprings, nanoribbons, nanocapsules, branched nanomaterials, and any combinations thereof. The nanomaterials can be made of or comprise, e.g., carbon, metal or alloy, metal oxide, polymer, or any synthetic materials. In some embodiments, the nanomaterials can comprise an active agent described herein, e.g., active agent-loaded nanoparticles.
- As used herein, the term “particulates” refers to fine particles, powder, flakes, etc., that exist in a relatively small form. In some embodiments, the particulates are small enough to be inhaled by a subject. In some embodiments, the particulates can be produced as a by-product of a chemical reaction, e.g., burning a fuel. In some embodiments, the particulates can be produced by, for example, grinding, shredding, fragmenting, pulverizing, atomizing, or otherwise subdividing a larger form of the material into a relatively small form. Examples of particulates can include, but are not limited to, soot, dust, smoke, aerosols, and any combinations thereof.
- As used herein, the term “aerosols” refers to gaseous suspensions or solutions of dispersed solid or liquid particles, e.g., but not limited to, sprays, colloids, mists and respirable aerosols. The aerosols can be in suspension, solution or dry powder form. An aerosol can comprise an active agent described herein, e.g., cells (including, e.g., but not limited to, bacteria and/or virus), proteins, peptides, antigens, antibodies or portions thereof, enzymes, nucleic acids, siRNA, shRNA, aptamers, small molecules, antibiotics, therapeutic agents, molecular toxins, nanomaterials, particulates, environmental contaminants or pollutants (e.g., but not limited to, microorganisms, organic/inorganic contaminants present in food and/or water, and/or air pollutants). As used herein, the term “respirable aerosol” refers to an aerosol having a component that can be delivered to the lungs of a subject, and/or be deposited on the surfaces of a subject's nasal passages and/or adsorbed onto the tissue of the nasal passages.
- As used herein, the term “treating” refers to therapeutic treatment wherein the purpose is to prevent or slow the development of the disease or disorder. Treatment is generally “effective” if one or more symptoms or clinical markers are reduced. Alternatively, a treatment is “effective” if the progression of a disease is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or decrease of markers of the disease, but also a cessation or slowing of progress or worsening of a symptom that would be expected in absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (e.g., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already diagnosed with a disease or disorder, as well as those likely to develop a disease or disorder.
-
- 1. Huh D, Matthews B D, Mammoto A, Montoya-Zavala M, Hsin H Y, and Ingber D E. Reconstituting organ-level lung function on a chip. Science 2010, 328: 1662.
- 2. Grosberg A, Alford P W, McCain M L, Parker K K. Ensembles of engineered cardiac tissues for physiological and pharmacological study: Heart on a chip. Lab on a Chip 2011, 11: 4165.
- 3. Edward L, LeCluyse, Alexandre E., Hamilton G A, Viollon-Abadie C, Coon D J, Jolley S, and Richert L. Isolation and Culture of Primary Human Hepatocytes, In: Helgarson C, ed., Basic Cell Culture Protocols: Methods in Molecular Biology—Third Edition, Humana Press, 2004.
- 4. Darby S, Moore M, Wikswo J P, Reiserer R, Friedlander T, Schaffer D K, Seale K T. A Metering Rotary Nanopump for Microfluidic Systems, Lab on a Chip 2010, 10: 3218.
- 5. Velkovsky M, Snider R, Cliffel D E, Wikswo J P. Modeling the Measurements of Cellular Fluxes in Microbioreactor Devices Using Thin Enzyme Electrodes, Journal of Mathematical Chemistry 2011, 49: 251.
- 6. Eklund S E, Taylor D, Kozlov E, Prokop A, Cliffel D E. A Microphysiometer for Simultaneous Measurement of Changes in Extracellular Glucose, Lactate, Oxygen, and Acidification Rate, Anal. Chem. 2004, 76: 519.
- 7. Force T, Krause D S, & Van Etten R A (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature reviews. Cancer 7(5):332.
- 8. Zhu W, et al. (2008) Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation: CIRCULATIONAHA. 108.799700.
- 9. Finlayson K, Turnbull L, January C T, Sharkey J, & Kelly J S (2001) [3H] Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. European journal of pharmacology 430(1):147-148.
- 10. https://shop.lonza.com/shop/prd/human-bronchial-smooth-muscle-cells/lonza_b2b/7.0-7_2_86_69_76_10_13/2/DF3699C5729946F18852001A4B525E10/11. Chiba et al., 2009
- 12. Zhou et al., Human Bronchial Smooth Muscle Cell Lines Show a Hypertrophic Phenotype Typical of Severe Asthma, AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, VOL 169 2004
- 13. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200931.htm
- 14. http://www.homesteadschools.com/dental/courses/LocalAnesthesia/part2.htm
- All patents and other publications identified in the specification and examples are expressly incorporated herein by reference for all purposes. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.
Claims (30)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/125,433 US20190032021A1 (en) | 2011-12-09 | 2018-09-07 | Organ Chips And Uses Thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161569029P | 2011-12-09 | 2011-12-09 | |
PCT/US2012/068766 WO2013086502A1 (en) | 2011-12-09 | 2012-12-10 | Organ chips and uses thereof |
US201414363105A | 2014-06-05 | 2014-06-05 | |
US16/125,433 US20190032021A1 (en) | 2011-12-09 | 2018-09-07 | Organ Chips And Uses Thereof |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/363,105 Division US10087422B2 (en) | 2011-12-09 | 2012-12-10 | Organ chips and uses thereof |
PCT/US2012/068766 Division WO2013086502A1 (en) | 2011-12-09 | 2012-12-10 | Organ chips and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/439,694 Continuation US20240182868A1 (en) | 2024-02-12 | Organ Chips And Uses Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190032021A1 true US20190032021A1 (en) | 2019-01-31 |
Family
ID=48574980
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/363,105 Active 2034-11-14 US10087422B2 (en) | 2011-12-09 | 2012-12-10 | Organ chips and uses thereof |
US16/125,433 Abandoned US20190032021A1 (en) | 2011-12-09 | 2018-09-07 | Organ Chips And Uses Thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/363,105 Active 2034-11-14 US10087422B2 (en) | 2011-12-09 | 2012-12-10 | Organ chips and uses thereof |
Country Status (2)
Country | Link |
---|---|
US (2) | US10087422B2 (en) |
WO (1) | WO2013086502A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3753485A1 (en) * | 2019-06-20 | 2020-12-23 | Nokia Technologies Oy | Electrode apparatuses and methods of forming electrode apparatuses |
WO2021118934A1 (en) * | 2019-12-09 | 2021-06-17 | Georgia Tech Research Corporation | Microengineered tissue barrier system |
WO2021152591A1 (en) * | 2020-01-29 | 2021-08-05 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Blood-brain-barrier systems |
WO2021202539A3 (en) * | 2020-03-30 | 2021-11-04 | Javelin Biotech, Inc. | Microfluidic devices and methods of designing and using microfluidic devices |
WO2021261961A1 (en) * | 2020-06-26 | 2021-12-30 | (주) 멥스젠 | Cryopreservation method for organ-on-a-chip |
KR20220141391A (en) | 2021-04-12 | 2022-10-20 | 서울대학교병원 | Kidney-mimicking organ chip comprising tubular culture section and interstitial culture section |
WO2022260436A1 (en) * | 2021-06-08 | 2022-12-15 | (주) 멥스젠 | Microfluidic chip including tumor spheroids |
WO2023275871A1 (en) * | 2021-07-01 | 2023-01-05 | Ramot At Tel Aviv University Ltd. | Multi-layered modular organ-on-a-chip platform |
US11760966B2 (en) | 2019-06-14 | 2023-09-19 | University Of Connecticut | Multigel tumor-on-a-chip system |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA3162352A1 (en) | 2010-10-01 | 2012-04-05 | Modernatx, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
KR102351944B1 (en) | 2011-02-28 | 2022-01-18 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Cell culture system |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9266725B2 (en) | 2011-04-27 | 2016-02-23 | The Board Of Trustees Of The Leland Stanford Junior University | Nanotube structures, methods of making nanotube structures, and methods of accessing intracellular space |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013086502A1 (en) | 2011-12-09 | 2013-06-13 | President And Fellows Of Harvard College | Organ chips and uses thereof |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
US11001797B2 (en) * | 2012-04-13 | 2021-05-11 | President And Fellows Of Harvard College | Devices and methods for in vitro aerosol delivery |
LT2922554T (en) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminally modified rna |
WO2014133624A2 (en) | 2012-12-10 | 2014-09-04 | President And Fellows Of Harvard College | Membrane-based fluid-flow control devices |
JP2016504050A (en) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | Signal sensor polynucleotide for modification of cell phenotype |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
PL3019619T3 (en) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
AU2014287013B2 (en) | 2013-07-12 | 2020-01-23 | President And Fellows Of Harvard College | Systems and methods for cell culture device interconnection and fluidic device interconnection |
US9855554B2 (en) | 2013-07-22 | 2018-01-02 | President And Fellows Of Harvard College | Microfluidic cartridge assembly |
US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
US10987059B2 (en) | 2013-11-17 | 2021-04-27 | Ramot At Tel-Aviv University Ltd. | Electronic scaffold and uses thereof |
NL2011895C2 (en) * | 2013-12-04 | 2015-06-08 | Mikhail Alexandrovich Ponomarenko | Fluidic device and perfusion system for in vitro tissue reconstruction. |
GB2581749B (en) | 2013-12-20 | 2021-03-03 | Harvard College | Organomimetic devices and methods of use and manufacturing thereof |
CN106459898A (en) * | 2013-12-20 | 2017-02-22 | 哈佛大学校长及研究员协会 | Low shear microfluidic devices and methods of use and manufacturing thereof |
US10174289B2 (en) | 2014-05-28 | 2019-01-08 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
EP3169626A4 (en) | 2014-07-14 | 2018-04-04 | President and Fellows of Harvard College | Systems and methods for improved performance of fluidic and microfluidic systems |
WO2016061464A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intetine using pluripotent stem cells and methods of making and using same |
CA2964422C (en) | 2014-10-27 | 2018-06-12 | The Governing Council Of The University Of Toronto | Microfluidic device for cell-based assays |
CA2968655C (en) | 2014-11-25 | 2021-11-16 | President And Fellows Of Harvard College | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same |
US20180355298A1 (en) * | 2014-12-15 | 2018-12-13 | The Regents Of The University Of California | Multi-organ cell culture system and methods of use thereof |
EP3265552B1 (en) * | 2015-03-04 | 2021-12-29 | President and Fellows of Harvard College | Fluidic device for quantifying the dynamic permeability and hydraulic conductivity of living tissue layers |
WO2016158417A1 (en) * | 2015-03-27 | 2016-10-06 | 国立研究開発法人農業生物資源研究所 | Hepatocyte culture device capable of enhancing accumulation and excretion of hepatic metabolite in and into bile canaliculus-like structure, and method for evaluating candidate compound sensitive to excretion into bile or blood and hepatic metabolite of said candidate compound using said hepatocyte culture device |
WO2016168653A1 (en) * | 2015-04-17 | 2016-10-20 | Worcester Polytechnic Institute | Thin film with microchannels |
GB2555319A (en) | 2015-05-22 | 2018-04-25 | Harvard College | Methods, systems, and compositions for determining blood clot formation, and uses thereof |
US10202569B2 (en) | 2015-07-24 | 2019-02-12 | President And Fellows Of Harvard College | Radial microfluidic devices and methods of use |
CA2993956A1 (en) | 2015-07-27 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Lung disease models on a chip |
US10465155B2 (en) | 2015-08-10 | 2019-11-05 | Board Of Regents, The University Of Texas System | Non-linear flow path devices and methods for cell culture |
US10799865B2 (en) | 2015-10-27 | 2020-10-13 | Berkeley Lights, Inc. | Microfluidic apparatus having an optimized electrowetting surface and related systems and methods |
WO2017087759A1 (en) * | 2015-11-18 | 2017-05-26 | President And Fellows Of Harvard College | Cartridge-based system for long term culture of cell clusters |
WO2017096207A1 (en) * | 2015-12-03 | 2017-06-08 | The Government Of The United States Of America, As Represented By The Secretary Of The Navy | Modular bioreactor for culture of biopaper based tissues |
US20170158997A1 (en) * | 2015-12-04 | 2017-06-08 | President And Fellows Of Harvard College | Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof |
CA3013313A1 (en) * | 2015-12-04 | 2017-06-08 | President And Fellows Of Harvard College | Open-top microfluidic devices and methods for simulating a function of a tissue |
US20190093077A1 (en) * | 2015-12-04 | 2019-03-28 | EMULATE, Inc. | Devices and methods for simulating a function of a liver tissue |
WO2017095899A1 (en) * | 2015-12-04 | 2017-06-08 | President And Fellows Of Harvard College | Gradient microfluidic devices and uses thereof |
EP3389678B1 (en) | 2015-12-16 | 2022-06-15 | Ramot at Tel-Aviv University Ltd. | Particles comprising decellularized omentum |
JP6602952B2 (en) * | 2016-02-29 | 2019-11-06 | 富士フイルム株式会社 | Kit for quantifying bile acids in biological samples and method for quantifying bile acids in biological samples |
CA3205061C (en) | 2016-03-30 | 2024-02-13 | EMULATE, Inc. | Methods of determining tumor marker expression in human tumor cells |
US11066650B2 (en) | 2016-05-05 | 2021-07-20 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
WO2017214541A1 (en) | 2016-06-09 | 2017-12-14 | The Board Of Trustees Of The Leland Stanford Junior University | Nanostraw well insert devices for improved cell transfection and viability |
GB2567529B (en) * | 2016-07-12 | 2021-03-31 | Emulate Inc | Additive channels |
CA3032997A1 (en) | 2016-07-12 | 2018-01-18 | EMULATE, Inc. | Compositions and methods of cell attachment |
EP3484491B1 (en) | 2016-07-18 | 2022-09-07 | President and Fellows of Harvard College | Human lymphoid tissue-on-chip |
EP3497443A4 (en) * | 2016-08-11 | 2020-04-01 | Novoheart Limited | Systems and methods for modeling disease and assessing adverse side effects of therapeutics therefor |
AU2017326179B2 (en) * | 2016-09-13 | 2022-12-08 | President And Fellows Of Harvard College | Methods relating to intestinal organ-on-a-chip |
JP7102414B2 (en) | 2016-09-13 | 2022-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Non-destructive nanostraw intracellular sampling method for long-term cell monitoring |
WO2018071354A1 (en) * | 2016-10-14 | 2018-04-19 | Wake Forest University Health Sciences | Multi-organ "body on a chip" apparatus utilizing a common media |
US20180106784A1 (en) * | 2016-10-19 | 2018-04-19 | R.J. Reynolds Tobacco Company | Microfluidics Aerosol-Evaluation Apparatus |
WO2018094003A1 (en) * | 2016-11-16 | 2018-05-24 | President And Fellows Of Harvard College | Coupled organ-on-chip systems, devices, and methods of use for mimicking a de-coupled organ |
AU2017366833B2 (en) | 2016-12-02 | 2020-02-20 | EMULATE, Inc. | In vitro epithelial models comprising lamina propria-derived cells |
GB2571878A (en) | 2016-12-02 | 2019-09-11 | Emulate Inc | In vitro gastrointestinal model comprising lamina propria-derived cells |
AU2017373767B2 (en) | 2016-12-05 | 2021-09-16 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
WO2018115973A2 (en) * | 2016-12-22 | 2018-06-28 | Avectas Limited | Vector-free intracellular delivery by reversible permeabilisation |
US11913022B2 (en) | 2017-01-25 | 2024-02-27 | Cedars-Sinai Medical Center | In vitro induction of mammary-like differentiation from human pluripotent stem cells |
JP2020510417A (en) | 2017-02-17 | 2020-04-09 | コニク インコーポレイテッド | System for detection |
WO2018157073A1 (en) * | 2017-02-27 | 2018-08-30 | President And Fellows Of Harvard College | Integrated multi-electrode array and trans-endothelial electrical resistance in organ-on-a-chip microsystems |
US11767513B2 (en) | 2017-03-14 | 2023-09-26 | Cedars-Sinai Medical Center | Neuromuscular junction |
GB2575584B (en) | 2017-03-24 | 2022-09-28 | Harvard College | Bone marrow microfluidic devices and methods for preparing and using the same |
GB2578040B (en) * | 2017-05-23 | 2022-12-07 | Emulate Inc | Advanced pulmonary models |
DE102017209942B4 (en) | 2017-06-13 | 2019-05-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein | Device and method for the cultivation of cells |
JP7104140B2 (en) * | 2017-07-19 | 2022-07-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Instruments and methods using nanostraws to deliver biologically important cargo into non-adherent cells |
US11499128B2 (en) | 2017-09-22 | 2022-11-15 | The Regents Of The University Of Colorado | Organ-on-chip microphysiological system |
CN107828655A (en) * | 2017-11-15 | 2018-03-23 | 大连理工大学 | A kind of micro-fluidic chip and its application |
WO2019153004A1 (en) * | 2018-02-05 | 2019-08-08 | EMULATE, Inc. | Stem cell-based lung-on-chip models |
US11679546B2 (en) | 2018-02-09 | 2023-06-20 | The Regents Of The University Of Colorado, A Body Corporate | Bioprinter and methods of manufacturing an organomimetic device |
WO2019165279A1 (en) | 2018-02-23 | 2019-08-29 | EMULATE, Inc. | Organs-on-chips as a platform for epigenetics discovery |
WO2019163925A1 (en) * | 2018-02-26 | 2019-08-29 | 富士フイルム株式会社 | Flow path device |
CN108641931A (en) * | 2018-04-04 | 2018-10-12 | 浙江大学 | A kind of digitlization microarray organ chip and its application |
US11981918B2 (en) | 2018-04-06 | 2024-05-14 | Cedars-Sinai Medical Center | Differentiation technique to generate dopaminergic neurons from induced pluripotent stem cells |
US11480560B2 (en) | 2018-06-11 | 2022-10-25 | The Regents Of The University Of Colorado, A Body Corporate | Delivery of aerosolized respiratory pathogens |
CN109055204B (en) * | 2018-10-19 | 2024-03-26 | 杭州捷诺飞生物科技股份有限公司 | Organ chip for drug screening |
GB201901273D0 (en) * | 2019-01-30 | 2019-03-20 | Stemnovate Ltd | Method and apparatus for real time monitoring of cell and tissue culture |
US11725190B2 (en) | 2019-02-22 | 2023-08-15 | EMULATE, Inc. | Microfluidic proximal tubule kidney-on-chip |
TWI708842B (en) * | 2019-10-02 | 2020-11-01 | 中原大學 | Bionic organ device and method for making the same |
WO2021222724A1 (en) * | 2020-05-01 | 2021-11-04 | Cedars-Sinai Medical Center | Multi-lineage cardiovascular microfluidic organ-chip |
WO2022035335A1 (en) * | 2020-08-13 | 2022-02-17 | Ineb (Instituto Nacional De Engenharia Biomédica) | Fabrication of microactuator and in-line degasser in organ-ona_chip devices and methods thereof |
US20240110137A1 (en) * | 2021-02-26 | 2024-04-04 | Universidade Do Minho | Multiorgan-on-a-chip device with integrated microbiosensors, methods and uses thereof |
JPWO2022191222A1 (en) * | 2021-03-10 | 2022-09-15 | ||
CN113088452A (en) * | 2021-04-25 | 2021-07-09 | 复旦大学附属中山医院 | Aorta organoid chip, preparation method, chip system and application |
WO2022235546A1 (en) * | 2021-05-02 | 2022-11-10 | The Brigham And Women's Hospital, Inc. | Apparatus and method for a biomimetic human alveolar lung-on-a-chip model |
CN113174332B (en) * | 2021-05-06 | 2023-07-21 | 华东理工大学 | Bionic kidney organ chip structure and bionic liver kidney chip structure |
CN113462565A (en) * | 2021-07-05 | 2021-10-01 | 华东理工大学 | Skin chip device |
WO2023152143A1 (en) * | 2022-02-08 | 2023-08-17 | Centre National De La Recherche Scientifique | Permeability measurement device and method |
CN115558601B (en) * | 2022-11-30 | 2023-06-06 | 苏州大学 | Mini mammal model and application thereof |
CN116445282B (en) * | 2023-06-20 | 2023-09-26 | 清华大学 | Microfluidic system and application thereof in constructing bionic organ microenvironment |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089993A1 (en) * | 2002-05-01 | 2005-04-28 | Paolo Boccazzi | Apparatus and methods for simultaneous operation of miniaturized reactors |
US20090215022A1 (en) * | 2006-05-22 | 2009-08-27 | Biovest International, Inc. | Extra-capillary fluid cycling system and method for a cell culture device |
US20090275072A1 (en) * | 2003-09-16 | 2009-11-05 | Incube Laboratories, Inc | In Vitro bio-reactor circuit |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5827729A (en) * | 1996-04-23 | 1998-10-27 | Advanced Tissue Sciences | Diffusion gradient bioreactor and extracorporeal liver device using a three-dimensional liver tissue |
US7759113B2 (en) | 1999-04-30 | 2010-07-20 | The General Hospital Corporation | Fabrication of tissue lamina using microfabricated two-dimensional molds |
US6734000B2 (en) * | 2000-10-12 | 2004-05-11 | Regents Of The University Of California | Nanoporous silicon support containing macropores for use as a bioreactor |
US20080102438A1 (en) | 2004-10-27 | 2008-05-01 | Yannas Ioannis V | Novel Technique to Fabricate Molded Structures Having a Patterned Porosity |
JP5167150B2 (en) * | 2006-02-03 | 2013-03-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Designed cell growth on polymer thin film and its biotechnological application |
DE602007012282D1 (en) | 2006-10-12 | 2011-03-10 | Massachusetts Inst Technology | MULTI-WELL MICROMASTERING BY ABLATION |
EP2248121A2 (en) * | 2008-02-11 | 2010-11-10 | The General Hospital Corporation | System and method for in vitro blood vessel modeling |
DE102008018170B4 (en) | 2008-04-03 | 2010-05-12 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Microfluidic system and method for the construction and subsequent cultivation and subsequent investigation of complex cell arrays |
ES2672201T3 (en) | 2008-07-16 | 2018-06-13 | Children's Medical Center Corporation | Imitation device of organs with microchannels and methods of use |
WO2013086502A1 (en) | 2011-12-09 | 2013-06-13 | President And Fellows Of Harvard College | Organ chips and uses thereof |
WO2013158939A1 (en) | 2012-04-18 | 2013-10-24 | Hemoshear, Llc | In vitro model for pathological or physiologic conditions |
-
2012
- 2012-12-10 WO PCT/US2012/068766 patent/WO2013086502A1/en active Application Filing
- 2012-12-10 US US14/363,105 patent/US10087422B2/en active Active
-
2018
- 2018-09-07 US US16/125,433 patent/US20190032021A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050089993A1 (en) * | 2002-05-01 | 2005-04-28 | Paolo Boccazzi | Apparatus and methods for simultaneous operation of miniaturized reactors |
US20090275072A1 (en) * | 2003-09-16 | 2009-11-05 | Incube Laboratories, Inc | In Vitro bio-reactor circuit |
US20090215022A1 (en) * | 2006-05-22 | 2009-08-27 | Biovest International, Inc. | Extra-capillary fluid cycling system and method for a cell culture device |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11760966B2 (en) | 2019-06-14 | 2023-09-19 | University Of Connecticut | Multigel tumor-on-a-chip system |
EP3753485A1 (en) * | 2019-06-20 | 2020-12-23 | Nokia Technologies Oy | Electrode apparatuses and methods of forming electrode apparatuses |
WO2021118934A1 (en) * | 2019-12-09 | 2021-06-17 | Georgia Tech Research Corporation | Microengineered tissue barrier system |
US11932839B2 (en) | 2019-12-09 | 2024-03-19 | Georgia Tech Research Corporation | Microengineered tissue barrier system |
WO2021152591A1 (en) * | 2020-01-29 | 2021-08-05 | B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University | Blood-brain-barrier systems |
WO2021202539A3 (en) * | 2020-03-30 | 2021-11-04 | Javelin Biotech, Inc. | Microfluidic devices and methods of designing and using microfluidic devices |
WO2021261961A1 (en) * | 2020-06-26 | 2021-12-30 | (주) 멥스젠 | Cryopreservation method for organ-on-a-chip |
KR20220000847A (en) * | 2020-06-26 | 2022-01-04 | (주) 멥스젠 | Methods for cryopreservation of organ-on-a-chip |
KR102380496B1 (en) * | 2020-06-26 | 2022-04-01 | (주) 멥스젠 | Methods for cryopreservation of organ-on-a-chip |
KR20220141391A (en) | 2021-04-12 | 2022-10-20 | 서울대학교병원 | Kidney-mimicking organ chip comprising tubular culture section and interstitial culture section |
WO2022260436A1 (en) * | 2021-06-08 | 2022-12-15 | (주) 멥스젠 | Microfluidic chip including tumor spheroids |
WO2023275871A1 (en) * | 2021-07-01 | 2023-01-05 | Ramot At Tel Aviv University Ltd. | Multi-layered modular organ-on-a-chip platform |
Also Published As
Publication number | Publication date |
---|---|
WO2013086502A1 (en) | 2013-06-13 |
US10087422B2 (en) | 2018-10-02 |
US20140342445A1 (en) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190032021A1 (en) | Organ Chips And Uses Thereof | |
Wang et al. | Multiorgan microphysiological systems for drug development: strategies, advances, and challenges | |
Wu et al. | Organ-on-a-chip: Recent breakthroughs and future prospects | |
US20240084235A1 (en) | Organomimetic devices and methods of use and manufacturing thereof | |
Ghaemmaghami et al. | Biomimetic tissues on a chip for drug discovery | |
Bhatia et al. | Microfluidic organs-on-chips | |
Caplin et al. | Microfluidic organ‐on‐a‐chip technology for advancement of drug development and toxicology | |
Duzagac et al. | Microfluidic organoids-on-a-chip: Quantum leap in cancer research | |
Barros et al. | Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs | |
JP2022009363A (en) | Organ mimicking device having microchannel and use and production method thereof | |
Park et al. | 3D miniaturization of human organs for drug discovery | |
Kızılkurtlu et al. | Lung on a chip for drug screening and design | |
Yan et al. | Organ-on-a-chip: A new tool for in vitro research | |
Li et al. | Microfluidic organ-on-a-chip system for disease modeling and drug development | |
CN103764813A (en) | Device and method for culturing cells in a biomimetic environment | |
US20210341462A1 (en) | Artificial human pulmonary airway and methods of preparation | |
Rothbauer et al. | A decade of organs-on-a-chip emulating human physiology at the microscale: a critical status report on progress in toxicology and pharmacology | |
Monteduro et al. | Organs-on-chips technologies–A guide from disease models to opportunities for drug development | |
Singh et al. | Journey of organ on a chip technology and its role in future healthcare scenario | |
Ferrari et al. | Liver–Heart on chip models for drug safety | |
Yang et al. | PBPK modeling on organs-on-chips: An overview of recent advancements | |
Ahmed | Organ-on-a-chip microengineering for bio-mimicking disease models and revolutionizing drug discovery | |
Palaninathan et al. | Multi-organ on a chip for personalized precision medicine | |
Malik et al. | Critical considerations for the design of multi-organ microphysiological systems (MPS) | |
Liu et al. | Biosensors integrated 3D organoid/organ-on-a-chip system: A real-time biomechanical, biophysical, and biochemical monitoring and characterization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHU Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BAHINSKI, ANTHONY;HAMILTON, GERALDINE A.;INGBER, DONALD E.;AND OTHERS;SIGNING DATES FROM 20121212 TO 20121213;REEL/FRAME:047135/0582 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |